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1.1 CANCER IMMUNE THERAPIES 
Over the past decade, cancer treatment has seen the emergence of immune therapy as an 
effective and promising addition or alternative to surgery, chemotherapeutic agents and/or 
radiotherapy. The idea to treat malignant disease by utilizing the patient’s own immune system 
has solidified itself in dozens of clinical trials and countless pre-clinical and basic research studies. 
Amongst the most promising and currently employed immune treatments are:  
 
1.1.1 Targeting of immune checkpoints via antibody-based therapies  
Various phase III clinical trials (1-4) revealed the potential of using antibodies to enhance T 
cell activity by blocking co-inhibitory receptors or their ligands on the surface of T cells. In a 
healthy setting, up-regulation of receptors such as Programmed Cell Death protein 1 (PD-1) or 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a means to dampen an ongoing 
immune response – constituting a negative feedback loop following an antigen-mediated T cell 
response. In many instances, tumor cells have exploited this feedback loop by up-regulating 
co-inhibitory ligands. Antagonistic antibodies are able to inhibit interactions between co-
inhibitory receptors and ligands, thus enabling the maintenance of T cells in a prolonged state 
of activation. Along the same principle it is possible to target co-stimulatory receptors present 
on T cells using agonistic antibodies, aiding in initial T cell stimulation. At the time of writing, 
several FDA-approved antibodies have been tested in melanoma, non-small-cell lung 
carcinoma, renal cell carcinoma, head-and-neck cancer and bladder cancer patients and 
microsatellite-instability positive tumor in general, showing impressive clinical results. Blocking 
of CTLA-4 using the monoclonal antibody (mAb) Ipilimumab prolonged overall survival of 
melanoma patients previously treated with a glycoprotein 100 (gp100) peptide vaccine (1). 
Also blocking of PD-1 with the mAbs Pembrolizumab or Nivolumab prolonged median overall 
survival and progression-free survival of patients compared to standard treatment in various 
tumor types (2,5,6). Targeting PD-L1 with the mAb Atezolizumab prolonged overall survival 
from 12,6 months compared to 9,7 months with docetaxel in patients with previously treated 
non-small cell lung cancer (4). Targeting the PD-1/PD-L1 axis showed better anti-tumor 
effects and reduced side-effects when compared to Ipilimumab. Combined therapy using 
Nivolumab and Ipilimumab prolonged the progression free survival of previously untreated 
melanoma patients and increased objective response (OR: 57,6%) compared to single 
treatment with Nivolumab (OR: 43,7%) or Ipilimumab (OR: 19%) (7-9). Notably, the above 
mentioned antibodies are only a few examples of the checkpoint inhibitor repertoire currently 
undergoing application or assessment. 
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1.1.2 Vaccination with tumor-peptides, proteins or antigen-loaded 
autologous dendritic cells 
Vaccination studies aim at stimulating an anti-cancer immune response by providing the 
patient’s immune system with stimulation through antigen presenting cells (APCs) such as 
dendritic cells (DC). These are artificially loaded with tumor lysates, tumor-derived antigens or 
peptides in order to inducing activation and proliferation of tumor specific T cells. This 
approach may rely on peptide presentation by endogenous DCs, e.g., vaccinations with the 
telomerase peptide GV1001 or the NY-ESO-1157-165 peptide, which are expressed by many 
types of cancer (10,11). Alternatively, vaccinations may rely on isolation of DCs from patients 
via leukapheresis, loading them with a chosen antigen or with tumor lysates (12), followed by 
reintroducing them into the patient (13,14). Overall response rates (ORR) to vaccination 
therapy vary between different tumor types as well as vaccines and range from 8.5% in 
melanoma, over 11.5% in renal cell carcinoma to 15.6% in glioma patients (reviewed in (15)). 
In NSCLC patients vaccination with various antigens such as MAGE-A3 or  MUC-1 has yielded 
no clinical benefit (16-18). Notably, the number of complete responses in vaccination studies 
is lower than for checkpoint inhibitors. Pre-clinical evidence suggests that a combination of 
both approaches may yield better outcomes, but this remains to be established in clinical 
studies (19,20). 
 
1.1.3 Adoptive T cell therapy 
Adoptive transfer of T cells to treat cancer patients revolves around either isolation of tumor-
infiltrating lymphocytes (TILs) from tumor tissue or genetic engineering of T cells isolated from 
peripheral blood, and in vitro amplification of these T cells with stimulatory antibodies and/or 
cytokine support. After chemotherapeutic pre-treatment of the patient, these therapeutic and 
autologous T cells are then reinfused. Initial TIL-based therapies showed promising results 
with objective responses of 50% in metastatic melanoma patients and complete response 
rates of up to 22% (21-23). Despite these successes, TIL-therapy relies on the availability of 
tumor tissue for isolation and expansion of sufficient numbers of T cells, limiting it to certain 
tumor types and patient populations. Artificially equipping blood-derived T cells with a T cell 
receptor (TCR) or chimeric antigen receptor (CAR) specific for a chosen antigen is meant to 
circumvent this issue and make this treatment more universally applicable. Adoptive transfer 
of both CAR and TCR-engineered T cells have demonstrated clinical benefit, in particular the 
use of a TCR targeting the cancer testis antigen (CTA) NY-ESO-1 in patients with metastatic 
melanoma (OR:55%, CR18%), metastatic synovial sarcoma (OR: 61%) and multiple myeloma 
(OR: 80%) (24-26) as well as the use of a CAR targeting CD19 in patients suffering from B-
cell malignancies (OR: up to 93%) (27-30).  
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While these treatments are diverse (see also figure 1) and many other immunotherapeutic 
approaches exist, such as targeting checkpoints with drugs (i.e. Indoleamine-2,3-dioxygenase; 
“IDO”;  (31)), use of oncolytic viruses (32) and stimulation of innate immunity via TLR agonists 
(33), all of the above mentioned therapies have in common that their clinical success critically 
depends on CD8 T cells (directly in case of adoptive T cell transfer or some checkpoint inhibitors, 
and indirectly in case of DC vaccination) as their final effector cells to mediate anti-tumor 
immunity. The clinical relevance of CD8 T cells is further substantiated by observations that their 
presence in patients with solid tumors correlated with improved clinical outcome (34,35). Notably, 
beneficial effects of many standard of care treatments, such as chemotherapy or radiation, can be 
partially related to activation of tumor-specific T cells upon treatment-induced immunogenic cell 
death in malignant tissue ((36); reviewed in (37-39)).  
Out of this broad spectrum of immunotherapeutic agents, this thesis focuses on TCR gene therapy, 
the direct modification of patient-derived T cells to generate an anti-tumor therapeutic, its 
challenges and different strategies to enhance the efficacy of TCR engineered T cells. 
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Figure 1. Main categories of cancer immune therapies 
Depicted are the three most commonly applied branches of immune therapy to treat cancer patients (CAR = 
chimeric antigen receptor; DC = dendritic cell; TCR = T cell receptor; TIL = tumor infiltrating lymphocyte). 
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1.2 CURRENT CHALLENGES OF TCR GENE THERAPY 
Despite the promising results of the above-mentioned clinical trials with TCR-engineered T cells, 
and the progress that has been made over the last few years, treatment of cancer utilizing 
genetically engineered T cells still faces several challenges. These can be categorized into 1) 
selection and validation of tumor specific target antigens and corresponding TCRs and 2) T cell 
engineering to enhance therapy efficacy. We argue that addressing these challenges in an 
integrated, multi-faceted manner will critically impact the clinical outcomes of TCR gene therapy. 
In this thesis we provide examples of such an approach. 
So far, most therapies are limited to certain tumor types of high immunogenicity, such as 
melanoma. The degree of immunogenicity, meaning likelihood to elicit an immune response, is 
highly complex and dependent on multiple factors: e.g. accessibility of tumor tissue to immune 
cells; expression of immunogenic antigens (percentage of antigen-positive tumor cells as well as 
expression level per cell) as well as the tumor’s intrinsic ability to inhibit an immune response. 
While it is known that some types of cancer are more sensitive to immunotherapy than others, 
such as solid tumors with high mutational load (40) or hematologic B cell tumors that are 
accessible and efficiently present antigens to therapeutic T cells, it is important to realize that even 
amongst the same tumor types, tumor intrinsic, environmental, but also inter-patient differences 
can contribute to the ultimate effectiveness of a T cell response and greatly affect the clinical 
outcome (41-45). 
Selection of a suitable target antigen and selection of corresponding CARs or TCRs represent one 
approach to control the degree of immunogenicity. CARs are based on the antigen-binding domain 
of a monoclonal antibody, meaning they recognize their target antigen independent of MHC 
presentation. While this allows detection of broader patient populations, it limits CAR targets to a 
pool of structures naturally presented on the cell surface. TCRs recognize a specific antigen that is 
presented in the context of a human major histocompatibility complex (MHC), which is a highly 
diverse group of molecules normally reflecting the health status of a cell. So far most clinical TCR 
gene therapy trials utilized receptors restricted by human leukocyte antigen HLA-A1 and HLA-A2. 
Although among the most common restriction elements, they still only represent 15-50% of the 
Caucasian patient population (46).  
Target antigens for T cell therapies can be divided into four groups (47,48): 1) differentiation 
antigens and over-expressed antigens, both of which are of particular interest due to their high 
expression levels; 2) retroviral antigens which are incorporated in the human genome and may 
become re-expressed in tumors; 3) cancer germline antigens (CGAs), of which a selected number 
is characterized by absent expression in healthy tissue - in particular those with strict epigenetic 
regulation - and 4) neo-antigens, a type of antigen derived from mutations within the tumor and 
whose absence in other tissues provides them with a high safety profile. In chapter 3 we assess 
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the suitability of the CGA MAGE-C2 (MC2) in regard to its immunogenicity by testing four different 
MC2-specific TCRs. 
While assessing expression of target antigen is crucial for the efficacy of immune therapy, both in 
regard to homogeneity within the tumor as well as quantity per individual cell, ensuring that 
expression is tumor-restricted is equally crucial. T cell recognition and destruction of healthy 
tissues that is positive for the target antigen or highly similar antigens is the main reason for 
therapy related toxicity. With regard to these toxicities, we need to differentiate between on-target 
and off-target toxicity. In case of CD19-specific CAR T cells, concomitant loss of normal B cells is 
exemplary for on-target toxicity. The CD19 CAR binds to its target, which is not only expressed by 
the malignant, but also by healthy B cells. TCR T cell trials targeting over-expressed or 
differentiation antigens such as gp100 and MART1 have also faced on-target toxicities, leading to 
inflammation of skin, eyes, ears (49) and colon (50). Off-target toxicity is defined as the 
recognition of healthy tissue, lacking expression of target antigen, by therapeutic T cells. It is 
considered to be a phenomenon related to TCRs, often with enhanced degeneracy with respect to 
ligand binding, that under certain circumstances bind antigens highly similar to the target antigen. 
Targeting certain CGAs with affinity-enhanced TCR-engineered T cells was accompanied by lethal 
neurological (51) and cardiological toxicities (52). Most likely explanation for this encompasses 
promiscuity of the TCR’s recognition motif for the target antigen, e.g., allowing the binding of 
highly similar self-antigens ((51,52); Govers, manuscript in prep; also explained in chapters 3 
and 4). Other TCR-related causes of toxicity such as allo-MHC reactivity or TCR mis-pairing 
between introduced and endogenous TCR chains (see figure 2) cannot be excluded, but lack clear 
clinical evidence. 
To prevent occurrence of on- and off-target toxicities in clinical trials, it is crucial to establish a 
series of in vitro screens that determine the expression of target antigen in healthy tissues and 
predict the auto-reactivity of therapeutic TCRs ((52,53) and chapters 3 and 4). Despite a still 
growing panel of available antigen targets and corresponding TCRs, however, there is currently no 
established guideline for safety assessment of clinical TCRs. Chapter 4 of this thesis proposes an 
optimized pipeline of several in vitro and in silico assays to evaluate the risks posed by either the 
chosen antigen or therapeutic TCR. 
In many patients, T cells fail to clear the tumor completely or an initial response to TCR gene 
therapy is followed by tumor relapse and disease progression.  Here we distinguish between 
tumors either inherently evading immune detection or acquiring an immune suppressive micro 
environment over time. Examples of such evasive mechanisms are up-regulated expression of 
checkpoints (e.g., PD-L1 (54)); down-regulated antigen or HLA expression (55); the tumor’s ability 
to evade infiltration, migration and/or local activation of CD8 T cells (48,56) due to a changed 
expression of extracellular matrix components (reviewed in (57)), adhesion molecules and chemo 
attractants (58,59); and enhanced presence of immune suppressive cells like regulatory T cells 
(Tregs), M2-type macrophages or MDSCs ((60,61), see also figure 2). Please note that this list is 
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not intended to be complete and for a more detailed review, see chapter 2 and the review by 
Vinay et al (62).  
The exact occurrence and dominance of above-mentioned immune evasive mechanisms varies 
strongly between patients, tumor types, treatment history etc. As such, overcoming the immune 
inhibitory tumor microenvironment can be considered the most diverse and demanding challenge 
facing the efficacy of TCR gene therapy. However, recent findings by Charoentong et al indicate 
that there seem to be patterns dictating the escape mechanisms employed by tumors (45). Along 
these lines it may be possible to identify the dominant evasive mechanisms at play for particular 
patient subgroups. In an attempt to support adoptive T cell therapy, the laboratory of tumor 
immunology is generating integrated inventories of evasive mechanisms using state-of-the-art 
techniques (outside scope of current thesis).  In the second part of this thesis, we have designed 
and tested two strategies to counter local immune suppression. First, we have generated co-
stimulatory TCRs that, upon transduction, are expected to yield T cells with enhanced fitness 
(chapter 5). Second, in chapter 6 we have created T cells that next to the TCR transgene harbor 
gene constructs that encode for cytokines. These are produced upon activation of these so-called 
smart T cells in the tumor tissue and expected to sensitize tumors for a T cell response. 
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Figure 2. Clinical outcomes of TCR gene therapy and underlying mechanisms 
Depicted are clinical outcomes following treatment with TCR-transduced T cells, ranging from clearance of tumor 
cells, treatment-related toxicities as well as immediate failure to respond to therapy or non-durability of 
response. For each outcome, underlying mechanisms that potentially explain the observed outcome are listed in 
the corresponding boxes. Mechanisms indicated with a ‘*’ are based on preclinical data only. 
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1.3 SCOPE OF THIS THESIS – IMPROVING TCR GENE THERAPY 
REQUIRES CAREFUL SELECTION OF TARGET ANTIGENS AND TCRS AS 
WELL AS STRATEGIES TO COUNTER THE IMMUNE SUPPRESSIVE TUMOR 
MICROENVIRONMENT 
As evident from the above headings, successful therapy of solid tumors requires careful 
consideration of multiple factors, including (and the focus of this thesis) selection of target antigen, 
corresponding TCR and overcoming tumor-mediated T cell evasion. Chapter 2 provides a more 
detailed overview of the challenges that TCR gene therapy is facing and lists current approaches to 
overcome such challenges. In the subsequent chapters of this thesis, I have covered the following 
two main challenges: 
1. Selection and validation of tumor specific target antigens and corresponding TCRs 
2. T cell engineering to counteract local immune suppression. 
In Chapter 3 we chose and validated MAGE-C2 as a safe and effective target antigen for TCR gene 
therapy. MAGE-C2-specific T cells were able to target cell lines derived from melanoma, head-and-
neck squamous cell carcinoma, triple-negative breast cancer and bladder carcinoma. TCRs were 
derived from patient T cells, characterized and further selected based on in vitro T cell 
performances and tumor-specific recognition. (Challenge 1) 
Chapter 4 proposes a pipeline of assays to validate safety of target antigen and corresponding 
TCRs. MAGE-C2 antigen and selected TCRs from chapter 3 were used as examples in this chapter. 
(Challenge 1) 
In Chapter 5 we equipped TCRs with co-signaling elements derived from the co-stimulatory 
receptors CD28, OX40, ICOS, 4-1BB and CD40L.  Assessment of these co-stimulatory TCRs 
revealed that addition of ICOS signaling cassettes in particular enhanced T cell responsiveness in 
vivo in melanoma-bearing, immune competent mice, delaying tumor recurrence and improving on 
complete responses to therapy. (Challenge 2) 
Chapter 6 describes the generation of ‘smart T cells’ equipped with TCR transgenes as well as an 
inducible construct mediating secretion of IL-12 or IL-18 following TCR triggering. In addition to 
the establishment of a protocol to generate these smart T cells, we observed that therapeutic T 
cells that were able to release IL-18 upon target specific activation, manipulate the tumor micro-
environment and resulted in enhanced therapy response and prolonged survival. (Challenge 2) 
Finally, Chapter 7 summarizes and discusses the main findings of the chapters 3 to 6, and how 
our findings may address the earlier mentioned challenges and potentially translate into future TCR 
gene therapy trials.  
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ABSTRACT 
Adoptive transfer of T cells gene-engineered with antigen-specific T cell receptors (TCRs) has 
proven its feasibility and therapeutic potential in the treatment of malignant tumors. To ensure 
further clinical development of TCR gene therapy, it is necessary to target immunogenic epitopes 
that are related to oncogenesis and selectively expressed by tumor tissue, and implement 
strategies that result in optimal T cell fitness. In addition, in particular for the treatment of solid 
tumors, it is equally necessary to include strategies that counteract the immune-suppressive 
nature of the tumor micro-environment. Here, we will provide an overview of the current status of 
TCR gene therapy, and redefine the following three challenges of improvement: ‘choice of target 
antigen’; ‘fitness of T cells’; and ‘sensitisation of tumor milieu’. We will categorize and discuss 
potential strategies to address each of these challenges, and argue that advancement of clinical 
TCR gene therapy critically depends on developments towards each of the three challenges. 
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2.1 TCR GENE THERAPY: CLINICAL POTENCY AND TOXICITIES 
T cells possess distinct properties such as the ability to specifically recognize tumor antigens, 
serially kill tumor cells, self-replicate, form memory and induce a complete tumor response. It is 
because of these properties that the therapeutic use of T cells in certain types of cancer may be 
advantageous when compared to drugs, antibodies or small molecule inhibitors. 
 
T cell therapy intends to treat cancer by transferring autologous and ex-vivo expanded T cells to 
patients. Therapy with tumor-infiltrating T lymphocytes (TILs) preceded by non-myeloablative 
lymphodepletion resulted in objective responses in about 50% of metastatic melanoma patients in 
two different medical centers (1,2). Equally notable were the durable complete responses observed 
in these trials that ranged between 10 and 22% (ongoing for more than three years) (1,2). 
Likewise, adoptive transfer of tumor-specific T cell clones generated from autologous peripheral T 
cells resulted in regression of individual metastases, and responses in 8 out of 10 melanoma 
patients (3). In addition, co-culture of peripheral T cells with artificial antigen-presenting cells 
(APC) loaded with tumor antigens resulted in T cells that were clinically effective in 4 out of 7 
evaluable melanoma patients (4). Response rates observed with T cell therapy are generally higher 
than those observed for other treatments of melanoma, such as chemotherapeutic drugs, high-
dose cytokines, inhibitors of kinases or antibodies against T cell co-inhibitory molecules. See Table 
1 for an overview of clinical outcomes of T cell therapies and other treatments of melanoma.  
  
Despite its clinical successes, T cell therapy has its limitations in availability and generation of 
therapeutic T cells for a larger group of patients. Genetic introduction of T cell receptors (TCRs) or 
chimeric antigen receptors (CARs) into autologous T cells, termed gene-engineering of T cells, can 
provide an alternative that is more widely applicable and can potentially be extended to multiple 
types of cancer (5). Key preclinical achievements and clinical tests with TCR-engineered T cells, the 
focus of the current review, are depicted in Figures 1A and 1B, respectively. Therapeutic advances 
with CAR-engineered T cells is reviewed elsewhere (6). The principle of clinical TCR gene therapy is 
straightforward: transferral of TCRαβ genes into T cells; ex-vivo expansion of T cells; and infusion 
of T cells into the patient. In this way, TCRα and β genes are used as “off the shelf” reagents to 
confer tumor reactivity to patients whose tumor expresses the appropriate antigen and HLA 
restriction element. At the moment of writing this review, eight clinical trials using TCR-engineered 
T cells have reported their results (see Figure 1B and Table 2 for details), and at least another ten 
trials using TCR-engineered T cells are open and actively recruiting patients or will recruit patients 
soon (www.clinicaltrials.gov). 
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Table 1. Overview of standard and experimental none-gene-based therapies for 
metastatic melanoma 
Therapy Function 
Type of 
trial 
OR (%)* CR (%)* Refs. 
       
T cell therapy      
Tumor infiltrating 
lymphocytes (TILs) 
Adoptive transfer of                                              
tumor-specific T cells 
n.c. 52/93 (56) 20/93 (22) (1) 
 
 
 
n.c. 15/31 (48) 3/31 (10) (2)§ 
      
T cell clones 
 
 
n.c. 8/10 (80) n.r. (3) 
      
‘Educated T cells’ 
 
 
n.c. 4/9 (44) 1/9 (11) (4) 
      
Standard therapy      
High dose IL-2 
Cytokine that induces T 
cell growth 
n.c. 43/270 (16) 16/270 (6) (178) 
      
Dacarbazine (DTIC) 
 
Drug that alkylates DNA 
 
Phase III trial 18/149 (12) 4/149 (3) (179) 
      
      
Vemurafenib (PLX-4032) 
Small molecule that 
inhibits BRAF kinase 
activity 
Phase III trial 
106/219 
(48) 
2/219 (1) (180) 
      
Experimental therapy      
Dabrafenib 
Small molecule that 
blocks BRAF kinase 
activity 
Phase III trial  29/54 (54) n.r. (181) 
      
Dabrafenib + Trametinib 
Small molecules that 
block BRAF and MEK 
kinase activities  
Phase III trial 41/54 (76) n.r. (181) 
      
Ipilimumab (MDX-010) + 
vaccination 
Antibody that blocks T 
cell CTLA4 
Phase III trial 39/137 (28) 3/137 (2) (182) 
      
Ipilimumab + DTIC 
 
 
Phase III trial 34/252 (14) 26/252 (10) (183) 
      
Nivolumab (MDX-1106) # 
Antibody that blocks T 
cell PD1 
Phase I trial 5/39 (13) 1/39 (3) (184) 
 
 
 
 
Phase I trial 26/94 (28) n.r. (185) 
      
Nivolumab + Ipilimumab  Phase I trial 21/53 (40) n.r. (186) 
      
Pembrolizumab (MK-
3475) 
Antibody that blocks T 
cell PD1 
Phase I trial 51/135 (38) n.r. (187) 
      
Anti-PD-L1 (MDX-1105) 
Antibody that blocks 
tumor cell PDL1 
Phase I trial 17/135 (13) n.r. (188) 
 
* OR = Objective responses, CR = Complete responses, both according to Response Evaluation Criteria for Solid Tumors (RECIST). 
Number of patients with responses = before dash; total number of patients treated = after dash; percentage of responses = 
between brackets.  
§ Dr. Jacob Schachter, Cellular Therapy of Cancer Symposium, Sept 24-27th, Montpellier, France, 2010 
# This study included patients with metastatic melanoma, but also patients with renal cell carcinoma, colorectal cancer, prostate 
cancer and non-small-cell lung cancer. 
Abbreviations: BRAF = gene responsible for production of B-Raf-kinase; CTLA4 = Cytotoxic T-lymphocyte antigen 4; IL-2 = 
Interleukin 2; n.c. = not classified;  n.r. = none reported; mAb = monoclonal antibody; MAPK = Mitogen-activated protein kinase; 
PD1 = Programmed cell death 1 receptor; PDL1 = Programmed cell death 1 ligand. 
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Most clinical TCRs tested so far were HLA-A2-restricted and directed against either melanoma-
associated antigen recognized by T cells 1 (MART-1), glycoprotein (gp) 100, carcinoembryonic 
antigen (CEA), p53, melanoma-associated antigen (MAGE-)A3 or New York esophageal squamous 
cell carcinoma antigen (NY-ESO)1. Another TCR tested clinically was HLA-A1-restricted and 
directed against MAGE-A3. Collectively, these trials have not only demonstrated feasibility but also 
demonstrated significant clinical responses in patients with metastatic melanoma, colorectal 
carcinoma and synovial sarcoma (Table 2). Responses, although variable and tested in a 
cumulative number of about 80 patients (based on trials listed in Table 2), ranged from 12 to 67 
%. Notably, the finding that TCR gene-engineered T cells were able to traffic to the central nervous 
system and cause complete responses of brain metastasis in patients with melanoma was not only 
encouraging but also underscored the strength of T cell therapy towards metastasized and poorly-
accessible tumors (7). Clinical testing, however, also clearly demonstrated that therapy is currently 
hampered by treatment-related toxicity and a transient nature of tumor regression. Treatment-
related toxicity became evident from studies with TCRs, in particular those of high-affinity, directed 
against antigens that are over-expressed on tumors but also expressed on healthy cells. Toxicities 
included severe but treatable inflammation of skin, eyes, ears (MART-1/HLA-A2; gp100/HLA-A2) 
and colon (CEA/HLA-A2). In addition, lethal neurological toxicities were observed in two patients 
when targeting MAGE-A3/HLA-A2, and lethal cardiac toxicities were observed in three patients 
when targeting MART-1/HLA-A2 (another epitope as above) or MAGE-A3/HLA-A1. The transient 
nature of tumor regression became evident from observations that anti-tumor responses are 
initially significant but not sustainable and ultimately incomplete in 80 to 90% of patients. Table 2 
offers an up-to-date and detailed overview of toxicities as well as clinical responses reported for 
TCR gene therapy trials.  
 
Strategies that aim at preventing or limiting toxicities as well as tumor recurrences have already 
been developed, some of which need further preclinical testing and some of which have already 
been implemented in clinical trials. In this review, we have categorized these strategies along 
three renewed challenges, i.e., ‘choice of target antigen’; ‘fitness of T cells’ and ‘sensitisation of 
micro-milieu for T cell therapy’, as illustrated in Figure 2. We propose and will argue that 
optimizations along each or combinations of these challenges will contribute most significantly to 
the advancement of clinical TCR gene therapy. 
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Figure 1: Key achievements in the field of TCR gene therapy directed against solid tumors 
A: Timeline of selected preclinical findings that have contributed to the development of TCR gene therapy. 
B: Timeline of clinical findings with TCR gene-engineered T-cells. Details with respect to clinically used TCRs can 
be found in Table 2. 
 
 
 
 
2.2 CHOICE OF TARGET ANTIGEN 
Ideally, target antigens are selectively expressed by tumor tissue and not healthy tissue, and 
hence not expected to evoke a response against self. At the same time, target antigens should 
have proficient immunogenicity to initiate an effective anti-tumor response. 
  
A 
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2.2.1 Selective expression  
Tumor-associated antigens (TAAs) can generally be divided into four groups (8). 
 Differentiation antigens: cell surface proteins that are expressed at different stages of 
tissue development or cell activation. Expression of these antigens may discriminate tumor 
cells from surrounding healthy cells, but expression by healthy cells is not absent. Examples 
include MART-1, gp100, CEA and tyrosinase related protein (TRP)1 and 2. 
 Over-expressed antigens: cell surface proteins that are highly, but not selectively, 
expressed by tumor cells when compared to healthy cells. Examples include the epidermal 
growth factor receptor (HER)2 or survivin. 
 Cancer Testis Antigens (CTAs): proteins that are expressed by tumors and a limited 
number of healthy and adult cell types. A defined number of CTAs may not be expressed by 
healthy adult cell types. Examples include MAGE-A1, MAGE-C2 and NY-ESO1. 
 Neo-antigens: proteins that result from gene mutations or aberrations in tumor cells. These 
proteins are uniquely expressed by tumor cells but not healthy cells. Examples include 
mutated protein (p)53, B-Raf kinase and cyclin-dependent kinase 4 (CDK4). 
 
Looking at these four groups of TAAs, CTAs and neoantigens may represent the best available 
choices for therapy with TCR-engineered T cells. With respect to CTAs, over several hundreds of 
genes have been identified (see for a full description of CTAs: http://www.cta.lncc.br). 
Approximately 40 of these genes belong to multigene families that are located on the X 
chromosome. A selected number of mostly X-chromosome-located CTAs may be of interest for T 
cell therapy. First, these antigens are not expressed by healthy tissues except testes and placentas 
(determined using RT-PCR), and these latter tissues do not express Major Histocompatibility (MHC) 
molecules and cannot be targeted by T cells (9). Second, CTAs are expressed by tumor tissues of 
various histological origins as a result of aberrant epigenetic regulation (9), and expression of CTAs 
has been associated with advanced stages of disease and unfavourable patient prognosis (10). 
Along these lines, there is evidence that MAGE proteins are related to oncogenesis as they 
suppress p53-dependent apoptosis and cause fibronectin-controlled increase in tumor cell 
proliferation and metastasis (11-15). Third, CTAs are immunogenic proteins that have been 
reported to induce both humoral and cell-mediated immune responses in patients without the 
concomitant induction of toxicities (10,16,17). Undeniably, current patient studies emphasize the 
need for careful identification of target CTAs. In one study, Robbins and colleagues demonstrated 
that a TCR directed against NY-ESO1/HLA-A2 showed significant anti-tumor responses in patients 
with metastatic melanoma and synovial sarcoma without detectable toxicities (Table 2). 
Unexpectedly, in another study using a TCR directed against MAGE-A3/HLA-A2, two patients with 
metastatic melanoma lapsed into coma and died. These adverse events were most likely caused by 
T cell recognition of rare neurons that were positive for MAGE-A12 and possibly MAGE-A9 antigens, 
which contain shared or highly similar epitopes compared to MAGE-A3 antigen (Table 2). In a third 
study, in which a TCR was used directed against MAGE-A3/HLA-A1, one patient with melanoma 
and one patient with myeloma suffered from cardiovascular toxicity and died. This toxicity was 
TCR ENGINEERED T CELLS MEET NEW CHALLENGES TO TREAT SOLID TUMORS 
 
 
33 
 
 2 
possibly caused by T cell recognition of a similar but not identical peptide from the muscle protein 
titin (so-called ‘off-target’ toxicity, Table 2).  
With respect to neoantigens, the expression of these antigens may vary significantly among 
different patients, but their expression is unique to tumor tissues. In case a neo-antigen is the 
result of ‘driver mutations’, the antigen may constitute an ideal target for T cell therapy. Driver 
mutations are related to oncogenesis, may be linked to known genes (~400), and may provide 
tumors with a selective growth advantage (18,19). Nevertheless, it is important to realize that only 
15% of up to 100,000 mutations that are encountered in tumor genomes are considered ‘driver’ 
mutations (18,20). Moreover, not all driver mutations may result in new immunogenic antigens. A 
quest for neo-antigen targets does not only require next-generation sequencing techniques to 
identify tumor-specific mutations (21), but also techniques to determine whether a neo-epitope 
can be presented by MHC and recognized by T cells (22,23). 
 
In short, we consider epitopes from selected (non-shared) CTA and neo-antigens as potentially 
safe T cell target antigens. However, no matter what the antigen, it is recommended to perform 
stringent in silico analysis and preclinical testing to confirm the antigen’s absence from vital 
organs. Strategies used to identify titin as a cross-recognized peptide, such as amino acid 
scanning, gene database searches and use of 3-dimensional cell cultures, are potentially helpful in 
this respect (24). In addition, one could consider using suicide systems to deplete self-reactive T 
cells prior to proceeding with clinical testing (25-28). Although suicide genes provide the option to 
delete TCR-transduced T cells, it is questionable whether such a switch could counteract the fast 
kinetics of toxicity reported in the above-mentioned trials (29,30). 
 
2.2.2 Immunogenicity 
The immunogenicity of an antigen, i.e., its ability to initiate immune responses, is determined by 
the level of its expression, how it is processed and presented, and how well it is recognized by T 
cells. 
 
Level of expression and processing of antigens 
Ideally, target antigens should be expressed at high levels by most if not all tumor cells. Such a 
property is generally restricted to those antigens that are related to oncogenesis and that tumors 
cannot easily do without (see part 2.1). It is noteworthy that the production of antigens, such as 
those of MAGE-A family members and NY-ESO1, is enhanced and becomes more homogeneous 
within tumors by treatment with demethylation agents and/or histone deacetylases (31-34). In a 
phase II clinical study, in which haematological malignancies were targeted and which included 
treatments with epigenetic drugs, it was observed that T cell responses directed against CTA were 
enhanced with no evidence of adverse events (35). In addition, the production of antigens may 
depend on immune or intermediate proteasomes, rather than standard proteasomes, and on 
unconventional post-translational events such as reverse splicing and deamidation of proteins (36-
38). Such processing of antigens, in particular when mediated by immune proteasomes, may 
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benefit from local production of interferon (IFN)γ. Finally, the release and hence the availability of 
antigens may be enhanced via treatment-induced cell death following (co-treatments with) 
chemotherapy, irradiation and/or therapy with tyrosine kinase inhibitors (39,40). 
  
Cross-presentation of antigens 
Antigen cross-presentation may take part in the infiltration of antigen-specific CD8 T cells (41) and 
cause activation of T cells and subsequent stroma destruction, thereby preventing outgrowth of 
antigen-negative tumor cells. Recently, Engels and colleagues revealed that peptide:MHC affinities 
of 10 nM or less allowed for cross-presentation of antigens by stromal cells (42). Notably, using an 
experimental model in which mice transgenic for TCRs with different antigen specificities were used 
either as donors or recipients of T cells, they showed that the use of peptide targets that can be 
cross-presented result in complete anti-tumor responses. Destruction of tumor stroma, a 
bystander response that may put an advantage to T cells over drugs (43,44), may require optimal 
T cell fitness (as measured by production of IFNγ) and IFNγ-mediated preservation of Fas 
expression by stromal cells (45).  
 
Robustness of antigenicity 
Loss of tumor antigen expression after infusion of T cells, and its impact on the recurrence of 
tumors, is an important yet controversial aspect. Decreased antigen expression has been proposed 
to be a consequence of molecular alterations in tumor cells, such as genetic and epigenetic 
changes in antigen genes, MHC genes and genes related to antigen processing and presentation 
(46-48). Indeed, selective loss of antigen or HLA-A2 expression has been reported in primary and 
metastatic melanoma lesions in non-treated patients (49,50) as well as patients treated with T 
cells (51,52). Also, Landsberg and colleagues, using a gene-engineered model of melanoma, have 
eloquently demonstrated that a therapy-resistant phenotype may be directed by an inflammatory 
milieu and tumor necrosis factor (TNF)α’s ability to lead to epithelial dedifferentiation and 
decreased expression of melanoma antigens (53). In contrast to these findings, there is increasing 
evidence to support the view that tumors progress without loss of T cell antigens. In various 
preclinical models, in which either skin, lung or ovarium tumors were studied, it was observed that 
tumors progressed despite continued antigen expression (54-56). In these models, tumor 
progression was rather a consequence of reduced T cell infiltration and reduced T cell 
responsiveness We postulate that in the setting of T cell therapy, loss of target antigen, whether 
by T cell-dependent selection or epigenetic silencing (57,58), is not necessarily a driving 
mechanism in tumor recurrence (Straetemans et. al., manuscript submitted).  
 
Target multiple antigens simultaneously 
In current TCR gene therapy trials, single MHC class I-restricted antigens are targeted. Preclinical 
studies have suggested that the targeting of two or more antigens enhances the therapeutic 
potential of T cells. For example, adoptive transfer of two CD8 T cell populations to simultaneously 
target ovalbumine and gp100, rather than either one antigen, resulted in delayed recurrence of 
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tumors (59). Interestingly, treatment with viruses positive for three MHC class II-restricted 
antigens, i.e., neuroblastoma RAS, TRP1 and cytochrome c1, resulted in complete anti-tumor 
responses that were accompanied by significant CD4 T helper cell type 17 (Th17) responses (60). 
Since cooperation of CD4 and CD8 T cells appears important in the effector phase of an anti-tumor 
response and may contribute to the bystander elimination of tumor stroma (61), it may be 
worthwhile to simultaneously target MHC class I and II targets. With respect to human antigens, it 
is interesting to note that X-chromosome linked CTAs are co-ordinately expressed in tumor tissues 
(62), which may allow the simultaneous targeting of multiple CTAs.  
 
2.3 FITNESS OF T CELLS 
The responsiveness of T cells towards tumor antigen is generally tuned down, most likely at 
various levels. First, reactive T cells may be deleted during T cell development in the thymus; 
second, peripheral T cells may be susceptibility to anergy; and third, intra-tumoral T cells may 
require enhanced co-stimulation (63). To overcome such T cell tolerizing mechanisms one can 
optimize T cell fitness. Here, we define T cell fitness according to the following three T cell 
properties: functional T cell avidity, T cell co-signalling and T cell differentiation.  
 
2.3.1 Functional T cell avidity 
Functional T cell avidity is considered as the ability of T cells to respond to a given concentration of 
cognate peptide antigen, and can be enhanced via strategies, often involving gene-engineering of 
TCRαβ transgenes, that either increase the level of cell surface expression of TCR chains or the 
TCR’s affinity for peptide-MHC. 
 
Expression level of TCR transgenes 
One angle to enhance the surface expression of TCR transgenes is through optimization of the TCR 
gene transfer methodology, including choice of gene delivery method, use of optimal vector 
elements, and use of transgene cassettes (reviewed in (6,64)). Another angle to enhance the 
surface expression of TCR transgenes is through limitation or abolishment of TCR mis-pairing. TCR 
mis-pairing is the formation of TCR heterodimers that comprise one transgenic TCR chain and one 
endogenous TCR chain, and represents a phenomenon that is inherent to the generation of TCR-
engineered T cells. Importantly, TCR mis-pairing dilutes the surface expression of the transgenic 
TCRαβ chains, and mis-paired TCRs are of unknown specificity and can yield self-reactive T cells. 
Although in clinical trials performed so far, no formal observations of toxicities mediated by TCR 
mis-pairing have been made, preclinical studies have clearly demonstrated that TCR mis-pairing 
has the potential to induce harmful recognition of self-antigens (65,66). Strategies to promote 
preferential pairing between transgenic TCRα and TCRβ chains (and consequently prevent or 
reduce TCR mis-pairing) can be grouped according to those that depend on gene-engineering of 
TCR transgenes and those that do not. The first group of strategies are reviewed in (67). In short, 
these strategies include murinization of TCR (68), addition of cysteine amino acids to TCR (69,70), 
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mutations in TCR transmembrane and constant domains (71,72), and equipment of TCR with a 
signaling cassette that replaces TCR transmembrane and intracellular domains with the CD3ζ 
accessory molecule (73,74). More recently, a limited number of murine amino acids have been 
identified that are responsible for enhanced expression and preferential pairing of murinized TCRs 
(75,76). Similar efforts to minimize the number of amino acids in a CD3ζ signaling cassette failed, 
and it was observed that properties of TCRs equipped with CD3ζ signalling cassettes are best 
preserved when incorporating a complete CD3ζ molecule (77). The other group of strategies 
includes technologies that enhance expression levels of CD3 molecules in T cells and those that 
interrupt expression of endogenous TCR chains. Co-transfer of CD3 and TCR genes into T cells 
resulted in higher levels of TCR expression and allowed T cells to respond to lower concentrations 
of antigen, and to infiltrate and eliminate tumors with faster kinetics (78). RNA interference 
techniques have been shown to specifically down-regulate the expression of endogenous but not 
transgenic TCR chains (79,80). An alternative method encompasses the use of zinc finger 
nucleases and a sequential knock-out of endogenous TCRα and β chains, followed by introduction 
and sorting of TCRα and β transgenes (81). The latter method is relatively new and not yet widely 
or clinically applied, but holds promise to effectively address TCR mis-pairing. 
 
Affinity enhancement of TCRαβ transgenes 
Affinity-enhancement of tumor specific TCRs, and its exploitation, relies on the existence of a 
window for optimal TCR affinities. The existence of such a window is based on observations that 
TCRs specific for HLA-A2-restricted pathogens have KD values that are generally about 10-fold 
lower when compared to TCRs specific for HLA-A2-restricted tumor associated self-antigens (82). 
In support of this notion are the observations that a high-affinity MART-1/HLA-A2 TCR mediated 
improved objective response rates compared to a lower affinity MART-1/HLA-A2 TCR, and that an 
affinity-enhanced NY-ESO1 TCR mediated significant clinical responses (Table 2). Affinity-enhanced 
TCRs can be obtained through various routes. First, allo-reactive settings can be used to 
circumvent self-tolerance and yield T cells with a higher avidity when compared to T cells derived 
from autologous settings (= patients). Examples of such settings include in vitro generation of allo-
HLA reactive, peptide-specific T cells (83-85), and immunization of mice transgenic for human-
MHC or human TCR (86,87). Second, TCR affinities can be enhanced by rationally designed 
mutations of the TCR’s complementarity-determining regions (CDRs) (88,89). Third, high-affinity 
TCR variants can be selected from a library of CDR mutants by yeast, phage or T cell display (90-
92). Although the affinity of TCRs significantly contributes to the functional avidity of T cells, recent 
studies warrant caution when therapeutically implementing this strategy. Clinical reports suggest 
that CDR mutations in TCRs directed against CEA/HLA-A2, MAGE-A3/HLA-A2 and MAGE-A3/HLA-
A1, but not NY-ESO/HLA-A2, were possibly related to patient toxicities (Table 2). Investigations 
whether defined locations and types of mutations are more prone to lead to toxicities than others 
would most likely benefit further development of CDR-mutated TCRs. Also, preclinical reports 
suggest the existence of a functional ceiling with respect to TCR affinity (93,94). In fact, studies 
with primary human T cells transduced with affinity-enhanced TCRs directed against NY-
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ESO1/HLA-A2 (93) or gp100/HLA-A2 (Govers et. al., manuscript submitted) pointed to the 
existence of a KD threshold of 1 to 5 µM, below which T cell function became compromised. The 
functional impairment of high avidity T cells in the presence of high levels of antigen, as is often 
the case in tumors, may be related to enhanced expression of the exhaustion marker programmed 
cell death (PD1) and enhanced activity of its downstream sarcoma homology domain 2 
phosphatase (SHP)1 (95,96). 
 
2.3.2 T cell co-signalling 
T cell co-signaling is directed by interactions between co-stimulatory or co-inhibitory molecules and 
their ligands and determines, in addition to interactions between TCR and peptide-MHC, the 
functional outcome of T cells (reviewed by (97)). The best characterized co-stimulatory and co-
inhibitory molecules expressed by T cells are CD28 and cytotoxic T-lymphocyte associated protein 
(CTLA)4, respectively, which both interact with CD80 and CD86 ligands expressed by APCs. More 
recent examples of co-stimulatory and co-inhibitory molecules include inducible T cell co-
stimulation (ICOS), 4-1BB, OX40, CD40, B and T-lymphocyte attenuator (BTLA), and PD1. 
 
Tumors provide continuous stimulation with antigen often in the absence of co-stimulatory ligands, 
which may result in exhausted T cells with reduced proliferative capacity, reduced effector function 
(such as IFNγ production) (98) and up-regulated expression of T cell co-inhibitory molecules (99). 
Immunotherapy with monoclonal antibodies to block the T cell co-inhibitory molecules CTLA4, PD1, 
PDL1, or the combination of CTLA4 and PD1 showed clear clinical successes in the treatment of 
advanced melanoma (see Table 1). These clinical activities have provided an impetus for the 
development of blocking other co-inhibitory molecules and/or stimulation of co-stimulatory 
molecules (100-104). The beneficial outcome of targeting T cell co-signaling most likely relies on 
enhancement of infiltration of T effector cells (Teff) into tumor tissue and activation of Teff, as well 
as depletion of intra-tumoral T regulatory cells (Treg) (103-105). We would advocate explorative 
studies to test the combination of blocking T cell co-inhibitory molecules and adoptive transfer of 
Teff. In addition to this combination of immune therapies, two other approaches to implement T 
cell co-signaling in protocols of T cell therapy have already been clinically tested. First, TCR 
transgenes can be equipped with a signalling cassette that harbors a co-stimulatory molecule. 
Such a signalling cassette, designed in analogy to those used in co-stimulatory CARs (6), typically 
introduces accessory and co-stimulatory molecules to enhance the function of T cells expressing 
the TCR transgene. It is noteworthy that clinical trials using CARs containing CD28 or CD137 
demonstrated significant objective responses in patients with B cell leukemia (106-108), and while 
CARs may evoke immune responses, these were directed against murine idiotypes, but never 
against boundaries between genetically introduced human molecules (109). According to this 
rationale, single and two-chain TCR genes have been coupled to a combination of CD28 and CD3 
molecules and were shown to provide T cells with improved function in vitro (110,111) (Govers et. 
al., manuscript submitted). Second, T cells can be stimulated ex vivo with human artificial APC 
(aAPCs) that express co-stimulatory ligands (4,112). In addition to co-stimulatory ligands, these 
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aAPCs are mostly engineered to express HLA-A*0201 and used to stimulate T cells in the presence 
of common- cytokines other than interleukin (IL)-2. These combined activations allow for the 
generation of HLA-A2-restricted, antigen-specific T cells with a less differentiated phenotype 
(CD45RA+ CD62L+) and superior T cell functions in vivo (112). In a clinical study, T cells educated 
with aAPC presenting CD80, CD83, and a MART-1 peptide, and cultured in the presence of IL-2 and 
IL-15, resulted in objective responses in patients with metastatic melanoma (Table 1). Notably, 
inclusion of T cell co-stimulation by either one of the two above-mentioned approaches relieved the 
requirement for patient preconditioning with chemotherapy and/or in vivo IL-2 administration 
(4,106). 
 
2.3.3 T cell differentiation 
The differentiation of naïve T cells into mature CD8 Teff or CD4 Th1 or Th17 cells is required for T 
cells to make full use of their functional attributes directed against tumor cells, such as cytotoxicity 
and production of IFNγ and TNFα. The differentiation of T cells is largely driven by environmental 
stimuli, with cytokines being well-studied examples of such stimuli (113,114). Progression of T 
cells into a differentiated subset is not necessarily permanent, and in particular T helper cell 
subsets have shown plasticity and may change into another T helper cell subset (114). 
Differentiation of CD8 and CD4 T cells, although occurring according to similar principles, follow 
different routes and show different outcomes. Strategies to manipulate T cell differentiation to 
advance T cell therapy are discussed separately for both T cell subsets. 
 
CD8 T cells 
Naïve CD8 T cells can differentiate, depending on the quantity and quality of the initial antigenic 
and co-stimulatory stimuli, into stem cell memory T cells, central memory T cells, effector memory 
T cells or T effector cells (115). An important observation that came from preclinical studies was 
the inverse relationship between CD8 T cell differentiation and proliferation, and hence the inverse 
relationship between CD8 T cell differentiation and in vivo persistence and therapeutic activity 
(113). Two strategies have been reported to exploit this inverse relationship and improve adoptive 
T cell therapy. In one such strategy, as shortly mentioned in section 3.2, T cells are exposed to 
common- cytokines other than IL-2 prior to adoptive T cell transfer. For example, treatments with 
either IL-7+IL-15 or IL-15+IL-21 generated gene-engineered T cells with a less differentiated CD8 
T cell phenotype (i.e., central memory phenotype), prolonged peripheral persistence and potent 
antigen reactivity (116,117). In addition to soluble cytokines, Singh and colleagues reported on 
aAPC that express membrane-bound IL-15 and IL-21 and facilitate the generation of ‘young’ T cells 
(112). In other reports, the anti-tumor efficacy of T cells was enhanced either via in vivo 
administration of IL-15+IL-21 (118) or conjugation of nanoparticles, encapsulating these 
cytokines, to the surface of therapeutic T cells (119). In a second strategy, T cells are enriched for 
less differentiated T cell populations, i.e., based on CD62L expression, and subsequently used as 
recipient cells for gene transfer (120,121). A recently identified population of ‘stem-cell memory’ 
CD8 T cells, expressing high levels of CD95, IL2Rβ and demonstrating increased proliferative 
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potential and ability to mediate anti-tumour responses, may represent a promising subset of T 
cells for gene-engineering and therapeutic application (122). In fact, Cieri and colleagues have set 
up a protocol to obtain and gene-modify stem-cell memory CD8 T cells, which includes the use of 
CD3/CD28 mAbs and IL-7 and IL-15 and could potentially be translated to a clinical setting (123). 
 
CD4 T cells 
Naïve CD4 T cells can differentiate into multiple subsets, including Th1, 2, 9, 17, 22, follicular 
helper and various Tregs, often defined by the expression of ‘signature cytokines’ or typical 
functions, such as B cell activation or the down-modulation of T cell responses (124). With respect 
to anti-tumor responses, it appears that upon cell transfer Th1 and Th17 are the most potent CD4 
T cell subsets (125,126). Administration of CD4 T cells, and in particular Th1 cells, has been shown 
to prevent exhaustion of CD8 T cells, enhance tumor infiltration of CD8 T cells and result in 
effective tumor eradication (125,127-130). More recently, it was discovered that adoptive transfer 
of Th17 cells effectively mediate rejection of TRP1-positive tumours in a TCR-transgenic mouse 
model (126). Furthermore, Th17 cells appear to be long-lived and their molecular signature 
resembles that of stem-cell memory CD8 T cells (131). Interestingly, the anti-tumour activity of 
Th17 cells depended on its (incomplete) differentiation and conversion into Th1 cells, resulting in a 
co-existence of Th17 and Th1 cells, and it may very well be this multi-potent aspect that provides 
a therapeutic advantage.  
 
Collectively, these data argue in favor of a combined therapeutic use of CD8 T cells and Th1 or 
Th17 cells. To this end, CD4 T cells can be functionally endowed with MHC I-restricted TCR and/or 
CD8 via gene transfer (132-135). Alternatively, one could opt for strategies that induce in vivo 
conversion of CD4 T cells into Th1 cells, such as IL-12, IFNα, IFNγ, or blocking PD1 ligation (136-
139). Also, metabolic signals, such as activation of T cell mammalian target of rapamycin (mTOR) 
and aerobic glycolysis can enhance differentiation towards IFNγ-producing T cells and may be 
exploited therapeutically (140,141). 
 
2.4. SENSITISATION OF MICRO MILIEU FOR T CELL THERAPY  
Tumors, following initial regression upon treatment with T cells, most often become resistant to T 
cell therapy and recur. Recent understanding suggests that, at least in some tumors, therapy 
resistance may be part of a negative feedback loop that is initiated once an anti-tumor CD8 T cell 
has occurred (142). Therapy resistance is often characterized by a dis-balance between numbers 
and activation state of immune effectors cells versus those of suppressor cells. Strategies to 
manipulate numbers and activation state of immune cells are discussed separately for effector and 
suppressor cells. 
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2.4.1 Recruitment and activation of immune effector cells 
Immune effector cells that have been recognized for their contribution to an anti-tumor response 
are numerous and, in addition to CD4 and CD8 T cells, include natural killer (NK), natural killer T 
cells (NKT), macrophages and neutrophils. Here we will focus on Teff and macrophages and how 
manipulation of the micro-milieu may enhance their recruitment and activation. 
 
Enhance recruitment of T effector cells 
Clinical studies have demonstrated an unfavorable prognostic value of a limited CD8 T cell 
infiltration in melanoma, colorectal and ovarium carcinomas (143-145). Vascular changes have 
been reported to contribute to arrested T cell infiltration and include insufficient vascular 
maturation and enhanced expression of endothelin B receptor, regulator of G-protein signalling 5 
(Rgs5) and/or extracellular matrix components (reviewed in (146)). Such changes may be 
targeted, as evidenced by angiostatic therapy in which antibodies directed against vascular 
endothelial growth factor (VEGF) or angiopoietin 2, or in which T cells gene-engineered with a CAR 
directed against VEGF receptor (VEGFR)2 resulted in enhanced T cell infiltration (147-149). In 
addition, drugs that inhibit angiogenesis or endothelin receptor B were able to enhance the 
expression of intercellular adhesion molecule (ICAM)1 on endothelial cells and to normalize T cell 
infiltration (150,151). In various solid tumors, T cell infiltration appears to be facilitated by vessels 
that closely mimic high endothelial venules (HEV) and which may be part of ectopic lymphoid 
structures in tumor stroma (152,153). A better understanding of the development of such HEV in 
tumor stroma may provide novel targets to improve T cell infiltration in tumors. 
 
In addition to vascular changes, spontaneous cutaneous melanoma tumors in mice demonstrated a 
decreased mRNA expression of chemoattractants that contribute to recruitment of CD8 T cells, 
such as chemokine (CC motif) ligand (CCL)5 and chemokine (CXC motif) ligands (CXCL)9 and 10 
(146). In a subset of patients with melanoma metastases, lack of chemoattractants coincides with 
limited migration of CD8 T cells and limited presence of lymphoid structures (154). Current 
findings from our laboratory suggest that a decreased expression of selected chemoattractants and 
adhesion molecules are related to a decreased infiltration of CD8 T cells and tumor relapse 
following T cell therapy (Straetemans et. al., manuscript submitted). Interestingly, Hong and 
colleagues have shown that the chemotherapeutic drugs dacarbazine, temozolomide, and cisplatin 
enhanced the expression of CCL5, CXCL9 and CXCL10 in patient melanoma, which in turn 
correlated with improved immune control of tumors (155). Vice versa, T cells when gene-
engineered to express chemokine (CXC motif) receptor (CXCR)2 displayed enhanced trafficking 
towards tumor cells secreting the corresponding chemokine ligand CXCL1 (156). Also, in xenograft 
tumor models of mesothelioma and neuroblastoma, the genetic introduction of chemokine (CC 
motif) receptor (CCR)2 in T cells resulted in increased T cell infiltration in tumors secreting CCL2 
and was associated with significantly increased anti-tumor activity (157,158). Other molecules 
often present in the micro-milieu that, when targeted, resulted in enhanced T cell accumulation at 
the tumor site are indoleamine 2,3-dioxygenase (IDO) and reactive nitrogen species. Inhibition of 
TCR ENGINEERED T CELLS MEET NEW CHALLENGES TO TREAT SOLID TUMORS 
 
 
41 
 
 2 
IDO by a small molecule blocks tryptophan depletion, enhances T cell infiltration and delays tumor 
growth (159). Reactive nitrogen species induce TIL unresponsiveness (160), nitration of the TCR 
complex (161) and modification of the chemokine CCL2 (162). Drugs affecting the local production 
of reactive nitrogen species restore TIL function and improve intra-tumoral T cell migration and an 
anti-tumor T cell response (160,162). Taken together, the above studies show the drug-ability of 
molecules that are involved in T cell extravasation and T cell migration into tumor tissues, and 
advocate studies to combine such drugs with adoptive T cell therapy. 
 
Enhance T cell effector functions 
Early protocols of adoptive T cell therapy already demonstrated the beneficial effects of co-
treatments such as chemotherapy, vaccination and/or cytokine support on T cell activation 
(reviewed in (64)). More recently, additional strategies that enhance anti-tumor functions of Teff 
have been reported. A first strategy became apparent from clinical success with additional T cell 
co-stimulation or blocking of T cell co-inhibition (see section 3.2 and Table 1). A second strategy 
relates to the inhibition of T cell suppressive cytokines, such as transforming growth factor (TGF)β. 
For example, genetic introduction of a dominant-negative TGFβ receptor II in TCR-engineered T 
cells resulted in increased anti-tumor T cell responses in a spontaneous tumor model of prostate 
cancer (163). Another study tested the safety of mouse T cells engineered with this dominant-
negative receptor, and could not detect spontaneous proliferation of these T cells in vivo (164). 
Genetic knockdown of negative regulators of T cell activation represents yet another strategy to 
enhance T cell activation. T cells with siRNA-mediated knockdown of casitas B-lineage lymphoma b 
(Cbl-b) displayed a lower threshold for T cell activation and, when adoptively transferred in mice 
with disseminated leukemia, resulted in enhanced anti-tumor effects (165). These latter findings 
warrant further testing of T cells with enhanced T cell activation, including tests that assess the 
safe use of these T cells. 
 
Enhance recruitment and activation of macrophages  
High numbers of macrophages with a tumor-promoting (M2) phenotype, but not those with a 
tumor-inhibiting (M1) phenotype, correlate with poor prognosis for patients with various cancers 
(166). When conjugated to a vascular homing peptide and targeted to tumors, TNFα resulted in a 
switch from M2 to M1 macrophages, which was accompanied by normalization of tumor 
vasculature and enhanced infiltration of CD8 T cells (167). Interestingly, T cells gene-engineered 
to release the cytokine IL-12 were shown to improve the therapeutic efficacy of T cells, an effect 
that is likely mediated by cells of the innate immune system (168,169). T cells that express IL-12 
under the control of the Nuclear Factor of Activated T cell (NFAT) promoter, and deliver IL-12 
locally in the tumor environment upon encounter of cognate antigen, induce destruction of 
antigen-negative cancer cells with a prominent role for monocytes and monocyte-derived TNFα 
(168). Such findings are not necessarily restricted to IL-12 since IL-15, when provided locally into 
tumors, also enhanced the responsiveness of adoptively transferred T cells and facilitated the 
removal of antigen-negative tumor cells (170). 
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2.4.2 Reduce numbers and activity of immune suppressor cells 
Tregs, M2 macrophages and myeloid-derived suppressor cells (MDSC) are among the major 
immune suppressive cell types in the tumor micro-milieu. Immune suppressor cells can reduce T 
cell infiltration into the tumor and suppress local T cell responses by: release of reactive nitrogen 
and oxygen species (171); expression of IDO and arginase (159,172); and production of cytokines 
such as TGFβ, IL-4 and IL-13 (173). Despite initial removal of these cells by administration of 
chemotherapeutic agents, the populations of MDSCs and Tregs may recover at a faster rate than 
CD4 and CD8 Teff (174). Furthermore, Jensen and colleagues demonstrated that therapeutic CD4+ 
T eff can convert into a Foxp3+CD4+ Treg population (175). Various strategies have been reported 
to deplete or inactivate Tregs. These strategies include administration of anti-CD25 antibodies, 
combined intratumoral injection of anti-CTLA4 and OX40 mAbs, or blocking IDO (104,176). 
Interestingly, blocking IDO may induce conversion from Treg to Th17 helper cells, which can 
further contribute to anti-tumor T cell responses (176). With respect to MDSCs, it is of interest to 
note that classical chemotherapeutic agents, such as docetaxel, are able to deplete these cells. 
Docetaxel-mediated depletion of MDSC, when combined with adoptive T cell therapy and dendritic 
cell vaccination, was shown to enhance anti-tumor responses (174). Alternatively, differentiation of  
MDSCs into mature myeloid cells, which can be established upon administration of β-glucans 
(glucose monomers from cell walls), may also provide an angle to relieve immune suppression 
(177). 
 
2.5. FUTURE PERSPECTIVES 
By now, the feasibility of TCR gene therapy studies has been well established by the pioneering 
trials listed in Figure 1B, and is further enhanced by current optimizations and standardizations of 
protocols. TCR gene therapy, alike any cell-based therapy, requires specialized good manufacturing 
practice (GMP) and patient treatment facilities. Such facilities allow the generation and testing of 
virus batches and the gene processing and expansion of T cells, and are already integrated in 
multiple academic and private centers. Notably, parameters, such as time-lines and costs to 
manufacture a therapeutic T cell product, are considered competitive when compared to other 
clinical-grade products, such as antibodies. An ongoing EU project to treat metastatic oesophagus-
gastric cancer and melanoma with NY-ESO1 TCR-engineered T cells, in which we participate, shows 
that time-lines and costs to obtain a T cell product are about two weeks and 36 k€ per patient 
(13.5 k€ for production, quality testing and test runs of virus batch; and 22.5 k€ for T cell 
processing), respectively. For comparison: estimated per patients costs of Ipilimumab (3 mg/kg 
every 3 weeks, 4 times) and Vemurafenib (0.96 g twice daily for 6 months), both registered 
treatments for metastasized melanoma in the Netherlands since 2012, are 84 k€ and 57 k€ 
(Association of Health Insurances (CVZ), the Netherlands). The next step, and allowing a more 
valid comparison, would be the testing of T cell therapy versus standard treatment of care in a 
randomized trial. 
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Clinical testing of TCR-engineered T cells, when looking at single trials, demonstrated impressive 
and unprecedented efficacy but at the same time is hampered by treatment-related toxicity and a 
transient nature of tumor regression (Table 2). There exists a multitude of strategies that are 
developed and tested towards advanced safety and efficacy of TCR gene therapy. Here, we have 
defined three challenges and have categorized recent and successful strategies along these three 
challenges, which have been schematically depicted in Figure 2. With respect to the first challenge, 
i.e., choice for target antigen, an important criterion is minimal or no expression of such an 
antigen by healthy tissues. In this respect, non-shared and tumor-restricted CTAs as well as 
neoantigens should be considered as potentially safe target antigens. Advances in the isolation and 
characterization of anti-tumor T cells from individual patient samples may increase the number of 
CTAs and neoantigens that may qualify as target antigens. T cell-based recognition of similar, but 
unrelated peptides should be excluded, and to this end it is strongly recommended to perform 
stringent in silico analysis and preclinical tests to confirm that cross-reactive antigens are absent in 
healthy tissue. In order to improve patient safety further, measures to allow directed killing of 
engineered T cells have been tested and should be considered, at least for novel TCRs tested in the 
near future. In addition to tumor-restricted expression, another criterion to choose target antigens 
is maximal immunogenicity. Peptide epitopes that are cross-presented or the targeting of a more 
than a single peptide have been reported to induce complete anti-tumor responses, and may 
represent examples to consider when selecting target antigens. 
 
With respect to the second and third challenges, i.e., fitness of T cells and sensitisation of tumor 
micro-milieu, we would like to propose a two-step treatment protocol. The first step represents the 
transfer of fit T cells. T cell fitness involves optimal T cell avidity, additional T cell co-signalling, and 
using T cells with a preferred differentiation stage. T cell avidity can be optimized by enhancement 
of TCR affinity, yet reported treatment-related toxicities warrant caution when using affinity-
enhanced TCRs (Table 2) and recommend further studies to define rules of TCR binding of cognate 
versus non-cognate peptides. With respect to T cell co-signalling, antibodies that block T cell co-
inhibitory molecules and T cells gene-engineered with co-stimulatory receptors have demonstrated 
clinical successes. The implementation of such strategies in T cell therapy protocols holds promise 
for future trials. Also, developments to obtain and gene-modify early differentiation stages of CD8 
T cells, including stem-cell memory CD8 T cells, are at the brim of being translated to a clinical 
setting. Whatever the chosen route, an important measure for T cell fitness in vivo is the ability of 
these cells, whether it be CD8 T cells or certain subsets of CD4 T cells, to produce IFNγ and TNFα. 
The production of these cytokines not only determines T cell responsiveness, but also to what 
extent innate immune cells are recruited into the tumor and become activated to further improve 
an anti-tumor response and potentially avoid tumor relapse. The second step represents 
antagonism of an immune-suppressed milieu. Various strategies, such as antibodies or drugs to 
mediate angiostasis, chemotherapeutic agents to enhance intratumoral T cell infiltration, and local 
(T cell-mediated) delivery of cytokines, have proven beneficial to enhance the local ratio between 
effector and suppressor immune cells. Development of such a two-step protocol, together with the 
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targeting of a selected antigen, is the way forward and expected to further enhance the success 
rate of TCR gene therapy to treat solid tumors. 
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ABSTRACT 
Adoptive T cell therapy has shown significant clinical success for patients with advanced melanoma 
and other tumors. Further development of T cell therapy requires improved strategies to select 
effective, yet non-self-reactive TCRs. Here we isolated ten TCR sequences against four MAGE-C2 
(MC2) epitopes from melanoma patients who showed clinical responses following vaccination that 
were accompanied by significant frequencies of anti-MC2 CD8 T cells in blood and tumor without 
apparent side effects. We introduced these TCRs into T cells, pre-treated tumor cells of different 
histological origins with the epigenetic drugs azacytidine and valproate, and tested tumor and self-
reactivities of these TCRs.  
Pre-treatment of tumor cells up-regulated MC2 gene expression and enhanced recognition by T 
cells. In contrast, a panel of normal cell types did not express MC2 mRNA, and similar pre-
treatment did not result in recognition by MC2-directed T cells. Interestingly, the expression levels 
of MC2, but not those of CD80, CD86, programmed death-ligand 1 (PD-L1), or PD-L2, correlated 
with T cell responsiveness. One of the tested TCRs consistently recognized  pre-treated, MC2-
positive cell lines from melanoma, head-and-neck, bladder and triple-negative breast cancers, but 
showed no response to MHC-eluted peptides nor peptides highly similar to MC2.  
We conclude that targeting MC2 antigen, combined with epigenetic drug-enhanced antigenicity, 
allow for significant and tumor-selective T cell responses.  
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INTRODUCTION 
In recent years, treatment with T cells gene-engineered with T cell receptors (TCRs) has 
demonstrated significant clinical responses in patients with metastatic melanoma, colorectal 
carcinoma, synovial sarcoma and multiple myeloma (1-5). Clinical TCRs tested so far were HLA-A1 
or A2-restricted and directed against the melanocyte differentiation antigens Melanoma-Associated 
Antigen Recognized by T cells (MART)-1, glycoprotein (gp)100, Melanoma-Associated antiGEn 
(MAGE)-A3, New York ESOphageal squamous cell carcinoma (NY-ESO)-1, Carcino-Embryonic 
Antigen (CEA) or p53. Collectively, these trials were performed in a cumulative number of about 80 
patients and demonstrated objective responses ranging from 12 to 67% (1-3,6).  
The use of TCRs directed against antigens that are expressed on tumor cells but also, albeit at a 
lower level, on normal cells led in some cases to severe melanocyte destruction in skin and eyes or 
severe inflammation of the colon (2,3). A lethal event was observed with a patient infused with 
TCR transduced T cells targeting MART-1/HLA-A2 (EAAGIGILTV-epitope) (7). The accompanying 
cytokine release syndrome in combination with semi-acute heart failure and an epileptic seizure 
resulted in the patient’s death. In another study, targeting the cancer-germline gene-encoded 
MAGE-A3/HLA-A2 (KVAELVHFL-epitope) led to neurotoxicity and death of two patients due to the 
anti-MAGE-A3 TCR recognizing shared and highly similar MAGE-A9 and 12 epitopes (6). Also, 
targeting MAGE-A3/HLA-A1 (EVDPIGHLY-epitope) led to cardiotoxicity with fatal outcome in two 
patients (8) due to this TCR recognizing a highly similar peptide from the muscle protein Titin. In 
the latter two trials the TCRs were affinity-enhanced. 
Here we assessed the preclinical value of targeting MAGE-C2 (MC2) antigens with TCRs that were 
patient-derived and that were not affinity-enhanced. We chose MC2 as a target antigen for TCR 
gene therapy for several reasons. First, the MC2 antigen belongs to a subfamily of cancer-germline 
genes encoded by the X chromosome (in more detail described at http://www.cta.lncc.br). It is 
selectively expressed in tumors but not in normal tissue, except for male germline cells (9,10). 
Second, MC2 expression is found in advanced tumors of different histological origins where it is 
associated with poor patient survival (9) and may serve as a predictor for sentinel lymph node 
metastasis (11). Tumor types with significant MC2 expression include metastatic melanomas 
(about 40% at mRNA and protein levels) (9,11), head and neck squamous cell cancers (about 20% 
and 10% at mRNA and protein level respectively) (12,13), ER-negative, invasive ductal breast 
carcinomas (about 30% at protein level) (9,14) or bladder carcinomas (15% at mRNA level) (9). 
Third, MC2 has been shown to contribute to carcinogenesis by suppressing p53-dependent 
apoptosis (15) and inducing epithelial-to-mesenchymal transition (14). Finally, one of its most 
promising features is that MC2-derived antigenic peptides are targeted by T cell responses in a 
fraction of cancer patients, without detectable toxicity (16).  
MC2-derived antigenic peptides include MC2336-344 (ALKDVEERV/HLA-A2, ALK/A2) (17); MC2191-200 
(LLFGLALIEV/A2, LLF/A2) (17); MC2307–315 (SESIKKKVL/B44, SES/B44) (18) and MC242-50 
(ASSTLYLVF/B57, ASS/B57) (19). Even though all 4 peptides have been identified with patient-
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derived T cells (20,21), the ALK and LLF epitopes are of particular interest due to their restriction 
by HLA-A2*0101, the most common MHC class I allele among the Caucasian population. The 
processing of ALK depends on intermediate or immunoproteasomes whereas that of LLF depends 
exclusively on intermediate proteasomes (17,22). Exposure to IFNγ leads to the replacement of 
standard proteasomes by intermediate or immunoproteasomes, and activated intra-tumoral T cells 
secreting IFNγ are expected to increase the surface expression of these two MC2 epitopes 
(17,22,23).  
In this study, we established a panel of ten TCRαβ genes from patient-derived CD8-positive anti-
MC2 T cell clones. T cell clones were obtained from melanoma patients who experienced significant 
clinical responses following vaccinations with MAGE-A1 and/or A3 antigens that were accompanied 
by enhanced frequencies of CD8 MC2-specific T cells in blood, invaded lymph node and regressing 
cutaneous metastases (16,20,21). We sequence-identified these TCR genes and introduced them 
into peripheral T cells and evaluated T cell responses towards tumor cell lines of multiple 
histologies. In addition, we established a pre-treatment regimen consisting of azacytidine (AZA), 
valproate (VPA) and IFNγ, successfully increasing responses of TCR-transduced T cells towards 
MC2-positive tumor lines while maintaining non-responsiveness to MC2-negative cell lines. A large 
panel of normal cell types did not express MC2 mRNA. Notably, one of the tested TCRs consistently 
recognized pre-treated, MC2-positive tumor cell lines, but showed no response to other peptides, 
including those that are highly similar to MC2. We conclude that targeting MAGE-C2, together with 
epigenetic drug treatment of tumor cells, result in safe and effective T cell responses. 
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MATERIALS AND METHODS 
Patient-derived CD8 T cell clones and TCR genes  
We acquired a total of eight CD8 T cell clones (which are listed in table I) from two melanoma 
patients. The first patient EB81 received vaccinations with HLA-A1-restricted MAGE-A3168–176(EVD) 
and MAGE-A1161–169(EAD) epitopes. One year after vaccination, cutaneous metastases had 
disappeared, and patient remained tumor-free for more than 10 years. MC2-specific T cell clones 
were derived by limiting dilution from co-cultures of blood CD8 T cells and autologous tumor cells. 
Several anti-MC2 T cell clones were present in blood and tumors at higher frequencies after 
vaccination (20). In particular, frequencies of the ALK-specific T cell clone 16 increased > 3000-
fold in a regressing cutaneous metastasis and comprised 9% of all CD8+ T cells within an invaded 
lymph node (16). A second melanoma patient, LB2586, received vaccinations with autologous, 
monocyte-derived dendritic cells pulsed with MAGE-A3168–176 (EVD)/HLA-A1 and MAGE-A3243–
258(KKL) /HLA-DP4 peptides. Vaccination led to a mixed clinical response, progressing lesions were 
surgically removed, and patient showed an overall survival of more than five years. The anti-MC2 T 
cell clone CTL A, derived as described above, was found at tumor sites with a >1,000-fold higher 
frequency than in blood. Messenger RNA was obtained from all T cell clones, converted into cDNA, 
and TCR-V encoding regions were amplified according to one of two methods: (1) PCR using either 
a set of sense primers covering all TCR-Vα or β segments according to the ImMunoGeneTics 
(IMGT) database or (2) 5’ RACE PCR primers (SMARTer™ kit Clontech Laboratories, Inc., Mountain 
View, USA), in both cases combined with TCR-Cα or β antisense consensus primers. The 5’ RACE 
PCR was optimized to recover PCR products from low T cell numbers (~10,000 T cells). Initial 
products from either method were re-amplified by nested PCRs and subsequently cloned into the 
TOPO 2.1 vector (Invitrogen) and subjected to DNA sequencing. TCRα and β sequences were 
verified in at least 5 different colonies. Using the IMGT database and the HighV-QUEST tool 
Table I. MC2-specific T cell clones obtained from metastatic melanoma patientsa 
Epitope 
Amino acids 
(MC2 gene) 
Restriction 
element 
Clone name Clone ID Ref. 
ALKDVEERV 336–344 HLA-A2 
EB81-CTL 606 C/22.2 
EB81-CTL 721 C/3.13 
CTL 16 
CTL 40 
(16) 
LLFGLALIEV 191-200 HLA-A2 
EB81-CTL 606 C/19.3 
EB81-CTL 606 C/21.7 
EB81-CTL 606 A/16.2 
EB81-CTL 721 C/3.2 
CTL 4 
CTL 6 
CTL 11 
CTL 41 
(16) 
SESIKKKVL 307-315 HLA-B44 LB2586- CTLA CTL A (21) 
ASSTLYLVF 42-50 HLA-B57 EB81-CTL C/17.3 CTL 1 (16) 
a T cell clones were obtained from melanoma patients who experienced either a complete and durable response 
for more than 10 years following vaccination with MAGE-A1 and A3 (EB81 T cell clones) or a mixed response and 
an overall survival of more than five years following several injections of dendritic cells pulsed with two MAGE-
A3 peptides (LB2586 T cell clone). MC2 T cell clones were derived from co-cultures between peripheral CD8 T 
cells and autologous tumor cells, followed by limiting dilution. See Materials and Methods for details. (HLA= 
human leukocyte antigen; CTL = cytotoxic T-lymphocyte) 
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(http://www.imgt.org), the TCR V, D and J sequences were classified according to the Lefranc 
nomenclature. Next, TCRα- and β genes were codon optimized (GeneArt, Regensburg, Germany) 
and cloned into the pMP71 vector (a kind gift of Prof. Wolfgang Uckert, MDC, Berlin) using a TCRβ-
2A-TCRα cassette via NotI/MluI (TCRβ genes) and MfeI/EcoRI (TCRα genes).  
 
PBMC, packaging cells and reagents 
PBMC from healthy human donors were isolated by centrifugation through Ficoll-Isopaque 
(density=1.077 g/cm3; Amersham Pharmacia Biotech, Uppsala, Sweden). T cells were cultured in 
RPMI 1640 medium supplemented with 25mM HEPES, 200mM L-glutamine, 6% human serum 
(Sanquin, Amsterdam, The Netherlands), antibiotics (‘RPMI complete’) and 360 U/ml recombinant 
human interleukin-2 (IL-2) (Proleukin; Chiron, Amsterdam, The Netherlands), and stimulated 
every 2 weeks with a mixture of irradiated allogeneic feeder cells as described elsewhere (24). 
Packaging cells 293T and Phoenix-Ampho were cultured in DMEM supplemented with L-glutamine, 
10% FBS, nonessential amino acids, and antibiotics (DMEM complete). 
Additional reagents included the HLA-A2-binding peptides MC2336–344 (ALKDVEERV), MC2191-200
 
(LLFGLALIEV), MAGE-B4 (MB4)160-169(LVFGLALKEV), MAGE-B10 (MB10)162-171 (LIFGLDLKEV) (all 
from Eurogentec, Maastricht, The Netherlands); a library of 114 known HLA-A2-restricted self-
peptides, previously  described here: (6,25) (a kind gift by Dr. Matthias Obenaus, MDC, Berlin, 
Germany; originally established by Stefan Stevanovic and Hans-Georg Rammensee, University of 
Tübingen, Tübingen, Germany), human IFNγ (Peprotech, Rocky Hill, NJ, USA), 5’-azacytidine 
(AZA; Sigma Aldrich, St. Louis, USA), and valproic acid (VPA; Sigma Aldrich). For flow cytometry, 
the following monoclonal antibodies and peptide:MHC (pMHC) reagents were used: TCR-Vβ28-FITC 
(Beckman Coulter, Marseille, France); CD3-PerCP; CD8-APC; CD107a-PE; BB7.2-PE (all BD 
Biosciences, San Jose, CA); and PE-labeled pMHC multimers (dextramers; Immudex, København, 
Denmark).  
 
T cell transduction 
PBMC of healthy donors were activated with anti-CD3 mAb OKT3 and transduced with TCR-
encoding retroviruses (TCR T cells) or empty retroviruses (mock T cells) that were produced by a 
co-culture of 293T and Phoenix-Ampho packaging cells as described earlier (26,27). 
 
Tumor cell lines and pre-treatment regimens 
Melanoma, head-and-neck squamous cell carcinoma (HNSCC) and bladder carcinoma cell lines 
were cultured in DMEM complete, while triple-negative-breast-cancer (TNBC) and and esophageal 
cancer cell lines were cultured in RPMI 1640, L-glutamine, 10% FBS, and antibiotics. Melanoma cell 
lines: EB81-MEL derived from patient EB81 (MC2+ (determined by PCR), HLA-A2+ (A2+,determined 
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by PCR and flow cytometry); MEL78 (MC2+, A2+); MEL624 (MC2+, A2+); 518-A2 (MC2+, A2+); 607-
B (MC2+, A2+); and MZ2-MEL (MC2-, HLA-A2-). HNSCC cell lines: SCC9 (MC2+, A2+); SCC38 
(MC2+, A2+); 93VU120 (MC2+, A2+); and SCC14C (MC2-, A2-) (kind gifts by Profs. Ruud Brakenhof, 
VUMC, Amsterdam and Tom Ottenhof, LUMC, Leiden). TNBC cell lines: MDA-MB157 (MC2+, A2+); 
Sum159PT (MC2+, A2+); Sum225CWN (MC2+, A2+); and HCC1806 (MC2+, A2-). Bladder carcinoma 
cell lines: 1207 (MC2+, A2+); J82 (MC2+, A2+); and T24 (MC2+, A2-). Oesophageal carcinoma cell 
line: OEC-19 (MC2-, MB4+, A2+). Tumor cells were, prior to their use in T cells assays, either not 
treated, treated with human recombinant IFNγ (50 pg/ml for 48h) or treated with a combination of 
AZA (1µM for 72h), VPA (1mM for 48h following AZA treatment) and IFNγ (50pg/ml for 48h 
simultaneously with VPA).  
 
Gene expression of MC2 antigen and T cell co-signalling ligands 
Messenger RNA was obtained from tumor cell lines, reverse-transcribed and RT-PCR was 
performed to assess gene expression levels of MC2, in some cases MB4, HLA-A2, CD80, CD86, 
programmed death-ligand 1 and 2 (PD-L1, PD-L2) and GAPDH (primer sequences available upon 
request). PCR products were subjected to gel electrophoresis, after which intensities of products 
were quantified by densitometry (Quantity One v4.6.7 software), corrected for background noise 
and standardized for GAPDH intensities. For quantification of MC2 mRNA in healthy human tissues, 
qPCRs were conducted with a normal human tissue cDNA panel (OriGene Technologies, Rockville, 
USA) and primers and Taqman probes for MC2 (Gene ID: 51438) and GAPDH (Gene ID: 2597) 
(Life Technologies, Carlsbad, USA). 
 
T cell IFNγ production  
Transduced T cells (6×104/well of a 96-wellsplate) were co-cultured with either T2 cells (LCLxT 
lymphoblastoid hybrid cell line 0.1743CEM.T2) or tumor cells (2×104/well) in a total volume of 200 
µl of T cell assay medium (RPMI 1640, L-glutamine, 10% FBS, and antibiotics) for 24h at 37°C and 
5% CO2. T2 cells were pulsed with saturating (1 or 10µM) or titrated amounts (typically ranging 
from 1pM to 1µM) of MC2, MB4, MB10 peptides (the latter two found by NCBI Blast homology 
searches), or a panel of different peptides commonly restricted by HLA-A2 (list of contained 
peptides available upon request). Subsequently, supernatants were harvested and IFNγ levels 
were determined by standard ELISA (eBioscience, San Diego, USA). For TCR 6, half maximal 
effective concentrations of MC2 or MB4 peptides (EC50) required for T cell IFNγ production were 
calculated using trend line approximations (R2 ≥ 0.96). 
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Flow cytometry 
Transduced T cells or tumor cells (5×105) were washed with PBS and incubated with antibodies at 
4°C or with pMHC multimers at 37°C for 30min. Following staining, cells were washed with PBS 
and fixed with 1% paraformaldehyde. Events were acquired on a FACS Canto flow cytometer and 
analysed using FCS Express 4 software (BD Biosciences).  
For CD107a stainings, T cells (2×105/well of 96-wellsplate) were co-cultured with either T2 cells 
(2×104/well) or tumor cells (4×104/well) in a total volume of 100μl of T cell assay medium for 2-4h 
at 37°C and 5% CO2 in the presence of CD107a-PE antibody. After incubation, cells were 
harvested, stained with CD3-PerCP and CD8-APC antibodies, measured, and analysed for CD107a 
expression within CD3, CD8-positive T cells.  
For pMHC titrations, cultured T cells were stained with CD8-APC antibody and titrated amounts of  
PE-labeled pMHC multimers. In order to determine pMHC concentrations required to achieve half 
maximal binding, results were analysed using GraphPad Prism to determine EC50 values.  
 
Formation of surface-expressed peptide:MHC class I 
Assays to determine the stability of MC2 peptides:HLA-A2 complexes were performed as described 
elsewhere (28). In short, T2 cells (1x106/well of a 96-wellsplate) were incubated and loaded with 
titrated amounts of peptide in serum-free AIM V medium at 26°C for 14–16h, and then at 37°C for 
another 2h before staining for HLA-A*0201 surface expression with BB7.2-PE mAb. Events were 
acquired on a FACS Canto flow cytometer and analyzed using FlowJo software (TreeStar, Ashland, 
OR). Cells were gated for viability and data are presented as Mean Fluorescence Intensities (MFI) 
for different peptide concentrations.  
 
Statistical analysis 
Responses of TCR T cells towards MC2-positive versus MC2-negative tumor cell lines were 
corrected for responses of mock T cells and tested using one-tailed, unpaired Student’s t-tests. 
Correlations between T cell IFNγ response and gene expressions of MC2, HLA-A2, and co-
stimulatory and co-inhibitory molecules were calculated using Pearson’s correlation coefficients. 
Differences were considered statistically significant when p-values were <0.05. 
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RESULTS 
Patient-derived MC2-specific TCRs mediate T cell recognition of cognate epitopes with 
varying avidities 
We obtained TCRα and β genes from 8 patient-derived, MC2-specific T cell clones from two 
melanoma patients who experienced durable clinical responses after vaccination therapy 
(16,20,21). T cell clones 
were directed against the 
ALK/A2, LLF/A2, 
ASS/B57 or SES/B44 
epitopes (see table I), 
and with use of TCR-V-
specific PCR techniques 
we obtained 10 pairs of 
TCRα- and β sequences 
(see table II). Two clones 
(Cytotoxic T lymphocyte 
(CTL) 41 and CTL A) 
expressed two 
rearranged TCRα 
sequences, most likely as 
a result of incomplete 
allelic exclusion. T cells 
from healthy donors were 
transduced with pairs of 
TCRα and β genes and 
assessed for TCR surface 
expression and binding of 
pMHC multimers by flow 
cytometry. Focussing on 
HLA-A2-restricted TCRs, 
we observed that 
transductions with TCR 
16 (ALK) as well as TCR 
4, 6 and 11 (LLF) yielded 
populations of T cells that 
significantly bound cognate pMHC multimers (see supplementary figure 1). Transductions with 
TCRs 40, 41-I and 41-II yielded populations of T cells that showed no or very limited staining with  
Table  II. Sequence identification and gene classification of MC2-specific 
and patient-derived TCRsa 
Clone Epitope HLA- 
TCR 
chain 
V-GENE J (D)-GENE TCR 
              
EB81-CTL 16 ALKDVEERV A2 
α Vα3*01 Jα3*01 
TCR 16b 
β Vß28*01 Jß2-5*01 
EB81-CTL 40 ALKDVEERV A2 
α Vα13-1*02 Jα3*01 
TCR 40 
β Vß28*01 Jß2-5*01 
EB81-CTL 4 LLFGLALIEV A2 
α Vα12-2*01 Jα31*01 
TCR 4 
β Vß7-9*01 Jß2-1*01 
EB81-CTL 6 LLFGLALIEV A2 
α Vα12-2*01 Jα23*01 
TCR 6 
β Vß15*02 Jß2-3*01 
EB81-CTL 11 LLFGLALIEV A2 
α Vα14/DV4*01 Jα41*01 
TCR 11 
β Vß9*01 Jß2-7*01 
EB81-CTL 41 LLFGLALIEV A2 
α
1
 Vα8-1*01 Jα28*01 TCR 41 – I 
  
TCR 41 - II 
α
2
 Vα22*01   
β Vß9*01 Jß1-2*01 
EB81-CTL 1 ASSTLYLVF B52 
α Vα41*01  Jα54*01  
TCR 1 
β Vß7-2*04 Jß2-7*01 
LB2586-CTL A SESIKKKVL B44 
α
1
 Vα12-3*01 Jα13*01 
TCR A -I 
  
TCR A -II 
α
2
 Vα9-2*02 Jα37*01 
β Vß19*01 
Jß1-4*01 
(Dβ1*01) 
a cDNAs derived from T cell clones were PCR amplified using either a set of TCR-Vα or Vβ 
sense primers and a corresponding TCR-Cα or Cβ antisense primer or 5’RACE (rapid 
amplification of cDNA ends). Following nested PCRs and cloning, TCRα and β sequences were 
identified using www.imgt.org and classified according to the Lefranc nomenclature. See 
Materials and Methods for details. (HLA= human leukocyte antigen; CTL = cytotoxic T-
lymphocyte; TCR = T cell receptor; V= variable gene segment; J= joining gene segment; D= 
diversity gene segment). 
b underlined TCRs were surface expressed and demonstrated binding to pMHC complexes upon 
gene transfer into primary human T cells 
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Figure 1. MC2 TCR T cells bind pMHC and produce IFNγ in response to cognate epitope. 
T cells were transduced with anti-MC2 TCRs 4, 6, 11, 16 or not (mock) and FACSorted with the corresponding 
pMHC multimers. (A) TCR-transduced and sorted T cell populations were labeled with ALK:A2-PE (TCR 16) or 
LLF:A2-PE (TCR 4, TCR 6, TCR11). T cells were gated for live cells and dot plots are representative of 5 different 
experiments in two different donors. Percentages in upper right quadrants represent fractions of T cells stained 
by pMHC corrected for background stainings of corresponding mock T cells. (B) T cells from (A) were co-cultured 
with T2 cells pulsed with 1µM of ALK (for TCR 16) or LLF (for TCR 4, 6 and 11) peptide for 24h. IFNγ levels in 
culture supernatants were measured by ELISA, and displayed as mean ±SEM (n=4 experiments). IFNγ levels 
B 
A 
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from mock T cells and T cells incubated with unpulsed T2 cells ranged between 3 and 80 pg/ml. Data are from 
one healthy donor out of two tested with similar results. 
pMHC multimers (~1%). This was not the result of compromised TCR gene transductions since 
TCR-Vβ28-antibody staining of T cells transduced with TCR 40 (same Vβ-chain as TCR 16) revealed 
clear surface expression of the introduced TCRβ chain (data not shown). For subsequent 
experiments, we FACS-sorted TCR-transduced T cells and obtained T cell populations with a high 
(>70%) and stable binding of pMHC (figure 1A) with the exception of TCR 11 T cells, which 
gradually lost pMHC binding capacity over time (data not shown). 
To test TCR functions, transduced T cells were co-cultured with T2 cells pulsed with a saturating 
dose (1µM) of ALK (TCR 16) or LLF (TCR 4, 6 and 11) peptides. TCR-transduced but not mock T 
cells clearly produced IFNγ upon stimulation with peptide-loaded cells, with TCR 11 T cells 
producing lower amounts of IFNγ than T cells transduced with the other TCRs (figure 1B). With 
respect to T cell degranulation, findings were similar and TCR (but not mock) T cells up-regulated 
surface expression of CD107a upon stimulation with peptide-loaded cells. Again, T cells expressing 
TCR11 were the least responsive population (see supplementary figure 2A). 
In addition to an initial test of T cell function, we have conducted pMHC titrations as a measure of 
T cell avidity. These studies demonstrated that TCRs can be ranked from low to high EC50 to bind 
pMHC by CD8 T cells, as follows: TCR4<TCR6<TCR11/16 (figure 2A). When analyzing CD4 T cell 
populations, findings were similar but demonstrated that TCR11 and in particular TCR16 showed a 
significant drop in their abilities to bind pMHC (figure 2B). The observed hierarchy in T cell avidity, 
and in particular the CD8 dependence of TCR16, corresponded to the abilities of these T cells to 
up-regulate CD107a expression (see supplementary figure 2A). 
 
Pre-treating melanoma cells with epigenetic drugs and IFNγ increases MC2 gene 
expression and T cell stimulation 
Next, we tested T cell reactivities towards MC2-positive melanoma cell lines. As ALK and LLF 
peptides require processing by immune (ALK) or intermediate (ALK and LLF) proteasomes rather 
than standard proteasomes (22), we pre-treated melanoma cells with IFNγ to induce the 
expression of immune proteasome catalytic subunits. TCR T cells did not produce levels of IFNγ 
that exceed those of mock T cells when stimulated with untreated melanoma cells and exhibited 
weak to moderate IFNγ production after stimulation by IFNγ-pre-treated melanoma cells, in 
particular the EB81-MEL and 607B cell lines (figures 3A and B). In order to enhance the level of 
MC2 T cell responses, we resorted to an additional treatment with azacytidine (AZA) and valproate 
(VPA) for its reported effect on the expression of MAGE  antigens in cancer cells and their 
recognition by T cells in preclinical and clinical studies (29-35). AZA is a DNA methyl transferase 
inhibitor that allows expression of genes that are silenced through the demethylation of CpG 
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islands in promotor regions. VPA is a histone deacetylase inhibitor that blocks histone 
deacetylation, thereby relieving chromatin condensation and increasing gene expression. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. MC2 TCRs provide T cells with different avidities for MC2 peptide:HLA-A2 complexes 
For pMHC multimer titrations, MC2 TCR T cells were stained with either CD8-APC (A) or CD4-FITC (B) antibody 
and different concentrations of ALK:A2-PE (TCR 16) or LLF:A2-PE (TCR 4, TCR 6, TCR11). Maximal percentages 
of T cells that bound pMHC multimer were set at 100% and resulting curves and EC50 values were analyzed using 
GraphPad Prism (CD8: TCR 4 = 2.26x10-7M, TCR 6 = 3.48x10-7M,  TCR 11 = 6.67x10-7M,  TCR 16 = 6.63x10-7M; 
A 
B 
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CD4: TCR 4 = 3.16x10-7M, TCR 6 = 5.01x10-7M,  TCR 11 = 1.7x10-6M,  EC50  for TCR 16 could not be 
determined). Data are displayed as mean±SEM, n=3. 
 
Figure 3. T cell recognition of MC2-positive melanoma cells is limited. 
MC2 TCR T cells were co-cultured with tumor cells that were either positive or negative for MC2 (based on RT-
PCR data, indicated as ‘+’ or ‘-‘) at an E:T ratio of 3:1 for 24h. Melanoma cells were either untreated (A) or pre-
treated with human IFNγ (50pg/ml for 48h) (B). Levels of IFNγ produced by T cells in culture supernatants were 
measured by ELISA, and are displayed as means±SEM (n=3). IFNγ production by MC2 TCR T cells was corrected 
for IFNγ production by mock T cells (same donor and tumor cell line); IFNγ levels produced by mock T cells 
ranged between 10 and 95pg/ml. Data are from one healthy donor out of two tested with similar results. 
Statistical significant differences between responses of TCR T cells towards MC2+ versus MC2- target cells are 
calculated with Student’s t-test: *p<0.05 (below bars). 
 
 
 
Timing and dosage of AZA and VPA are based on the work of Goodyear and colleagues (29). We 
tested a combination of IFNγ, AZA and VPA on 6 melanoma lines, the non-cancerous keratinocyte 
cell line HaCaT and primary fibroblasts. Figure 4A shows that upon treatment with AZA/VPA/IFNγ, 
MC2 gene expression is up-regulated in 4 out of 6 tumor cell lines, but notably not in the non-
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cancerous cells. Treatment variably regulates gene expression of HLA-A2, which is only up-
regulated in 2 out of 6 melanoma lines. In addition, we assessed MC2 protein expression in pre-
treated tumor cells via flow cytometry using the antibody LX CT10.9 that has previously been 
validated for immune histochemistry (36). Stainings confirmed PCR data and demonstrated up-
regulated MC2 protein expression following AZA/VPA/IFNγ treatment (data not shown). Finally, 
melanoma and normal cells were tested for their ability to stimulate the production of IFNγ or up-
regulation of surface CD107a by MC2 TCR T cells (figure 4B and supplementary figure 2B). All 
tested MC2-positive melanoma lines stimulated two or more of the tested TCRs. These data 
demonstrate that melanoma cells, but not normal cells, exhibit improved recognition by MC2 TCR T 
cells following treatment with AZA/VPA/IFNγ. 
 
T cells directed against MC2 show significant responses against head and neck, breast 
and bladder cancer cells following pre-treatment with AZA/VPA/IFNγ 
To extend our results to non-melanoma tumor cell lines, we explored the gene expression of MC2 
and HLA-A2 in head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer 
(TNBC) and bladder carcinoma cell lines. As shown in Figure 4C, MC2 gene expression was up-
regulated in the majority of tumor cell lines following treatment (9 out of 11, with the exception of 
the TNBC cell lines MDA157MB and Sum159PT), and HLA-A2 gene expression was up-regulated to 
a more variable extent in tumor cell lines following treatment (6 out of 11, with the exception of 
the HNSCC cell line SCC 14C; the TNBC cell lines MDA157MB and HCC1806 and the bladder cancer 
cell lines J82 and T24). Importantly, treatment of HNSCC, TNBC and bladder carcinoma cell lines 
clearly resulted in an enhancement of IFNγ production (figure 4D) and up-regulation of CD107a 
(data not shown) by MC2 TCR T cells. All MC2-positive tumor cell lines tested yielded a significant 
response by at least one of the tested TCRs. As was observed for melanomas, AZA/VPA was 
required in addition to the IFNγ pre-treatment to maximize MC2-specific T cell responses. 
 
Figure 4. Treatment of melanoma, head-and-neck, bladder and breast carcinoma cells with AZA and 
VPA enhances MC2 gene expression and T cell recognition. 
(A) Melanoma cell lines (n=6), HaCaT keratinocytes, and fibroblasts (Fibrobl.) were pre-treated or not with AZA 
(1µM for 72h), VPA (1mM for 48h) and IFNγ (50pg/ml for 48h). RNA was isolated from 1x106 cells, followed by 
cDNA synthesis and RT-PCR with primers for detection of MC2, HLA-A2 and GAPDH transcripts. PCR products 
were subjected to gel electrophoresis, and intensities of MC2 and HLA-A2 bands were quantified by Quantity One 
(version 4.6.7), corrected for background noise and standardized for GAPDH levels, and displayed in relative 
intensity units/mm2. In (B) MC2 TCR T cells were co-cultured with pre-treated melanoma cells from (A) at an E:T 
ratio of 3:1 for 24h. IFNγ levels in culture supernatants were measured by ELISA, and displayed as means±SEM 
(n=5). IFNγ production by MC2 TCR T cells was corrected for IFNγ production by mock T cells; IFNγ levels 
produced by mock T cells ranged between 2 and 300pg/ml. (C) Cell lines from head-and-neck squamous cell 
carcinoma (HNSCC) (n=4), triple-negative breast carcinoma (TNBC) (n=4) and bladder carcinoma (n=3) were 
pre-treated as described in (A). RNA was isolated, used for RT-PCR and subjected to analysis of MC2 and HLA-A2 
expression. (D) MC2 TCR T cells were co-cultured with pre-treated tumor cell lines from (C) and analysed for 
IFNγ production as described in (B). IFNγ production of mock T cells ranged between 9 and 180pg/ml. Data are 
from one healthy donor out of two tested with similar results. Statistical significant differences between 
responses of TCR T cells towards MC2+ versus MC2- target cells are calculated with Student’s t-test: *p<0.05; 
**p<0.005 (below bars). 
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MC2 T cell responses are governed by expression level of antigen, but not expression of 
co-stimulatory or co-inhibitory molecules 
Even though pre-treatment of target cells elicited enhanced responses of MC2 TCR T cells, such T 
cell responses were heterogeneous with respect to different TCRs and different tumor target cells. 
In an effort to better understand this heterogeneity, we first assessed the relationship between 
individual TCR and T cell IFNγ responses. When analysing the breadth of T cell responses, TCR 6 
was the only TCR able to mediate a T cell response against all MC2/A2-positive tumor cell lines 
tested, irrespective of the tumor type (100% response, n=13 tumor cell lines), whereas TCR 4 and 
16 mediated T cell responses against 50% of these target cells, and TCR 11 only against 15% of 
them (figure 5A). Notably, TCR 6 mediated T cell responses against all four tumor types, yet TCR 4 
and 16 demonstrated a preference towards melanomas and TCR 11 against HNSCCs and bladder 
carcinomas (figure 5A). In addition to the breadth of response, we also analysed the quantities of 
IFNγ produced, which again were highest for T cells expressing TCR 6 (median IFNγ 
production=267pg/ml), lower for T cells expressing TCR 16 and TCR 4 (156 and 136pg/ml, 
respectively), and lowest for T cells expressing TCR 11 (97pg/ml) (figure 5B). Interestingly, the 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MC2 TCR 6 performs best with respect to tumor cell recognition.  
Breadth (A) and intensity (B) of T cell responses of each TCR were quantified based on the results shown in 
figures 4A and 4D. Panel (A) shows the proportions of tumor lines, out of a total of 13, that resulted in significant 
IFNγ production by TCR-transduced T cells; maximal contribution by each individual tumor type was set to 25% 
(melanoma: 5 cell lines; HNSCC: 3 cell lines; TNBC: 3 cell lines; bladder carcinoma: 2 cell lines). Panel (B) 
shows the levels of IFNγ produced by TCR-transduced T cells following co-culture with tumor lines 
(p<0.05=black; p>0.05=grey). The median production per TCR is indicated as a black bar (n=5 experiments; 13 
tumor lines per experiment).  
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highest quantities of IFNγ were found with melanoma target cells, followed by bladder carcinoma 
cell lines and then followed by HNSCC and TNBC lines. Collectively, these findings favour TCR 6, a 
TCR that provides T cells with intermediate to high avidity (figure 2), with respect to MC2-specific 
anti-tumor T cell responses. Secondly, we assessed the impact of the expression of genes coding 
for surface molecules critical for T cell stimulation, such as the MC2 antigen, HLA-A2, the co-
stimulatory molecules CD80 and CD86, and the co-inhibitory molecules PD-L1 and PD-L2. CD80 
and CD86, which were not or only negligibly expressed in tumor or normal cell lines, showed no 
change following AZA/VPA/IFNγ pre-treatment, whereas expressions of PD-L1 and PD-L2 were 
increased in some cell lines following pre-treatment (see figure 6A). This argues that 
AZA/VPA/IFNγ treatment does not generally enhance gene expression, but that the effect is 
restricted to genes such as the cancer germline gene MC2. Testing whether T cell responses 
depended on the expression levels of any of these genes, a significant correlation was only 
observed with expression levels of MC2 and not with any of the other investigated molecules (see 
figure 6B, shown for TCR 6 T cells, but observed for all TCRs, not shown). When categorizing 
tumor types according to the levels of MC2 expression, it appears that melanoma cells expressed 
the highest levels, followed sequentially by bladder carcinoma, TNBC and HNSCC (figure 6B). This 
result most likely explains the earlier observation that melanoma cells stimulated the highest T cell 
responses and warrants the use of pre-treatment of tumor cells to enhance MC2-specific T cell 
responses. 
 
TCR 6 shows no on-target or off-target toxicity in vitro 
To exclude possible on- and off-target toxicities, thereby enhancing the potential clinical value of 
MC2 TCRs, we have conducted a series of assays. First, qPCRs were performed for MC2 gene 
expression using a library of 48 human tissues, and revealed that the only tissue positive for MC2 
gene expression was testis (figure 7A) where expression was 51-fold lower than within our positive 
control, the EB81-MEL cell line. Spiking experiments demonstrated a sensitivity of these MC2-
specific qPCRs of 1 MC2-positive cell in 103 MC2-negative cells. Second, T cells transduced with 
TCR 6, the TCR that scored best according to our in vitro experiments, were co-cultured with T2 
cells loaded with HLA-A2-eluted self-peptides. These T cell stimulations demonstrated no cross-
recognition of TCR 6 against any of these peptides, with the only noticeable recognition being the 
one against the MC2 peptide (figure 7B). Thirdly, TCR 6-transduced T cells were co-cultured with 
the MAGE-B4 (MB4) peptide LVFGLALKEV and the MAGE-B10 (MB10) peptide LIFGLDLKEV that are 
both highly homologous to the MC2 peptide LLFGLALIEV according to NCBI blast searches (amino 
acids different from the MC LLF peptide being underlined). TCR 6 T cells were found to show some 
response to MB4 peptide, about 15% of the response seen against MC2 LLF peptide, but not to the 
MB10 peptide. Further titrations with MB4 peptide revealed that this peptide shows a higher EC50 
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Figure 6. Expression of MC2 antigen, but not HLA-A2, co-stimulatory or co-inhibitory molecules, 
correlates with T cell response. 
Cell lines from Melanoma, HNSCC, TNBC, bladder carcinoma and keratinocytes (HaCaT) and fibroblasts (Fibrobl.) 
were pre-treated or not with AZA, VPA and human IFNγ as described in legend to figure 4. In (A) RNA was 
isolated, used for RT-PCR and subjected to analysis of CD80, CD86, PD-L1, PD-L2 expression as described in 
legend to figure 4A. In (B) IFNγ response of TCR 6-transduced T cells is presented as a function of MC2 
expression of pre-treated tumor cell lines of different histologies (left side). Ranges of MC2 expression levels per 
tumor type are indicated above the trend line (mean±SEM, n=4). In addition, IFNγ response of TCR 6-
transduced T cells is presented as a function of either HLA-A2, CD80, CD86, PD-L1 or PD-L2 expression of pre-
treated tumor cell lines (right-side). Calculations are based on Pearson’s correlation coefficient. +++ = very 
strong effect (>75% of tested cell lines), ++ = strong effect (>50% of tested cell lines),  -/+ = low effect (>5% 
of tested cell lines), - = no effect (<5% of tested cell lines). 
 
 
value than the MC2 LLF peptide. Importantly, TCR 6-transduced T cells did not recognize target 
cells, such as the oesophageal cancer cell line OEC-19, expressing native MB4 (figures 7C, D and 
E). Collectively, these results provide clear evidence against risks for on- or off-target reactivities 
when targeting MC2 via TCR 6.  
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Figure 7. MC2 expression in healthy tissue is restricted to testis, and TCR 6 shows no reactivity to 
other, including highly similar epitopes. 
(A) MC2-specific qPCR was performed using a cDNA library of 48 healthy, human tissue samples. MC2 mRNA 
levels are expressed as -fold increase compared to testis, the only healthy sample positive for MC2 mRNA. Fold 
increase was calculated based on the ΔΔCt method and normalized for GAPH expression. Patient-derived MC2-
positive melanoma cell line EB81-MEL served as positive control. (B) TCR 6 T cells were co-cultured with T2 cells 
loaded with 10µM of 114 different HLA-A2-restricted peptides for 24h. IFNγ levels in culture supernatants were 
measured by ELISA, and displayed as mean (n=3). IFNγ response against the MC2 LLF peptide (positive control) 
is depicted as a triangle, and against no peptide (T2 cells only; negative control) is depicted as a hollow circle. 
(C) TCR 6 T cells were co-cultured with T2 cells loaded with 100nM of highly similar peptides of MB4 
(LVFGLALKEV) and MB10 (LIFGLDLKEV) (amino acids different from the MC LLF peptide being underlined). IFNγ 
levels in culture supernatants were measured by ELISA, and are displayed as mean±SEM (n=4). IFNγ response 
against the MC2 LLF peptide served as a positive control. (D) Again, TCR 6 T cells were co-cultured with T2 cells 
but now with titrated amounts of MB4 and MC2 LLF peptide for 24h. IFNγ levels in culture supernatants were 
measured by ELISA, and displayed as mean±SEM, (n=4). Curves and EC50 values were analyzed using GraphPad 
Prism (EC50 for MC2: 3.1x10
-9M; EC50 for MB4: 7.15x10
-9M). (E) Finally, TCR 6 T cells were co-cultured with 
either EB81-MEL (MC2+/MB4-/A2+), OEC-19  (MC2-/MB4+/A2+) or T2 (MC2-/MB4-/A2+) tumor cells. Expression of 
MC2, MB4 and HLA-A2 was verified or ruled out via RT-PCR. IFNγ levels in culture supernatants were measured 
after 24h by ELISA, and are displayed as mean±SEM (n=4). IFNγ production by TCR 6  T cells was corrected for 
IFNγ production by mock T cells; IFNγ levels produced by mock T cells ranged between 5 and 13pg/ml. 
  
CHAPTER 3 
 
78 
  
DISCUSSION 
In this study, we tested the preclinical value of targeting MC2 epitopes with patient-derived and 
non-affinity-enhanced TCRs, in particular TCRs specific for the HLA-A2-restricted epitopes ALK and 
LLF. When studying HLA-A2-restricted TCRs, we observed that 3 TCRs (out of 7) did not enable 
transduced T cells to bind pMHC. T cells expressing the other 4 TCRs (TCR 4, 6, 11 and 16) were 
used to determine EC50 values for their binding of pMHC-multimers (figure 2). These TCRs yielded 
T cells with varying T cell avidities towards pMHC, and when analyzing CD8 T cells and in particular 
CD4 T cells, we observed that TCR 16 and 11 mediated the weakest, TCR 6 an intermediate, and 
TCR 4 the strongest binding of pMHC. The observed variation among TCRs, however, is in line with 
reported T cell avidities of the parental CTL clones obtained from patient EB81 (17). In example, 
CTL 16 as well as our TCR 16-transduced T cells exhibited lowest avidity amongst the tested CD8 T 
cell clones, while this CTL clone was present at the highest frequencies in patient blood and an 
invaded lymph node (16). This suggests that high affinity of a TCR is not a pre-requisite for 
effective in vivo stimulation by naturally presented tumor antigens (37,38). Other reasons for 
differences of pMHC binding, apart from TCR affinity, may include that certain TCRs show 
enhanced proneness to mispair with endogenous TCR chains, which results in dilution of surface 
TCR expression (39), and that certain TCRs are less dominant with respect to CD3 assembly and 
surface expression (40). To minimize the occurrence of TCR mis-pairing, we have introduced TCRs 
into the pMP71 vector using a TCRβ-2A-TCRα cassette. Nevertheless, TCR mis-pairing cannot be 
completely excluded. Although not a primary topic of the current manuscript, we have explored 
additional strategies to limit TCR mis- -CD28 
cassette (41) into TCR 16 maximally enhances the fraction of pMHC-binding T cells (data not 
shown). 
Within the panel of LLF-specific TCRs, our results suggest that TCR 11 has the lowest ligand-
binding affinity, which is substantiated by two other lines of evidence. First, this TCR mediates the 
lowest level of IFNγ production in response to MC2/A2-positive tumor cell lines (see figure 6A/B), 
and secondly, this TCR mediates the lowest rate of proliferation as well as most rapid drop in 
numbers of TCR-positive T cells during culture of T cells (data not shown). In addition, TCR 11-
transduced T cells have a lowered ability to produce high levels (i.e., plateau levels) of peptide-
specific IFNγ when compared to TCR 4 or 6-transduced T cells (Figure 1B). TCR 11’s lower level of 
performance may be related to a lesser ability to serially trigger T cells (42) or to an enhanced 
ability to up-regulate expression of T cell PD1 (43), although we could not confirm the latter option 
experimentally (data not shown).  
When testing MC2 TCRs towards melanoma tumor targets, whether or not pre-treated with IFNγ to 
stimulate immune and intermediate proteasome-dependent processing of the ALK and LLF epitopes 
(17,22), we observed limited T cell responses (figure 3; and (26)). Pre-treatment of melanoma 
cells was extended with the epigenetic drugs AZA and VPA, which resulted in selective gene and 
protein expression of MC2 in tumor cells, but not normal cells, and enhanced T-cell 
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responsiveness. Importantly, we observed similar findings in multiple tumor types, including 
HNSCC, TNBC and bladder carcinoma. These results extend earlier studies that showed enhanced 
gene expression of NY-ESO1, MAGE-A1 and MAGE-A3 in cancer cell lines pre-treated with 
epigenetic drugs, but not in normal respiratory epithelia or lymphocytes (31,33,44). Interestingly, 
in our experiments different tumor cells responded differently to pre-treatment. For example, 
melanoma cell lines revealed a base level of MC2 expression that was further enhanced by 
AZA/VPA, whereas HNSCC cell lines only expressed MC2 following pre-treatment (figure 4C). Since 
earlier studies reported a MC2-positivity of only 8% of primary HNSCC (13), the above finding 
highlights the potential to increase patient populations eligible for MC2-specific T cell therapy when 
combined with epigenetic drug pre-treatment. Moreover, there is a timely notion that epigenetic 
drugs sensitize tumors to T cells, which goes beyond enhanced gene expression of target antigens 
(45,46). In example, epigenetic drugs have been reported to induce interferon type I gene and 
related genes, which can contribute to tumor immunogenicity (47), and these drugs are able to 
enhance expression of chemoattractants, increase CD8 T cell infiltration, and improve the 
therapeutic efficacy of adoptive T cell therapy (48). 
Our results with respect to drug-enhanced expression of MC2 by tumor cells are of particular 
interest to clinical trials with adoptive transfer of T cells since AZA and VPA already have been 
shown to be safe in patients with advanced hematological and solid malignancies (29,49-53). The 
selective effects of pre-treatment towards cancer cells versus normal cells may be related to an 
initiating event in the de-regulation of cancer-germline gene expression, which is the recruitment 
of the transcription factor BORIS (brother of the regulator of imprinted sites) to cancer-germline 
promotors. De-repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincides with DNA de-
methylation, dissociation of polycomb proteins, and presence of euchromatin marks within the 
respective promoters, a.o., a shift to BORIS at the cancer-germline promotor site (44). BORIS is a 
mammalian CCCTC-binding factor (CTCF)-paralog that is absent in normal cells, which prevents 
binding and function of CTCF and results in the opening and activation of DNA chromatin (54,55).  
Pre-treatment of tumor cells results in significantly enhanced responses of MC2 TCR T cells, 
although such responses are heterogeneous. Attempting to define parameters that are critical for 
MC2 T cell responses, we demonstrated that MC2-specific T cell responses are most optimal in vitro 
with TCR 6, and benefit most from higher expression levels of MC2, but not CD80, CD86, PD-L1 or 
PD-L2. The superiority of TCR 6 may in part be explained by affinity, considering the possible 
higher affinity of TCR 4 and its weaker T cell response, it may also in part be explained by TCR 
structure and level of TCR expression (40). The importance of antigen expression level for MC2 
TCR T cell responses builds on earlier studies (56), but antigen being a driver of MC2 T cell 
recognition irrespective of the expression of classical co-stimulatory and co-inhibitory molecules is 
a novel finding. Notably, the LLF epitope, the target of TCR 11, TCR 4 and in particular TCR 6, 
forms highly stable peptide:HLA-A2 complexes (see supplementary figure 3), potentially due to the 
LLF peptide harboring the preferred peptide-binding motif for HLA-A2, i.e., “XLXXXXXXV/L” 
(57,58). The EC50 values for HLA-A2 binding put the LLF epitope, but not the ALK epitope, below a 
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critical threshold of 10nM, which has been reported to enable peptide cross-presentation by 
stromal cells and enhance anti-tumor T cell responses (59).  
In this study we have selected MC2 as an effective and safe T cell target antigen, based on its 
selective expression by cancer cells. MC2 peptides not being presented by normal cells is a decisive 
factor with respect to the clinical value of this antigen for future studies. QPCR of a large series of 
human tissues demonstrated that there is no gene expression of MC2, except for testis (figure 7A). 
These findings confirmed earlier findings ((10,60), and www.proteinatlas.org/ENSG00000046774-
MC2/tissue as well as www.cta.lncc.br). Testis tissue is immune privileged (no MHC expression) 
and expected to express cancer germline antigens. In fact, our findings are in line with MC2 
protein stainings by Zhuang et al (36). Further safety tests included exposure of T cells expressing 
TCR 6 towards a peptide library as well as peptides that were found to be highly similar to the MC2 
LLF peptide. We observed that TCR 6-transduced T cells demonstrated no cross-recognition of any 
of 114 HLA-A2-eluted peptides tested (figure 7B). When testing peptides that are highly 
homologous to the MC2 LLF peptide, i.e., the MB4 LVF and MB10 LIF peptides, TCR 6 T cells 
showed a slight response to the MB4 but not MB10 peptide. Further experiments revealed that the 
MB4 peptide shows a higher EC50 value than the MC2 peptide, but most importantly, and in line 
with predicted peptide processing and MHC class I presentation 
(http://www.cbs.dtu.dk/services/NetCTLpan/), TCR 6-transduced T cells do not recognize target 
cells expressing native MB4 (see figures 7C, D and E). Collectively, these results provide clear 
evidence against risks for on- or off-target reactivities when targeting MC2 via TCR 6.  
Taken together, we demonstrate that T cell therapy benefits from the combination of targeting a 
safe, yet effective antigen, such as MC2, and epigenetic drug-enhanced antigenicity. Currently, we 
are preparing a phase I/II trial with adoptive transfer of MC2 TCR T cells, in combination with 
administration of AZA/VPA, to treat patients with metastatic melanoma and HNSCC. 
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Supplementary figure 1. MC2 TCRs, when expressed by T cells, bind pMHC to varying degrees. 
T cells were transduced with MC2 TCRs 4, 6, 11, 16, 40, 41 I, 41 II or not (mock) and analyzed by flow 
cytometry following staining either with ALK-PE pMHC (TCR 16, TCR 40) or LLF-PE pMHC (TCR 4, TCR 6, TCR 11, 
TCR41-I, TCR41-II). Results are displayed as bars (mean±SEM, n=3-9) of CD3, CD8-positive cells binding pMHC. 
Statistical significant differences of dextramer binding between TCR T cells and their respective mock control are 
calculated with Student’s t-test: *p<0.05. 
  
* * 
*
* 
*
CHAPTER 3 
 
86 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 2. MC2 TCR T cells up-regulate expression of CD107a in response to peptide-
loaded target cells and pre-treated melanoma cell lines 
(A) MC2 TCR T cells pre-treated with epigenetic drugs (from figure 1A) were co-cultured with T2 cells pulsed with 
1µM of ALK (for TCR 16) or LLF (for TCR 4, 6 and 11) peptide. CD107a-PE labelled antibody was added for 2h, 
and its binding to cells measured by flow cytometry. Results are displayed as percentages (mean ± SEM, n=3) of 
viable, CD3, CD8-positive or CD8-negative cells expressing CD107a. Data are from one healthy donor out of two 
tested with similar results. (B) MC2 TCR T cells were co-cultured with six melanoma cell that were pre-treated 
with AZA, VPA and IFNγ (see legend to figure 4 for details) at an E:T ratio of 3:1. Tumor cell positivity for MC2 
(based on RT-PCR data) is indicated below the graph. Results are displayed as percentages (mean ± SEM, n=3) 
of viable, CD3, CD8-positive cells expressing CD107a corrected for CD107a expressions of mock T cells (same 
donor, incubation with same tumor cell line); CD107a expressions of mock T cells ranged between 0,04 and 
5,27%. Data are from one healthy donor out of two tested with similar results. Statistical significant differences 
between responses of TCR T cells towards MC2+ versus MC2- or MC2+/HLA-A2- target cells (of same tumor 
type) are calculated with Student’s t-test: *p<0.05; **p<0.005 (below bars). 
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Supplementary figure 3. ALKDVEERV and LLFGLALIEV form surface-expressed complexes with HLA-
A*0201. 
T2 cells were pulsed with titrated amounts of ALK or LLF peptide and formation of pMHC class I complexes on the 
cell surface was quantified via flow cytometry using a PE-labeled HLA-A2 mAb. The gp100 peptide YLEPGPVTA 
and a random peptide GAGAGAGAG were used as positive and negative peptide controls, respectively. The 
graphs represent Mean Fluorescence Intensities (MFI) as mean ±SEM, n=3. EC50 values of peptide: MHC class I 
binding (peptide concentration to yield half-maximal MFI of HLA-A2 expression) are displayed above each 
peptide. 
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ABSTRACT 
Adoptive therapy with T cell receptor (TCR)-engineered T cells has shown promising results in the 
treatment of patients with tumors, and the number of TCRs amenable for clinical testing is 
expanding rapidly. Notably, adoptive therapy with T cells is challenged by treatment-related side 
effects, which calls for cautious selection of target antigens and TCRs that goes beyond their mere 
ability to induce high T cell reactivity. Here, we propose a sequence of in vitro assays to improve 
selection of TCRs, and exemplify risk assessments of on-target as well as off-target toxicities using 
TCRs directed against Cancer Germline Antigens. The proposed panel of assays covers parameters 
considered key to safety, such as expression of target antigen in healthy tissues, determination of 
a TCR’s recognition motif towards its cognate peptide, and TCR’s cross-reactivity towards non-
cognate peptides.  
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INTRODUCTION 
Therapeutic use of anti-tumor T cells has proven feasible in a multitude of trials over the last 
decade. Alongside the demonstration of clinical benefit and enthusiasm about the therapeutic 
efficacy, the occurrence of toxicities has stimulated awareness of safety pitfalls. While initial 
studies demonstrated recognition, and sometimes destruction of healthy tissues (1-3), later 
studies demonstrated lethal adverse effects in individual patients (4,5). These studies highlight the 
two main challenges facing safety of T cell receptor (TCR) gene therapy: on- and off-target 
toxicities. With a quickly expanding panel of TCRs that have generally been selected for their ability 
to provide T cells with high avidities towards tumor antigens, there is an urgent need for 
streamlining the safety assessment of these TCRs prior to clinical usage. 
 
SELECTING TARGET ANTIGENS 
An ideal target antigen for adoptive T cell therapy (AT) displays two important features: it is 
immunogenic and shows selective and homogenous expression in tumor tissue. Immunogenicity is 
best explained as an antigen’s ability to be recognized by and sufficiently activate T cells, a feature 
that is generally well addressed when selecting a target antigen and its corresponding TCR 
(reviewed in (6)). In example, characteristics related to the immunogenicity of  two MAGE-C2 
(MC2) antigen epitopes are summarized in Table I. Selective expression in tumor tissue, and hence 
its absence in healthy tissues, would reduce the risk for on-target toxicities. Differentiation, over-
expressed or onco-fetal antigens are not absent from healthy tissues and the targeting of these 
antigens, e.g. MART-1 or carcinoembryonic antigen (CEA), by TCR-transduced T cells has resulted 
in severe destruction of melanocytes in the eyes, ears and skin (1) or inflammation of the colon 
(2,3). Candidate antigens that are exclusively expressed by tumor tissues include neo-antigens 
and oncoviral antigens. Neo-antigens are derived from somatic DNA alterations and their 
identification requires analyses of mutations, gene expression, and algorithms that predict antigen 
processing and presentation by major histocompatibility complex (MHC) (7-9). AT studies with 
tumor infiltrating lymphocytes (TILs) in patients with melanoma and cholangiocarcinoma showed 
that clinical benefit was associated with T cell responses against neo-antigens (9-11). Current 
exploitation of neo-antigens in AT, however, is challenged by the uncertainty of current algorithms 
accurately predicting immunogenicity, and the fact that neo-antigens are usually specific per 
patient (12-14). Viral antigens are present in more than 10% of human cancers and are often the 
result of viral insertion into the genome and subsequent reactivation in tumors. AT studies using 
TILs reactive against either HPV or EBV have shown clinical successes in patients with cervical 
cancer or nasopharyngeal carcinoma, respectively (15,16). In addition to neo-antigens and onco-
viral antigens, also certain cancer germline antigens (CGAs) demonstrate tumor-selective 
expression. In fact, CGAs are expressed in gonadal tissues and some in thymus (17), and certain 
CGAs are considered to be selectively de-repressed in tumor tissues (for detailed reviews, see 
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(6,18,19)). MAGE-A3 and NY-ESO1 are examples of CGAs that have already been targeted by TCR-
engineered T cells in patients with metastatic melanoma, metastatic synovial sarcoma or multiple 
myeloma (4,20). Although off-target toxicities were observed with the targeting of the former 
antigen (most likely an issue of the TCRs; see next section), the safe use of selected CGAs was 
suggested by the targeting of NY-ESO1 demonstrating clinical benefit without toxicities (20,21). 
We recommend for any antigen, with the exception of neo-antigens, to test the antigen’s absence 
from a large panel of healthy organs. Online databases such as the protein atlas 
(http://www.proteinatlas.org/) or the CGA database (www.cta.lncc.br) combine extensive data 
from transcriptomic analyses and antibody stainings from numerous normal, non-cancerous cell 
lines and tissues. When applying these tools to assess the expression of MC2, we observed that 
mRNA expression is restricted to cells from cancers and testes, the latter considered to possess an 
immune privileged status (no MHC expression; thus no detection by T cells). The use of 
commercially available cDNA libraries of a large series of healthy tissues enables researchers to 
extend online analyses and quantify antigen expression with a laboratory assay. When performing 
qPCR using such a cDNA library, we demonstrated absence of MC2 mRNA in healthy tissues as 
illustrated in figure 1A. In case specific antibodies are available, we would recommend to follow-up 
qPCR with immune histochemistry. Using an MC2-specific antibody, we confirmed the presence of 
MC2 protein in testis and melanoma as well as its absence in multiple healthy tissues, such as 
brain, heart, intestine and lung (see figure 1B). However, both qPCR and immune histochemistry 
cannot formally exclude the presence of rare antigen-positive cells within a tissue, e.g. stem cells. 
For example, mRNA of certain CGAs has been detected only in medullary thymic epithelial cells but 
not total thymus (17). As an additional means to exclude target antigen expression, sophisticated 
in vitro cell cultures have been developed to closely mimic complete tissues or organs (commented 
in next section) (5,22). 
 
SELECTING THERAPEUTIC TCRs 
Once the safety of the target antigen has been assessed, one can start selecting TCRs. Procedures 
to obtain tumor-reactive T cells and hence TCRs can generally be divided into those that rely on 
tolerant and those that rely on non-tolerant repertoires of T cells. Tolerant repertoires, where 
deletion of T cells with avidity outside the thymic selection window has occurred, have been used 
to obtain T cell clones from patients following successful TIL therapy, peptide vaccination, or using 
in vitro pulsing of autologous dendritic cells (23,24). Notably, the thymic selection of T cells is 
most likely a trade-off between producing a self-tolerant yet sufficiently diverse and responsive 
TCR repertoire, and escape of self-reactive TCRs cannot be negated. Indeed, TCRs specific for 
over-expressed antigens and obtained from the native repertoire have been shown to initiate 
autoimmune side effects (1). The use of non-tolerant repertoires, with the rationale of allowing the 
generation of high-avidity T cells, has been applied in allogeneic in vitro as well as in vivo systems.  
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Table I  Properties of cognate MAGE-C2 epitopes and corresponding TCRs that relate to T cell 
reactivity 
Epitopes 
 
LLFGLALIEV 
(MAGE-C2191-200) 
 
ALKDVEERV 
(MAGE-C2336-344) 
HLA-A2 
binding 
 
predicted affinitya:               9.9nM 
measured affinityb:              2.5µM 
 
predicted affinitya:           342.2nM 
measured affinityb:          20.0µM 
     
TCR 
 
TCR 6  TCR 16 
TCR genesc 
 
α-chain:  Vα12-2*01 / Jα23*01 / Cα 
β- chain: Vβ15*02 / Jβ2-3*01 / Cβ2 
 
α-chain:  Vα3*01 / Jα3*01 / Cα 
β- chain: Vβ28*01 / Jβ2-5*01 / Cβ2 
pMHC 
bindingd 
 
EC50 CD8
+ T cells: 348nM 
EC50 CD4
+ T cells: 501nM 
 
EC50 CD8
+ T cells: 663nM 
EC50 CD4
+ T cells:      n.d.   
functional T 
cell aviditye 
 
EC50: 3.19nM  EC50: 73.8nM 
tumor cell 
recognitionf 
 
EB81-MEL: 
518-A2: 
607-B: 
SCC-9: 
93-VU-120: 
SUM-195-PT: 
1090pg/ml 
605pg/ml 
835pg/ml 
311pg/ml 
292pg/ml 
217pg/ml 
 
EB81-MEL: 
518-A2: 
607-B: 
SCC-9: 
93-VU-120: 
SUM-195-PT: 
 
1738pg/ml 
461pg/ml 
626pg/ml 
207pg/ml 
26pg/ml 
466pg/ml 
 
a according to http://www.cbs.dtu.dk/services/NetCTLpan/. 
b T2 cells were pulsed with titrated amounts of ALK or LLF peptide and formation of pMHC class I complexes on 
the cell surface was quantified via flow cytometry using PE-labeled HLA-A2 mAb (23). 
c cDNAs derived from patient-derived T cell clones were PCR amplified using either a set of TCR-Vα or Vβ sense 
primers and a corresponding TCR-Cα or Cβ antisense primer or 5’RACE (rapid amplification of cDNA ends). 
Following nested PCRs and cloning, TCRα and β sequences were identified using www.imgt.org and classified 
according to the Lefranc nomenclature (see (23) for details). 
d TCR T cells were pulsed with titrated amounts of PE-labeled pMHC multimer, and binding was quantified via flow 
cytometry. 
e TCR T cells were antigen-presenting cells that were pulsed with titrated amounts of cognate peptide, and 
functional T cell avidity was quantified via ELISA measurements of IFNγ production. 
f TCR-transduced T cells were co-cultured with 3 melanoma, 2 head-and-neck carcinoma and 1 triple-negative 
breast cancer cell lines all positive for HLA-A2 and MC2 (determined by qPCR) at an E:T ratio of 3:1 for 24h. Cell 
lines were treated with epigenetic drugs Azacytidine and Valproate as well as IFNγ prior to co-culture (see (23) 
for details). IFNγ levels in 24h culture supernatants were measured by ELISA; displayed values are means of five 
experiments. Note that epigenetic drugs induce enhanced and tumor-selective expression of MC2 in vitro (23) as 
well as enhanced tumor immunogenicity in vivo (18). 
n.d. = not determined. 
 
For example, HLA-mismatched antigen-presenting cells (25) or artificial antigen-presenting cells 
pulsed with peptides of interest facilitate the in vitro generation of tumor-reactive T cells (26). In 
vivo, mice transgenic for human HLA as well as mice transgenic for human TCR and HLA-A2 genes 
(27) have been immunized and used as a source of TCRs. After having obtained antigen-reactive T 
cells, sequences of the TCRα and β chains can be determined by molecular techniques such as 5′ 
RACE (23), enhanced PCR methods, capturing and indexing of genomic DNA-encoding TCR chains 
(28), or sequencing and pairing of TCR chains based on combinatorial algorithms (29). 
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It is important to note that TCRs derived from above-mentioned repertoires, in particular the non-
tolerant repertoir, have not been selected in the presence of all patient MHC alleles and in the case 
of mice neither against human peptides present in the thymus, and may show allo- and non-
cognate reactivity. Moreover, TCRs, even though obtained from highly tumor-reactive T cells, have 
an inherent degeneracy for peptide recognition and are able to recognize more than a single 
peptide. This dynamic flexibility in antigen recognition is in part accredited to the bending ability of 
the TCR-CDR domains (30,31), but also to the dominant interaction of the TCR with a restricted 
number and order of amino acids present in the MHC-presented peptide. To minimize the risk of 
selecting a TCR that recognizes non-cognate self-peptides, we recommend a series of assays that 
assess the risk of this so-called off-target toxicity. These assays are illustrated with two patient-
derived MC2-specific TCRs 6 and 16 with details and evaluation of anti-tumor T cell responses 
mediated by TCR6 and TCR16 summarized in Table I. 
 
Recognition of random epitopes 
Initial assessment of a TCR’s self-reactivity can be done by testing the responsiveness of TCR-
transduced T cells towards random peptides known to be presented by the respective HLA 
restriction allele. Mathematical projections indicate that amongst a pool of ~1012 peptides, a single 
TCR may react with >106 peptides, supporting the notion of TCR degeneracy for peptide 
recognition, which potentially contributes to a more diverse TCR repertoire (32). We co-cultured 
TCR6 and TCR16 T cells with antigen-presenting cells loaded with saturating concentrations of 
>100 common, HLA-A2-eluted self-peptides (4). As depicted in figure 2, both T cell populations 
mediated a T cell response to their respective cognate peptides, but to none of the other peptides. 
Importantly, these data hint to lack of cross-reactivity of these two TCRs, but we cannot fully 
exclude recognition to random peptides. Another assessment of self-reactivity can be conducted by 
testing TCR-transduced T cells towards allogenic HLA molecules. In order to exclude activation of T 
cells upon recognition of foreign HLA molecules, panels of lymphoblastoid B cell lines with various 
HLA allotypes have proven valuable (33,34).  
 
Recognition of cognate epitope via critical amino acids 
Further assessment of a TCR’s self-reactivity, and a key assay in this communication, is the testing 
of a TCR’s intrinsic capacity to recognize peptides highly homologous to its cognate epitope 
(35,36). To this end, one can determine the recognition motif, i.e. the position and sequence of 
amino acids within the cognate epitope that are crucial for binding to the TCR. This motif is unique 
per TCR and can be considered a surrogate measure for the extent of cross-reactivity of TCRs 
(22,33). The importance to assess such motifs became apparent from two recent clinical trials 
using 
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Figure 2. TCRs do not recognize random peptides eluted from the restricting MHC allele. 
TCR6 or TCR16 T cells were co-cultured with T2 cells loaded with 1µM of 114 different HLA-A2-eluted peptides 
(4) for 24h. Cognate MC2 peptides (TCR6: LLFGLALIEV; TCR16: ALKDVEERV) served as positive controls. IFNγ 
levels in 24h culture supernatants were measured by ELISA and are displayed as mean ± SEM (n=3). Left-hand 
panel is adapted from (23); Copyright © 2016 The American Association of Immunologists, Inc. 
 
using AT with TCR-engineered T cells. The first trial targeting MAGE-A3 and A9 (MA3/9) in the 
context of HLA-A2 utilized the TCR 9W11 and reported neurological toxicities in two patients with 
metastatic melanoma (4). The second trial targeting MA3 in the context of HLA-A1 utilized the TCR 
a3a and reported cardiac toxicities in one patient with metastatic melanoma and one patient with 
multiple myeloma (5). Both TCRs were affinity enhanced in vitro and mediated toxicity by 
recognizing peptides highly similar to the cognate peptide, namely peptides derived from MAGE-
A12 and Titin present in brain and heart tissue, respectively. These studies clearly underline the 
need to assess recognition motifs, and the search for T cell reactivities against homologous self-
peptides, prior to clinical application. The importance of recognition motifs is timely and its 
assessment has only occurred for a limited number of TCRs to date, which is summarized in Table 
II.   
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Table II Recognition motifs of TCRs utilized in clinical and pre-clinical research 
TCR 
name 
target 
antigen 
HLA 
-  
cognate 
epitope 
recognition 
motifa 
number of 
antigens 
with motifb 
number of 
epitopes with 
high MHC 
affinity 
(<10µM)c 
refs. 
a3a MAGE-A3 A1 EVDPIGHLY ExDPIxxxY 5 0 (22) 
9W11 MAGE-A3 A2 KVAELVHFL -xxE-xH--d - - (43) 
T1367 MAGE-A1 A2 KVLEYVIKV xxxEYxIKx 62 6 (33) 
s24-
TCR 
survivin A2 ELTLGEFLKL xLTxGEFLKx 1 1 (44) 
gp100 
wt 
gp100 A2 YLEPGPVTA xLEPGPxxA 4 4 
Govers, 
Ms. 
submitted 
fl-MPD  gp100 A2 YLEPGPVTA YxEPxxxxx >1000 >500 (45) 
fl-296  gp100 A2 YLEPGPVTA YxExxxxxx >1000 >500 (45) 
TCR 4 MAGE-C2 A2 LLFGLALIEV xxFGLxLxxx 260 122 (23) 
TCR 6 MAGE-C2 A2 LLFGLALIEV LxFxLxLxEx 28 9 (23) 
TCR 11 MAGE-C2 A2 LLFGLALIEV xxFGLxLxEx 21 17 (23) 
TCR 16 MAGE-C2 A2 ALKDVEERV xLKDVEERx 2 2 (23) 
aRecogniton motifs are defined through T cell IFNγ production in response to alanine scanned cognate epitopes.  
bnumber of human proteins containing matching recognition motif according to ScanProSite 
(http://prosite.expasy.org/scanprosite/). 
cnumber of proteins containing matching recognition motif (according to b) and a predicted affinity value <10µM 
for binding of the peptide to its respective MHC; affinity calculations according to NetMHCpan 
(http://www.cbs.dtu.dk/services/NetMHCpan/). 
drecognition motif incomplete, amino acids on positions 2-4 and 6-7 are based on stimulation assays conducted 
by Chinnasamy et al. with a panel of MAGE-peptides with highly similar sequences (43); ‘-‘ indicates amino acids 
with unknown relevance to the recognition motif. 
 
 
Using a set of altered peptide ligands (APLs), peptides containing individual alanines replacements 
at every single position in the cognate peptide (in case of an endogenous alanine→glycine), we 
conducted stimulation assays with TCR6 and 16 T cells. Critical amino acids are defined as those 
that, when testing the respective APLs, result in a drop of the T cell response (generally using IFNγ 
production as a readout) of > 50% when compared to the response toward the cognate peptide. 
Following the determination of these motifs, as exemplified in figure 3A, we used ScanProSite 
(http://prosite.expasy.org/scanprosite/) (37) and identified target antigens, listed in figure 3B, 
that harbor the recognition motif and represent potential cross-reactive targets for TCRs 6 and 16. 
Subsequently, these self-peptides were tested for their ability to induce T cell responses towards 
HLA-A2-postive antigen presenting cells loaded with saturating concentrations (1µM) of peptide. 
These experiments yielded a short list of self-peptides that are actually recognized by the TCRs 
under study, defined as those that resulted in at least a T cell IFNγ response > 2.5% of the 
response to cognate peptide (figure 3B: underlined antigens).  
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Figure 3. TCRs recognize cognate peptide via unique or restricted motif. 
(A) TCR6 or TCR16 T cells were co-cultured with T2 cells loaded with 1µM of cognate peptides or peptides with a 
single alanine replacement (Altered Peptide Ligands (APL), in case of alanine in original peptide: glycine). IFNγ 
levels in 24h culture supernatants were measured by ELISA. IFNγ response to APLs is displayed as mean % 
relative to response to cognate peptides ± SEM (n=4). Responses < 50% (dashed line) were indicative of amino 
acids critical for TCR recognition (recognition motif: underlined amino acids). Left-hand plot is adapted from (23). 
(B) Homologous motifs from (A) were queried against a human protein database using ScanProSite. This yielded 
27 and 1 non-cognate matches for TCR6 and TCR16, respectively. Subsequently, TCR6 or TCR16 T cells were co-
cultured with T2 cells loaded with 1µM of these 27 and 1 peptide(s), and IFNγ levels were measured in 24h 
culture supernatants by ELISA (n=4). Underlined peptides induced a T cell IFNγ response > 2.5% of the 
response to cognate peptide. Homology to cognate peptide (diverging amino acids underlined) as well as 
peptide-MHC affinity (IC50 calculations according to NetMHCpan; http://www.cbs.dtu.dk/services/NetMHCpan/) 
are indicated for those peptides with a detectable IFNγ response. 
  
TCR 6: 27 non-cognate matches 
(LxFxLxLxEx) 1 MAGE-C2 (cognate)a   LLFGLALIEV  0.01µM  1 MAGE-C2 (cognate)  ALKDVEERV 0.34µM 
2 MAGE-B4    LVFGLALKEV  0.10µM  2 MAGE-C1   ALKDVEERA 4.29µM 
3 MAGE-B10        
4 ATP-binding cassette sub-family C member 11 LCFALFLSEC 15.00µM  
5 BTB/POZ domain-containing protein 3      
6 CDK5 and ABL1 enzyme substrate 1       
7 Coiled-coil domain-containing protein 148      
8 Cilia- and flagella-associated protein 43         
9 Dynein assembly factor 3, axonemal  LIFSLALEEP  9.81µM     
10 Probable ATP-dependent RNA helicase DDX58         
11 ELM2 and SANT domain-containing protein 1    
12 Probable E3 ubiquitin-protein ligase HERC4   LRFYLTLPEC  9.94µM 
13 Heparan sulfate glucosamine 3-O-sulfotransferase     
14 Kinetochore-associated protein 1     
15 Melanoma-associated antigen B1   
16 Mirror-image polydactyly gene 1 protein LKFKLELQEK 36.91µM 
17 Myosin-15 
18 Proteasome subunit beta type-3  LKFRLNLYEL 13.77µM 
19 26S proteasome non-ATPase regulatory subunit 6 
20 SRR1-like protein  
21 Titin 
22 Zinc finger protein 578   LSFHLHLPEL  2.97µM 
23 Zinc finger protein 766 
24 Zinc finger protein 880 
25 Zona pellucida sperm-binding protein 3 
26 Major facilitator superf. domain-contain. Prot. 1 LPFRLKLNEI 23.95µM 
27 RcPSMB3 
28 C3orf67 protein 
TCR 16: 1 non-cognate match 
(xLKDVEERx) 
A 
B 
TCR 16 (ALKDVEERV) TCR 6 (LLFGLALIEV) 
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Recognition of non-cognate epitopes that contain recognition motif 
Once self-peptides that can be recognized by TCR T cells have been identified, we recommend to 
execute two additional tests to more stringently assess the risk for self-reactivity. These tests aim 
to provide measures for T cell avidity as well as efficiency of cellular processing and presentation. 
Towards the first test, one can titrate amounts of non-cognate peptides and determine the 
concentration of these peptides that elicits 50% of the maximal T cell response (EC50). For both 
TCR6 and 16 T cells, we found that only a single self-peptide, namely a peptide from the antigen 
MAGE-B4 (MB4) or MAGE-C1 (MC1; see figure 3B for homology and predicted peptide-HLA 
binding), respectively, revealed detectable EC50 values that were only 2-5 fold lower than those of 
the cognate peptides (figure 4). Extent of homology and predicted peptide-MHC binding of peptides 
that induce T cell IFNγ are listed in figure 3B, which shows that loss of homology and peptide-MHC 
affinity was least affected for MB4 and MC1 peptides. All other self-peptides revealed no T cell 
reactivities at titrated doses, or at the very best 5 log scales lower compared to cognate peptide. 
These were considered not recognizable by the TCRs under study and excluded from further 
assays. Towards the second test, one can predict whether self-peptides are the result of antigen 
processing and presentation to enable T cell recognition in vitro. NetCTLpan 
(http://www.cbs.dtu.dk/services/NetCTLpan/) (38) takes proteasomal C terminal cleavage, TAP 
transport efficiency, and peptide MHC class I binding of peptides into account, and can be 
employed to obtain an initial score for antigen processing and presentation. Analysis of the MB4 
peptide, but not MC1 peptide, yielded a high score according to this web-based tool. Such 
predictions may not be fully accurate and should be verified using cells known to express the 
antigen or antigen presenting cells (e.g. dentritic cells) transfected with antigen-encoded RNA 
followed by co-cultivation with TCR-transduced T cells. To this end, we stimulated TCR T cells with 
the esophageal cancer cells line OEC-19, which natively expresses the MB4 and MC1 antigens, but 
is devoid of the MC2 antigen, and observed that both TCRs failed to initiate T cell activation against 
either MB4 or MC1 (see figure 4B). When using cell lines that natively express the MC2 antigen, as 
a control for the processing and presentation of MAGE antigens, we observed that both TCRs did 
initiate T cell activation. It is noteworthy that standard tissue culture systems may not always 
accurately reflect antigen processing and presentation. This was evidenced by the recognition of 
Titin by the TCR a3a that could only be observed in more elaborate tissue culture systems, such as 
3D cultures of beating cardiomyocytes derived from induced pluripotent stem cells (22). In case 
the above two assays do not exclude self-reactivity of TCR T cells, one could pursuit assessment of 
the tumor-selective expression of such new antigens. In case expression of new antigens is not 
selective for tumors, the corresponding TCR should be excluded. Using online tools (39) as well as 
qPCR (figure 1A), MB4 showed expression within epididymis and vagina, whereas MC1 showed no 
expression in any of the healthy non-gonadal tissues. These data highlight the stringent safety 
profile of TCR16, the TCR selected for a clinical trial to treat melanoma and head-and-neck 
carcinoma, currently prepared at Erasmus MC. 
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Figure 4. TCRs mediate negligible T cell avidity nor recognize natively presented non-cognate 
peptides that harbor recognition motif. 
(A) Non-cognate peptides underlined in figure 3B were titrated from 10µM (10-5M) to 1pM (10-12 M) and tested 
for T cell IFNγ response as described in previous legends and displayed as mean ± SEM (n=4). EC50 values for 
cognate and selected non-cognate peptides were calculated in GraphPad, using non-linear regression; n.d. = not 
detectable. (B) TCR6 or TCR16 T cells were co-cultured with tumor cell lines or T2 cells (as a negative control). 
Expression status of MC2, MC1, MB4 and HLA-A2 for these cells was assessed via qPCR and indicated below plots 
with plus or minus. IFNγ levels in 24h culture supernatants were measured by ELISA and are displayed as mean 
± SEM (n=3). Left-hand plots are adapted from (23); Copyright © 2016 The American Association of 
Immunologists, Inc. 
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Future perspective of in vitro assays assessing risk of TCR-mediated toxicities 
The proposed collection and sequence of in vitro assays to assess risks for toxicities are presented 
in figure 5. We advocate this testing for TCRs with clinical intent, in particular those TCRs reactive 
against a self-peptide and derived from a non-tolerant repertoire and/or following gene-
enhancement. In extension to gene-enhancement, introduction of TCR-CDR mutations has been a 
commonly used tool to generate high-affinity TCRs (2,4,5,20). While such gene-enhanced TCRs 
recognize target peptides at increased affinities when compared to the corresponding wild-type 
TCRs, consequently such TCRs are also at risk to recognize non-cognate peptides. To test whether 
affinity enhancement led to an increase in degeneracy for peptide recognition, we made use of a 
panel of 8 TCRs specific for the same cognate peptide gp100181-188:HLA-A2) but harboring 2-3 
mutated amino acids in either their CDR2β, CDR3α or CDR3β domains (Govers, Ms submitted). 
Upon assessment of the recognition motifs and search for motif-harboring self-peptides, it became 
apparent that enhanced affinity was accompanied by drastic increase in the TCR’s ability to 
recognize self-peptides (Table III). These data extend earlier findings regarding a correlation 
between affinity enhancement and loss of TCR specificity (40), and warrant caution when trying to 
change the TCR-CDR structure as it compromises the stringent recognition of cognate peptide 
(31,41).   
Taken together, here we propose a platform of in vitro assays that in combination with available 
online-databases and tools allows for optimal toxicity risk-assessment for target antigens and TCRs 
currently under consideration for clinical trials.  
 
 
 
Table III          TCR affinity enhancement and its effect on off-target recognitiona 
TCR name 
KD 
[μM] 
target 
antigen 
cognate 
epitope 
recognition 
motifa 
number of 
antigens 
with motifb 
number of epitopes 
with high MHC 
affinity (<10µM)c 
gp100 wt 18.5 gp100/HLA-A2 YLEPGPVTA xLEPGPxxA 4 4 
gp100 TCR 1 7.9 gp100/HLA-A2 YLEPGPVTA xLExGPxxA 23 13 
gp100 TCR 2 4.0 gp100/HLA-A2 YLEPGPVTA xLExGPxxx 240 97 
gp100 TCR 5 1.1 gp100/HLA-A2 YLEPGPVTA xLExGPxxx 240 97 
gp100 TCR 8 0.026 gp100/HLA-A2 YLEPGPVTA xLxxxxxxx >10000 >10000 
aGovers, Ms, submitted. 
bnumber of human proteins containing matching recognition motif according to ScanProSite 
(http://prosite.expasy.org/scanprosite/). 
cnumber of human proteins containing matching recognition motif (according to b) and a predicted affinity value 
of <10µM for binding of the peptide to its respective MHC; affinity calculations according to NetMHCpan 
(http://www.cbs.dtu.dk/services/NetMHCpan/). 
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Figure 5. Platform of in vitro assays to select antigens and TCRs with limited risk for in vivo toxicity. 
Flowchart proposes a series and sequence of in vitro techniques, exemplified in figures 1 to 4 and explained in 
detail in text. Such a sequence of assays would facilitate selections of potentially safe target antigens and TCRs 
prior to their use in clinical trials 
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ABSTRACT 
Adoptive therapy with T cell receptor (TCR)-engineered T cells constitutes a promising treatment 
approach for patients with solid tumors. However, this therapy is currently challenged by non-
durable responses, and accumulating evidence suggests that  numbers and activity of intra-
tumoral T cells as well as persistence of peripheral T cells is not optimal. Here, we addressed this 
challenge by gene-engineering TCRs to incorporate co-stimulatory molecules derived from CD28, 
OX40, ICOS, 4-1BB or CD40L. T cells expressing co-stimulatory TCRs with CD28, OX40 or ICOS 
showed enhanced pMHC binding when compared to wt TCR, but showed lowered functional avidity 
following antigen exposure in vitro. Notably, adoptive transfer of T cells expressing these co-
stimulatory TCRs into immune competent, melanoma-bearing mice enhanced anti-tumor responses 
and prolonged overall survival. In fact, TCR:ICOS T cells resulted in 50% complete responses at 
day 115 and tumor recurrences at >40 days after T cell transfer (wt TCR: 0% and 20 days, 
respectively). In mice treated with TCR:ICOS T cells, TCR transgene-positive T cells demonstrated 
enhanced numbers of CD8 T cells in the blood stream and in tumor tissue, and the latter showed 
an enhanced frequency of CD40L-positive T cells. In conclusion, we show that TCRs with an ICOS 
signaling domain improve accumulation and activation of intra-tumoral CD8 T cells as well as the 
peripheral persistence of CD8 T cells following adoptive transfer, and significantly aid to tumor 
clearance. 
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INTRODUCTION 
Adoptive therapy with T cell receptor (TCR-)engineered T cells has demonstrated its feasibility in 
patients suffering from a broad spectrum of malignancies. Trials targeting melanoma antigen 
recognized by T cells 1 (MART-1), glycoprotein (gp)100, carcinoembryonic-antigen (CEA), 
melanoma-associated antigen 3 (MAGE-A3) or NY-ESO-1 have shown promising objective response 
rates in metastatic melanoma, colon carcinoma, synovial sarcoma and multiple myeloma, ranging 
from 12 to 90% (1-6). Despite initial responses to treatment, ongoing and complete responses 
occurred only in about maximally 20% of patients while the majority of patients initially responding 
to treatment eventually suffer from tumor relapse. Recurrence of tumor cells is considered a 
consequence of mechanisms utilized by the tumor to evade T cell infiltration, migration and/or 
local activation. And although diverse in nature, these mechanisms are generally related to 
changes in: antigen processing and presentation; lack of T cell effector cells; immune-suppressor 
cells; and/or checkpoint inhibitors (for an overview, please refer to (7,8)). Recently, the expression 
of co-inhibitory receptors by tumor-infiltrating lymphocytes, such as PD-1, LAG3 or TIM3, has 
gained interest with respect to immune evasion. Binding of these receptors by their ligands 
triggers a negative feedback loop that limits accumulation and activation of intra-tumoral T cells. 
In fact, clinical use of so called checkpoint-inhibitors such as pembrolizumab, nivolumab (α-PD1) or 
ipilimumab (α-CTLA4) has demonstrated significant enhancement of endogenous T cell responses 
against solid tumors in a fraction of patients (9-13). 
Even though a variety of escape mechanisms exists, proficient T cell co-stimulation ultimately 
constitutes a prerequisite to enable sufficient T cell accumulation and activation within tumor 
tissue. An eloquent example along these lines is that the rescue of T cell activation with anti-PD-1 
antibody depends on the availability of CD28 signaling (14,15). Tumor cells exploit the 
requirement of T cell co-stimulation by reducing the expression of co-stimulatory ligands and 
enhancing the expression of co-inhibitory ligands, thus preventing successful T cell recruitment and 
activation within the tumor microenvironment (16,17). In an attempt to counter suboptimal T cell 
co-stimulation, one can incorporate co-signaling domains into TCRs or chimeric antigen receptors 
(CARs), thus converging both antigen-specific as well as co-stimulatory signaling pathways into a 
single receptor. In CARs such efforts have already been shown to enhance tumor regression in a 
therapeutic setting (18-20). We have shown previously that incorporation of a signaling cassette 
consisting of CD28 and CD3ε into TCRs results in enhanced responses of therapeutic T cells 
directed against EBV or melanoma target antigens (21,22). Here, we have generated and tested 
the therapeutic effect of TCRs equipped with OX40 (CD134), ICOS (CD278), 4-1BB (CD137) or 
CD40L (CD154) in vitro as well as in a mouse melanoma model. We assessed these novel co-
stimulatory TCRs with regard to their surface expression, T cell function and phenotype in vitro. 
Following adoptive T cell therapy, we assessed T cells expressing these co-stimulatory TCRs for 
their ability to improve tumor clearance and survival in melanoma-bearing mice, and for peripheral 
persistence, accumulation in tumor tissue and expression of co-signaling receptors.  
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MATERIALS AND METHODS 
Cell culture and reagents 
The human embryonic kidney 293T and Phoenix-Amp cell lines, both used to package retroviruses 
carrying RNA encoding TCRαβ, were grown in DMEM with 10% (v/v) Fetal Bovine Serum (FBS; 
Greiner Bio-one Alphen a/d Rijn, The Netherlands), 200nM L-glutamine, 1% MEM non-essential 
amino acids and antibiotics (DMEM complete). Clones derived from mouse melanoma cell lines 
B16BL6 (B16 wt) and B16:A2-YLEP (expresses a fusion protein between the human glycoprotein 
(gp)100280-288 epitope (YLEPGPVTA) and the HHD molecule (23)) were cultured using DMEM 
complete, which in case of B16:A2-YLEP cells contained neomycin (1 mg/ml G418, Calbiochem, La 
Jolla, CA). T2 cells (LCLxT lymphoblastoid hybrid cell line 0.1743CEM.T2) were cultured in RPMI 
1640 medium supplemented with L-glutamine, 10% FBS, and antibiotics. Mouse splenocytes were 
cultured in mouse T cell medium consisting of RPMI 1640 medium supplemented with 25 mM 
HEPES, 200 nM L-glutamine, 10% FBS, 1% MEM non-essential amino acids, 1 mM sodium 
pyruvate, 50 μM β-mercaptoethanol, antibiotics and 180 IU/ml human recombinant (rh)IL-2 
(Proleukin; Chiron, Amsterdam, The Netherlands). For flow cytometry the following antibodies and 
pMHC multimers were used: anti- TCR-Vβ14-FITC (Beckman Coulter, Fullerton, CA); CD3-BV510, 
CD8-APC-Cy7 CD4-BV650, 4-1BB-BV421, LAG3-BV421 (all BD Biosciences, San Jose, CA); TIM3-
APC, BTLA-APC, PD-1-PE-Cy7, OX40-APC  (all Biolegend, San Diego, CA), OX40-PE, CTLA4-PE, 4-
1BB-PE, CD40L-PE, CD4-Qdot605, LAG3-APC, ICOS-APC, ICOS-PE-Cy7, CD14-PerCP (all 
eBiosciences, San Diego, CA); and gp100/A2Kb pMHC tetramer-PE (a kind gift by Dr. David Cole, 
Cardiff University, UK). 
 
Construction of costimulatory TCRs  
TCRα and β genes specific for the human gp100280-288 epitope presented by HLA-A2 (gp100/A2) 
were derived from clone CTL-296 (24), murinized and codon-optimized as described earlier (25). 
Subsequently, TCR genes were cloned into the pMP71 vector (kindly provided by prof. Wolfgang 
Uckert, Max-Delbrück Center, Berlin, Germany) with TCRα and β genes separated by an optimized 
T2A ribosome skipping sequence. TCR:28ε was generated as described in (22). Murine OX40, 
ICOS, 4-1BB and CD40L intracellular signaling domains were ordered via Geneart (Life 
Technologies, Carlsbad, USA) and introduced into the TCR:28ε format (thereby replacing the 
intracellular CD28 domain) via overlap PCR using Q5 High Fidelity DNA Polymerase (New England 
Biolabs, Ipswich, UK). The resulting TCRs: TCR:28ε; TCR:28-OX40ε; TCR:28-ICOSε; TCR:28-
41BBε; and TCR:28-CD40Lε are schematically depicted in Figure 1. Primer sequences used for the 
generation of the costimulatory cassettes are available upon request. The TCR constructs were 
verified by sequencing, using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) and the ABI sequence analyzer.  
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Figure 1. Schematic illustration of co-stimulatory TCRs.  
Figure depicts a line-up of co-stimulatory TCRs in which transmembranal and intracellular domains of the wt TCR 
are replaced by the transmembranal domain of CD28, the intracellular domains of either CD28, OX40, ICOS, 4-
1BB or CD40L, each followed by the intracellular domain of CD3ε. See Materials and Methods for a detailed 
description of origin and introduction of separate components into co-stimulatory TCRs. 
 
 
T cell transduction 
Total mouse splenocytes were isolated, activated with Concanavalin A (0.5µg/ml) and rhIL-2 in 
mouse T cell medium, and transduced with retroviral supernatant from a co-culture of TCR-
transfected 293T and Phoenix-Amp cell lines as described by Pouw and colleagues (25). Control 
(mock) T cells were transduced with empty retroviral vector.  
 
Flow cytometry 
T cells (5×105) were washed with PBS and incubated with antibodies at 4°C or with pMHC tetramer 
at 37°C for 30 min. Following staining, T cells were washed again and fixed with 1% 
paraformaldehyde. Absolute T cell counts in mouse blood samples were determined using Flow-
Count Fluorospheres. Stainings for co-stimulatory and co-inhibitory receptors were performed 
using either TCR-transduced T cells that were 24h exposed to B16:A2–YLEP or B16 wt cells, or 
using tumor infiltrating lymphocytes (TILs) harvested from regressing or relapsing tumors (see 
description of adoptive T cell therapy for time points of tumor collection). Events were acquired on 
a FACS Canto flow cytometer and analysed using FCS Express 4 software (BD Biosciences).  
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T cell stimulation assays 
TCR-transduced T cells were stimulated as described above. In order to enhance HLA-A2 transgene 
expression, B16 cells were pre-treated with 100 IU/ml murine IFNγ for 24 h prior to in vitro 
assays. TCR-transduced T cells were tested at 60.000 T cells and 20.000 B16 cells per well of 
tissue culture-treated 96-well round-bottom plates. T cells with medium and T cells with 
Concanavalin A served as negative and positive controls, respectively. In some experiments, T2 
cells were loaded with gp100 peptide concentrations ranging from 1 pM to 100 µM immediately 
prior to co-culture with T cells. After 24h at 37°C, 5% CO2, culture supernatants were harvested, 
and assessed for the presence of IFNγ by ELISA (eBioscience, San Diego, USA). To determine 
peptide concentrations required to achieve half-maximal binding, results were analyzed using 
GraphPad Prism. 
 
Adoptive T cell therapy  
Experiments with mice were approved by the Experimental Animal Committee of the Erasmus MC 
Cancer Institute and carried out in accordance with institutional and national guidelines. For 
adoptive T cell therapy studies we used HLA-A2 transgenic mice that express a chimeric HLA-
A*0201 transgene (HHD, referred to as HLA-A2 (26)). Adoptive transfer of T cells was done as 
described before (22,23). In short, at day -12, mice were injected subcutaneously with 0.5×106 of 
a B16:A2-YLEP clone, and at days -4 and -3 mice received a total of two Busulfan injections 
intraperitoneally (16.5 μg/kg each) and a single Cyclophosphamide injection intraperitoneally (200 
mg/kg), respectively. Mice were treated with T cells at day 0 and grouped according to one of the 
following treatments: mock T cells (number of T cells equal to wt TCR T cell group); wt TCR T cells; 
TCR:28ε T cells; TCR:28-OX40ε T cells or TCR:28-ICOSε T cells (in all TCR groups, 6×106 
transduced T cells were administered). Tumor growth was measured by caliper 3 times a week and 
tumor volumes were estimated with the formula 0.4 x (A x B2) where A represents the largest 
diameter and B the diameter perpendicular to A. Mice were monitored up to 115 days after 
administration of T cells and anti-tumor responses were classified as follows: complete responses 
showed no palpable tumor; partial responses showed a minimum of 30% tumor regression 
followed by relapse; non-responses did not reach 30% tumor regression. The day of relapse was 
defined as the first day with detectable size-increase of tumor that took place over the course of at 
least 3 days, preceded by at least 30% tumor regression. Survival was monitored daily during the 
same time period. Peripheral blood was collected at day 7 after T cell transfer and at weekly 
intervals thereafter, and used to determine numbers of CD3+ T cells. Tumor tissues of regressing 
tumors were collected at day 5 after T cell transfer and tumor tissues of relapsing tumors were 
collected when mice were sacrificed due to tumor burden exceeding 1400mm3. All tissues were 
snap-frozen in liquid nitrogen and stored at -80°C.  
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Isolation of TILs 
Resected tumor tissue was cut up into small fragments, incubated with collagenase (Sigma Aldrich, 
St Louis, USA) and passed through a 70 µm cell strainer to produce a single cell suspension. Cells 
were subsequently cultured in mouse T cell medium supplemented with rhIL-2 (180 IU/ml) at a 
concentration of 50 000 cells/ml. For flow cytometric analysis, cells were harvested after 72 h. 
 
Statistical analyses 
The different TCR treatment groups were compared with the Student’s t-tests, or the Mantel-Cox 
test in case of survival data using GraphPad Prism5 (GraphPad Software, La Jolla, CA). P values < 
0.05 were considered statistically significant. 
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RESULTS 
Co-stimulatory TCRs mediate lowered T cell avidity in vitro 
We designed a set of five co-stimulatory TCRs specific for human gp100280-288 epitope, all harboring 
a three-party fusion of the transmembranal (tm) domain of CD28, the intracellular (ic) domains of 
either CD28, OX40, ICOS, 4-1BB or CD40L, and the ic domain of CD3ε (see figure 1). When 
assessing the surface expression of these novel TCRs after transduction into mouse splenocytes, it 
became apparent that T cells transduced with wt TCR showed TCR Vβ14-specific antibody staining 
in 55% of cells (see figure 2A, upper left). In contrast, T cells transduced with TCR:28ε, TCR:28-
OX40ε and TCR:28-ICOSε showed antibody staining in 22-26% of cells, while T cells transduced 
with TCR:28-41BBε or TCR:28-CD40Lε showed antibody staining in 0-6% of cells. Staining of T 
cells with pMHC was in line with these observations (figure 2A, upper right). Although inclusion of 
tm CD28 into these new TCRs is based on the format of TCR:28ε with reported surface expression 
and function ((22); and this manuscript), we did test inclusion of the autologous tm domain (i.e., 
TCR:41BBε), but were not able to rescue surface expression (Supplementary figure 1). Due to the 
lack of functional expression of TCR:28-41BBε and TCR:28-CD40Lε, both constructs were omitted 
from further experiments. Notably, while co-stimulatory TCRs showed expression in a lowered 
fraction of T cells, expression levels of individual TCR molecules per cell were enhanced on both 
CD4+ and CD8+ T cells (see MFI of pMHC stainings, figure 2A, lower panels). 
Next to expression levels, we assessed the ability of surface expressed co-stimulatory TCRs to 
mediate T cell activation upon stimulation with cognate epitope. When stimulating T cells using 
titrated amounts of gp100 peptide, we observed that TCR:28ε, TCR:28-OX40ε and TCR:28-ICOSε 
T cells produced lower amounts of IFNγ compared to wt TCR T cells (see figure 2B). EC50 values, 
which equals the amount of peptide necessary to result in half-maximal IFNγ production, revealed 
the following hierarchy with respect to functional T cell avidity: wt TCR (EC50: 1.3nM), TCR:28ε 
(18.7nM), TCR:28-ICOSε (23.9nM) and TCR:28-OX40ε (47.7nM). In addition to cytokine 
production, we also performed flow cytometric analysis of TCR-transduced T cells following co-
culture with antigen-positive tumor cells. These analyses did not reveal significant differences 
among TCRs with respect to antigen-induced expression of co-signalling receptors in either CD4+ 
or CD8+ T cells (see supplementary figure 2). 
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Figure 2. Co-stimulatory TCRs mediate lowered peptide responsiveness in vitro. 
(A) T cells were transduced with wt TCR, TCR:28ε, TCR:28-OX40ε, TCR:28-ICOSε, TCR:28-41BBε or TCR:28-
CD40Lε (all TCRs specific for human gp100/A2) and analysed by flow cytometry following staining with TCR-
specific Vβ14 antibody or a gp100/A2 tetramer in combination with CD3, CD4 and CD8 antibodies. Results are 
displayed as mean % of T cells positive for TCR transgene or MFI of T cells binding for pMHC (±SEM, n=3-5). (B) 
T cells from (A) were co-cultured with T2 cells pulsed with a titrated amount from 100µM to 10pM of human 
gp100 (YLEPGTVPA) peptide for 24h. IFNγ levels in culture supernatants were measured by ELISA, and displayed 
as mean (±SEM, n=3-5). EC50 values were calculated as mentioned in Materials and Methods, and listed in 
figure. Statistical significant differences between wt and co-stimulatory TCR T cells were calculated with 
Student’s t-test: *p<0.05; **p<0.005; ***p<0.005. 
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T cells expressing co-stimulatory TCRs, in particular those with OX40 or ICOS, delay 
tumor recurrence and prolong survival 
HLA-A2 transgenic mice with palpable B16:A2-YLEP tumors (~400mm3) received chemotherapy 
and a single transfer of either 6×106 wt TCR, TCR:28ε, TCR:28-OX40ε, TCR:28-ICOSε or mock T 
cells (see Materials and Methods for details). While mice treated with wt TCR T cells showed initial 
regression upon treatment, all mice showed tumor relapse generally around day 20 after T cell 
transfer (median day of relapse, see figure 3A). Tumor relapse did not occur or was significantly 
delayed in all groups treated with co-stimulatory TCR T cells. Notably, 50% of mice receiving 
TCR:28-ICOSε T cells remained tumor free till the end of the experiment (day 115 after start of T 
cell transfer) and the other 50% of treated mice demonstrated tumor relapse at day 43. In case of 
treatments with TCR:28-OX40ε T cells or TCR:28ε T cells, percentages of tumor-free mice at end 
of experiment were 14% and 0%, respectively, and days of tumor relapse were 27 and 31, 
respectively. Moreover, when analysing survival and responsiveness to treatment, it became 
apparent that the TCR:28-ICOSε T cells mediated highest survival (see figure 3B) which coincided 
with the highest rates of complete and partial responses (see figure 3C). 
 
OX40 and ICOS TCRs result in enhanced persistence in blood and accumulation of T cells 
in tumor tissue, in particular of CD8 T cells  
Weekly peripheral blood measurements of treated mice revealed that co-stimulatory TCR T cells 
were present in larger numbers throughout therapy when compared to wtTCR T cells (see figure 
4A). T cell numbers usually peaked at day 14 after transfer, coinciding with the time point of 
maximal tumor regression in all treated groups. The number of wt TCR T cells stabilized at 65 per 
μl over the following weeks, whereas those of TCR:28ε, TCR:28-OX40ε and TCR:28-ICOSε T cells 
stabilized at an average of 100, 160 and 265 per μl, respectively. Remarkably, the ratio of CD8+ to 
CD4+ T cells shifted in T cells expressing co-stimulatory TCRs. While wt TCR T cells demonstrate a 
ratio of 0.12, TCR:28ε, TCR:28-OX40ε and TCR:28-ICOSε T cells demonstrate ratios of 0.9, 2.2 
and 1.3, respectively (see figure 4B). Notably, we observed that the total number of TCR+ T cells 
one week after transfer correlated to the day of tumor relapse, and in fact served as a predictive 
marker for therapy efficacy (see figure 5C). 
 
 
Figure 3. Adoptive T cell transfer with TCRs equipped with OX40 or ICOS domains delay tumor 
recurrence and enhance overall survival of melanoma-bearing mice 
HLA-A2 transgenic mice bearing established tumors derived from inoculated B16:A2-YLEP clone (day -12) were 
conditioned with Busulfan and Cyclophosphamide (days -4 and -3) and treated with 6×106 mock T cells or T cells 
transduced with wt TCR, TCR:28ε, TCR:28-OX40ε or TCR:28-ICOSε (day 0). Figure (A) depicts tumor growth 
curves of individual mice (n=6-7 per group). Tumor sizes were measured 3 times a week with a caliper. Dashed 
lines indicate median day of tumor relapse per treatment group (definition of tumor relapse is described in 
Materials and Methods). Percentages of mice being tumor-free at day 115 after T cell transfer are listed in each 
panel. ‘†’ indicates death of mouse unrelated to tumor outgrowth. Figure (B) presents overall survival curves of 
treatment groups. In figure (C) stacked bars represent % of mice with different anti-tumor responses to therapy 
at day 115 after T cell transfer as defined in Materials and Methods.  
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Figure 4. T cells expressing OX40 or ICOS-containing TCR show enhanced persistence in blood 
following adoptive transfer and are enriched for CD8 T cells 
HLA-A2 transgenic mice bearing established B16:A2-YLEP tumors were conditioned with chemotherapy and 
treated with T cells as described in legend to figure 3. (A) Peripheral blood was collected from mice at the 
indicated time points after T cell transfer and absolute numbers of TCR+CD3+ T cells were determined by flow 
cytometry using Flow-Count Fluorospheres. Data are presented as mean numbers per μl blood ±SEM (n=1-7, 
dependent on survival of mice). Statistically significant differences between T cell numbers of mice treated with 
wt TCR T cells and co-stimulatory TCR T cells on day 14 after transfer were calculated with Student’s t-test: 
*p<0.05. (B) Data are presented as mean ratio of CD8+:CD4+ T cells from (A). At the time of transfer, 
CD8+:CD4+ T cell ratios were as follows: wt TCR = 0.03; TCR:28ε = 0.14; TCR:28-OX40ε = 0.1 and  TCR:28-
ICOSε = 0.14. (C) Day of relapse (defined in Materials and Methods) was correlated with total number of 
TCR+CD3+ T cells in blood at day 7 after T cell transfer. Color scheme for individual mice is identical to (A) and 
(B). 
 
Our T cell analyses in peripheral blood were supported by the analyses done in tumors. After 
isolation of TILs from regressing tumors, we observed that TCR+ T cells were present at higher 
frequencies following treatment with TCR:28-OX40ε and TCR:28-ICOSε T cells (~12% of total 
CD3+ T cells), whereas TCR+ T cells were present at lower frequencies following treatment with wt 
TCR and TCR:28ε T cells (~4% of total CD3+ T cells) (see figure 5A). The frequencies of TCR+ T 
cells in relapsing tumors dropped ~10-fold in all treatment groups when compared to regressing 
tumors, with the exception of the TCR:28-ICOSε group. The frequency of TCR+ T cells was 0.1% 
following treatment with wtTCR T cells, whereas the frequencies of TCR+ T cells increased to 0.6% 
C 
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and 1.8% following treatment with TCR:28ε and TCR:28-OX40ε T cells, respectively. In case of 
treatment with TCR:28-ICOSε T cells, relapsing tumors were marked by a substantially increased 
frequency of 13% TCR+ T cells. Again, the ratios of CD8+:CD4+ TILs were inverted in all co-
stimulatory TCR T cell-treated mice when compared to wt TCR (see figure 5B). Next, we 
investigated whether tumor recurrence was associated with differential expression of co-signalling 
receptors in CD3+ TILs. Flow cytometry analyses revealed  that CD8+ TILs of mice treated with 
TCR:28-ICOSε showed an enhanced fraction of T cells positive for CD40L (see figure 6A), while 
CD8+ TILs from mice treated with any co-stimulatory TCR displayed a trend of increased 
frequencies of T cells positive for PD1, LAG3 or TIM3 (see figure 6A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 5. CD8 T cells transduced with 
OX40 or ICOS-containing TCRs show 
increased frequencies in regressing 
tumors 
Mice were treated as described in legend to 
figure 3 and tumor tissues of regressing tumors were collected from 2 mice per treatment group at day 5 after T 
cell transfer. Tumor tissues of relapsing tumors were collected following outgrowth of tumors (>1400mm3) (n=2-
5 per group). TILs, obtained as described in Materials and Methods and defined as CD3+ fraction of cells isolated 
from tumor tissue, were analysed via flow cytometry following staining with CD3, CD4, CD8 and TCR-specific 
Vβ14 antibodies. Figure (A) displays percentages of TCR+ T cells found within short-term cultures of CD3+ T cells 
of regressing and relapsing tumors, while figure (B) shows the ratios of CD8+/CD4+ T cells within TCR+CD3+ T 
cells of regressing tumors. Statistical significant differences between wt and co-stimulatory TCR T cells were 
calculated with Student’s t-test: *p<0.05. 
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Figure 6. TILs expressing TCR:28-ICOSe show enhanced % of CD40L-positivity 
TILs as described in Figure 5 underwent flow cytometric analysis of the expression of co-stimulatory as well as 
co-inhibitory receptors in the CD8+ TILs. (A) This figure depicts the mean % of CD8+ TILs positive for the 
indicated receptors (±SEM, n=2-6 per group) in relapsing tumors. Statistical significant differences between wt 
and co-stimulatory TCR T cells were calculated with Student’s t-test: *p<0.05; **p<0.005; ***p<0.005. (B) this 
figure displays the distribution (in mean %) of CD8 TILs (n=2-6 per group) that are either negative for co-
stimulatory receptors (as in A) or positive for 1, 2 or 3 co-stimulatory receptors (upper panel). The same analysis 
has also been performed for co-inhibitory receptors (lower panel). 
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DISCUSSION 
In this study we have successfully engineered novel co-stimulatory TCRs equipped with the 
intracellular domains of either CD28, OX40, ICOS, 4-1BB or CD40L. This approach has been 
previously employed in chimeric antigen receptors (second or third generation CARs). These co-
stimulatory CARs were shown to enhance tumor regression in a therapeutic setting (19,20,27). 
Similar modifications, i.e., inclusions of heterologous domains into TCR chains, proved challenging 
given the complex mode of surface expression, antigen binding and function of TCRs. Re-iterating 
design and experimental testing of TCRs containing CD28 and CD3ε (22) allowed us to define non-
autologous amino acid boundaries that minimally curtail TCR surface expression and function, 
providing a basis for the in vitro and in vivo evaluation of these new TCRs. 
T cell transductions revealed that levels of surface expression of TCR:28ε, TCR:28-OX40ε and 
TCR:28-ICOSε per CD8+ T cell were enhanced up to 2-fold, whereas the fractions of T cells positive 
for these co-stimulatory TCRs were about half that of T cells positive for wt TCR (25 vs 50% 
expression). The enhanced per-cell expression levels are most likely due to reduced mis-pairing of 
endogenous and introduced TCR chains directed by the tm CD28 domain, as evidenced by Govers 
and colleagues for TCR:28ε (22). The reduced fractions of T cells expressing the co-stimulatory 
TCRs may be due to multiple reasons. For one, introduction of non-autologous sequences into a 
TCR may carry the risk of changing the structure of the TCR in a way that impedes surface 
expression. In a related manner, lack of surface expression may be linked to an inverse effect of 
size of the total transgene. This is supported by the complete lack of expression of TCR:28-
CD40Lε, a transgene that is 1.5 to 2-fold larger in size than wt TCR. This finding is in extension to 
the reported negative impact on surface expression by increased size of 3rd generation CARs that 
were equipped with multiple intracellular domains (18). Second, the natural dimeric arrangement 
of TCRα- and β-chains may interfere with proper trimer formation that is naturally required for 
surface expression and function of the TNFR superfamily members OX40 and 4-1BB (28). Co-
stimulatory molecules derived from the immunoglobulin superfamily members CD28 and ICOS 
normally form dimers, and although speculative, may be a better fit for the TCR format. Along 
these lines, the successful incorporation of OX40 or 4-1BB domains into CARs, and other domains 
such as CD28 or ICOS for that matter as well (20,29,30), may be due to the monomeric nature 
and thus intrinsic flexibility of CARs. To resolve the intrinsic inflexibility of TCRs, we have 
conducted experiments with TCR:4-1BB variants, but could not rescue the expression of this TCR 
despite inclusion of tm 4-1BB (and restoring non-autologous boundaries) (Supplementary figure 
1). Functional assessment of T cells expressing co-stimulatory TCRs revealed a lowered functional 
avidity as determined by EC50 values of peptide-induced IFNγ production. This lowered avidity may 
be in part the result of the structural restraints between the extracellular TCR and the CD28 tm 
domains (22) as mentioned above. However, the EC50 differences between TCR:28-OX40ε and 
TCR:28-ICOSε T cells, despite similar surface expression levels, also suggest distinct signalling 
downstream of these TCRs. Production of other cytokines, such as IL-2 (31), is expected to be 
enhanced in T cells equipped with additional CD28, while ICOS signalling was shown to induce only 
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a minor increase in IL-2 production (32-34). In addition, we expect a reduced production of IL-10 
by TCR:28-OX40ε T cells, as was observed in CARs equipped with such a co-stimulatory domain 
(35). Besides, cytokine production, we have also assessed the expression of co-signaling receptors 
following antigen-stimulation, and found no significant differences with respect to surface 
expression of these receptors in vitro (see supplementary figure 2). 
When testing co-stimulatory TCRs in an adoptive therapy setting, we observed significant delay of 
tumor recurrence and, in particular in the case of TCR:28-ICOSε T cells, complete and long-term 
tumor remissions were observed in half of the mice. Similar results with regard to tumor clearance 
were observed in CARs equipped with ICOS signalling when treating mice suffering from glioma 
and mesothelioma (33,36). TCR:28-OX40ε and TCR:28ε performed similarly with respect to 
delaying tumor relapse when compared to wt TCR, but lagged behind TCR:28-ICOSε T cells with 
respect to complete responses. In an effort to explain this superior response in vivo, we have 
assessed peripheral persistence and accumulation within tumor tissues of T cells expressing co-
stimulatory TCRs. All co-stimulatory TCRs under study stood out for their enhanced persistence in 
the blood, with TCR:28-ICOSε T cells again performing best with >200 TCR+ T cells/µl blood being 
detectable even 115 days after T cell transfer. In addition, the CD8+:CD4+ ratio of peripheral T 
cells was significantly enhanced up to 18-fold when comparing co-stimulatory TCRs versus wt TCR.  
While sufficient numbers of CD4+ T helper cells are required to maintain and support tumor 
rejection, it noteworthy that sufficient numbers of cytotoxic CD8+ T cells are critical to ultimately 
result in effective tumor rejection. The increases in absolute numbers of both CD4+ and CD8+ T 
cells, together with the relative increase in CD8 T cells, are indicative of an ongoing and effective 
immune response in our model. Moreover, total numbers of TCR+ T cells measured in blood at day 
7 after T cell transfer correlated with start of relapse and were in fact indicative of non-
responsiveness to therapy in case of very low TCR+ T cell frequencies. Survival and persistence of 
adoptively transferred T cells in the blood stream have been rendered crucial factors for durable 
anti-tumor responses in clinical studies (37,38). 
Our observations in peripheral blood of enhanced numbers of TCR+ T cells were mirrored in 
regressing tumors. Regressing tumors of mice treated with TCR:28-OX40ε or TCR:28-ICOSε T cells 
showed higher percentages of TCR+ T cells within TILs, and all groups treated with co-stimulatory 
TCR T cells showed an enhanced ratio of CD8+:CD4+ TILs when compared to wt TCR T cells. These 
findings extend earlier reports where enhanced CD8 to CD4 TIL ratios have been identified as 
beneficial prognostic factor in preclinical and clinical studies (39,40). The observed CD8 T cell 
dominance also matches studies in which ICOS engagement was found to promote effector status, 
function and persistence of CD8+ T cells (41,42). Indeed, flow cytometric assessment of CD8+ TILs 
within relapsing tumors revealed that treatment with co-stimulatory TCRs enhanced the 
frequencies of T cells expressing co-inhibitory receptors, indicative of enhanced frequencies of T 
cells in an activated state (reviewed in  (43)). The enhanced performance of both TCR:28-OX40ε 
or TCR:28-ICOSε T cells compared to TCR:28ε may be explained by the CD28-independent 
signaling of the former two TCRs (14,15). As CD8+ TILs are generally marked by enhanced PD-1 
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expression, and PD-1 inhibits CD28 signaling (14,15), TCR:28-OX40ε or TCR:28-ICOSε T cells may 
be less susceptible to PD-1-mediated T cell inactivation. Notably, the expression of CD40L is 
significantly up-regulated in CD8+ TILs following treatment with TCR:28-ICOSε T cells, which 
suggests that additional ICOS-signalling aids to their activation state (44). CD40L may favourably 
affect DC:T cell interactions, and these interactions are generally considered beneficial to the 
outcomes of adoptive T cell therapy (45,46). The exact contribution of the CD4+ T cells towards the 
enhanced therapeutic effect of TCR:28-ICOSε T cells deserves further studies. Along these lines, it 
is noteworthy that enhanced frequency of CD4+ICOShigh T cells was accompanied by enhanced 
tumor reactivity in studies utilizing CTLA-4 blockade (47,48). On the other hand, ICOS signalling is 
reported to be of particular importance in the development of CD4+ T helper 17 (TH17) and T 
regulatory cells (49-54).  
The enhanced T cell numbers within tumor tissues may also be linked to a change in metabolism 
mediated by TCRs with additional co-signalling elements. Indeed, Cao and colleagues showed that 
upon activation, CD8+ T cells up-regulated their energy production through means of glycolysis in 
order to cope with the increased demands in proliferation and effector function (55). Interestingly, 
triggering of ICOS as well as OX40 have been reported to favor a switch towards a glycolytic 
metabolism via the PI3K-Akt–mTOR pathway at the expense of oxidative phosphorylation (56-58). 
Indeed, Kawalekar and colleagues demonstrated that CARs equipped with co-stimulatory signaling 
cassettes may show differential metabolic exhaustion (59). To this end, we are currently studying 
the effects of co-stimulatory TCRs on transcriptomics and metabolomics.  
Taken together, we show that equipping TCRs with co-stimulatory domains, in particular ICOS, 
significantly delays tumor recurrence, results in enhanced numbers of peripheral and intra-tumoral 
CD8 T cells, and mediates complete responses, providing a rationale for further studies into this 
TCR format with respect to adoptive T cell therapy. 
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Supplementary Figure 1: Surface expression and pMHC binding of TCRs that incorporate 4-1BB is not 
rescued by the autologous transmembranal domain of 4-1BB.  
T cells were transduced with the following TCR variants: wt TCR, TCR:28ε, TCR:28-41BBε, TCR-41BBε (with tm 
4-1BB). TCR-transduced T cells were stained with (A) anti-Vβ14 antibody or (B) gp100/A2 pMHC, and analyzed 
by flow cytometry as described in legend to Figure 2. Results are displayed as mean % of T cells positive for TCR 
or T cells that bind pMHC (±SEM, n=2-5). Statistical significant differences between wt and co-stimulatory TCR T 
cells were calculated with Student’s t-test: *p<0.05; **p<0.005; ***p<0.005. 
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Supplementary Figure 2. Co-stimulatory TCRs do not mediate differential expression of co-signaling 
receptors following antigen exposure in vitro 
T cells transduced as described in legend to figure 2A were co-cultured with either B16:A2-YLEP or B16wt cells 
for 24h. Subsequently, T cells were analyzed by flow cytometry for expression of co-stimulatory (CD28, OX40, 
ICOS, 4-1BB and CD40L) and co-inhibitory receptors (PD-1, LAG-3, TIM-3, CTLA-4 and BTLA) in both CD4+ 
(upper panel) and CD8+ (lower panel) subsets of TCR+ T cells. Bars depict the mean change in %  (±SEM, n=3) 
upon antigen stimulation compared to non-antigen stimulation (the latter set to 100%). Statistical significant 
differences between wt and co-stimulatory TCR T cells were assessed with Student’s t-test 
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ABSTRACT  
 Adoptive therapy with engineered T cells shows promising results in treating patients with 
malignant disease, but is challenged by incomplete responses and tumor recurrences. Here, we 
aimed to direct the tumor microenvironment in favor of a successful immune response by local 
secretion of interleukin (IL-) 12 and IL-18 by administered T cells. To this end, we engineered T 
cells with a melanoma-specific T cell receptor (TCR) and murine IL-12 and/or IL-18 under the 
control of a nuclear-factor of activated T-cell (NFAT)-sensitive promoter. These T cells produced IL-
12 or IL-18, and consequently enhanced levels of IFNγ, following exposure to antigen-positive but 
not negative tumor cells. Adoptive transfer of T cells with a TCR and inducible (i)IL-12 to 
melanoma-bearing mice resulted in severe, edema-like toxicity that was accompanied by enhanced 
levels of IFNγ and TNFα in blood, and reduced numbers of peripheral TCR transgene-positive T 
cells. In contrast, transfer of T cells expressing a TCR and iIL-18 was without side effects, 
enhanced the presence of therapeutic CD8+ T cells within tumors, reduced tumor burden and 
prolonged survival. Notably, treatment with TCR+iIL-12 but not iIL-18 T cells resulted in enhanced 
intra-tumoral accumulation of macrophages, which was accompanied by a decreased frequency of 
therapeutic T cells, in particular of the CD8 subset. In addition, when administered to mice, iIL-18 
but not iIL-12 demonstrated a favorable profile of T cell co-stimulatory and inhibitory receptors. In 
conclusion, we observed that treatment with T cells engineered with a TCR and iIL18 T cells is safe 
and able to skew the tumor microenvironment in favor of an improved anti-tumor T cell response. 
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INTRODUCTION 
Up to now, dozens of clinical trials have demonstrated the effectiveness of adoptive therapy with T 
cells that are gene-engineered with T cell receptors (TCRs) or chimeric antigen receptors (CARs). 
Therapeutic successes are most prominent for the treatment of hematological malignancies (1-6), 
whereas in the majority of patients with solid tumors, initial regressions are challenged by rapid 
tumor recurrences. 
Patient responsiveness to immune therapies appears to be related to numbers and location of 
tumor infiltrating lymphocytes (TILs) (7,8). Tumors that have low or negligible numbers of TILs 
may demonstrate intrinsic changes that result in limited T cell infiltration, movement and 
activation, and as such pose barriers to T cell treatments when compared to tumors with high 
numbers of TILs (9,10). In fact, predictive value towards response to clinical T cell therapies has 
recently been attributed to determinants of immunogenicity, such as extent of antigen 
presentation, composition of immune infiltrates, and presence of inhibitors of T cell activity (11). 
Expectedly, intervention with such determinants has the ability to enhance the sensitivity of 
tumors for T cell treatment (12). 
Here, we investigated to what extent local depositions of IL-12 and IL-18 in the tumor tissue would 
enhance the efficacy of adoptive T cell therapy. IL-12 is a heterodimer that consists of the subunits 
p35 and p40 and, although primarily produced by antigen-presenting cells, it is also a product of T 
cells (13,14). Initial studies showed IL-12’s ability to enhance the cytolytic activity of T cells (15), 
aid in the recruitment of macrophages (16), and induce a TNFα-mediated shift towards M1-type 
macrophages (17,18). IL-18 is a pro-inflammatory IL-1-like cytokine that is primarily produced by 
macrophages and is able to drive T and NK cell maturation (reviewed in (19)). Both cytokines 
enable an immunological shift towards Th1-type T cell responses. Notably, IL-12 increases the 
proportion of T cells expressing the IL-18 receptor 1 subunit (IL-18R1), resulting in further 
enhancement of IFNγ production by IL-12 plus IL-18-stimulated T cells (20,21). Despite IL-12’s 
beneficial impact on anti-tumor immune responses in preclinical models, which also holds in early-
phase trials, systemic administration of recombinant IL-12 has been reported to result in 
hepatotoxicity and high systemic levels of IFNγ (22,23). In contrast, administration of IL-18 
revealed no such toxicities in studies with melanoma and renal cell cancer patients, however, did 
not reveal clinical responses either (24-26). We argue that delivery of these two cytokines directly 
at the site of the tumor, either alone or together, will minimize toxic effects and at the same time 
maximize immune-stimulatory effects. In earlier studies, we have shown that the use of CAR-
engineered T cells with inducible IL-12 (iIL-12) enhanced tumor killing without toxicity by 
increasing the numbers and activation of tumor infiltrating macrophages (18). In the current 
study, we have extended these findings and exploited TCR-engineered T cells to provide antigen-
specific and intra-tumoral release of IL-12 and IL-18, and investigated the impact of these 
enhanced T cells on tumor growth, toxicity, T cell phenotype and function. 
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MATERIALS AND METHODS 
Cell culture and reagents 
The human embryonic kidney 293T and Phoenix-Amp cell lines, both used to package retroviruses 
carrying RNA encoding TCRαβ and/or iIL-12 or iIL-18, were grown in DMEM with 10% (v/v) Fetal 
Bovine Serum (FBS; Greiner Bio-one Alphen a/d Rijn, The Netherlands), 200nM L-glutamine, 1% 
(v/v) MEM non-essential amino acids and antibiotics (DMEM complete). Clones derived from mouse 
melanoma cell lines B16BL6 (B16WT) and B16:A2-YLEP (gene-engineered to express a fusion 
protein between the human glycoprotein (gp)100280-288 epitope (YLEPGPVTA) and the HHD 
molecule (27)) were cultured using the same medium, which in case of B16:A2-YLEP cells 
contained neomycin (1 mg/ml) (G418, Calbiochem, La Jolla, CA). In order to enhance HLA-A2 
transgene expression, B16 cells were pre-treated with 100 IU/ml murine IFNγ (Sanquin, 
Amsterdam, The Netherlands) for 24 hours prior to in vitro assays. Mouse splenocytes were 
cultured in mouse T cell medium consisting of RPMI 1640 medium supplemented with 25 mM 
HEPES, 200 nM L-glutamine, 10% FBS, 1% MEM non-essential amino acids, 1 mM sodium 
pyruvate, 50 μM β-mercaptoethanol, antibiotics and 50 IU/ml human recombinant IL-2 (Proleukin; 
Chiron, Amsterdam, The Netherlands). For flow cytometry the following antibodies and pMHC 
multimer were used: anti-TCR-Vβ14-FITC (Beckman Coulter, Fullerton, CA); CD3-PE, CD3-BV510, 
Ly6G-PE-Cy7, CD8-APC-Cy7, F4/80-APC-Cy7, CD4-BV650, 4-1BB-BV421, LAG3-BV421 (all BD 
Biosciences, San Jose, CA); TIM3-APC, BTLA-APC, PD-1-PE-Cy7, OX40-APC (all Biolegend, San 
Diego, CA); CD45-FITC, OX40-PE, CTLA4-PE, 4-1BB-PE, CD40L-PE, CD4-Qdot605, LAG3-APC, 
ICOS-APC, ICOS-PE-Cy7, CD14-PerCP, CD335-eF660 (all eBiosciences, San Diego, CA); and 
gp100/A2Kb pMHC tetramer-PE (a kind gift by Prof. Andrew Sewell, Cardiff University, UK). For 
immunofluorescent stainings, the following primary and secondary antibodies were used: rat anti-
mouse CD3 (clone 17A2), rat anti-mouse CD335 (clone 29A1.4), rat anti-mouse Ly6G (clone RB6-
8C5) (all three from eBiosciences) and rat anti-mouse CD68 (clone FA-11; BioLegend); and donkey 
anti-rat IgG Alexa Fluor 488 (Life Technologies, Carlsbad, California, USA).  
 
TCR and inducible IL-12 and IL-18 constructs 
TCRα and β genes specific for the human gp100280-288 epitope presented by HLA-A2 (gp100/A2) 
were derived from CTL-296 clone (28), murinized and codon-optimized as described earlier (29). 
Subsequently, TCR genes were cloned into the pMP71 vector (kindly provided by prof. Wolfgang 
Uckert, Max-Delbrück Center, Berlin, Germany) with TCRα and β genes separated by an optimized 
T2A ribosome skipping sequence. Sequences of murine IL-12 (a linked dimer consisting of p35 
(NM_000882) and p40 (NM_002187)) and the processed form of IL-18 (NM_001562) were ordered 
from Geneart (not codon-optimized) and cloned into a pSIN vector, which contains 6 repeats of the 
NFAT response element and a minimal mIL-2 promotor, as described in (18). The plasmids with 
iIL-12 and iIL-18 contain a neomycin resistance gene to allow for selection of transduced T cells. 
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T cell transduction 
Total mouse splenocytes were isolated, activated with Concanavalin A (0.5µg/ml) and rhIL-2 in 
mouse T cell medium, and transduced with retroviral supernatant from a co-culture of single 
construct (either TCR, iIL-12 or iIL-18) transfected 293T and Phoenix-Amp cell lines as described 
by Pouw and colleagues (29). To generate T cells that express TCR and either iIL-12 or iIL-18, T 
cells were simultaneously incubated with two retroviral supernatants in a 1:1 ratio (yielding 
TCR+iIL-12 or TCR+iIL-18 T cells). To obtain T cell populations that provide an inducible source for 
both cytokines, used in some experiments, TCR+iIL-12 and TCR+iIL-18 T cells were mixed in a 1:1 
ratio (yielding TCR+iIL-12+iIL-18 T cells). Control (mock) T cells were transduced with empty 
retroviral vector. TCR and mock T cells were cultured as described above, whereas T cells 
harboring (in addition to the TCR) iIL-12 or iIL-18 underwent selection with 1mg/ml of G418 
starting at 24h after transduction and lasting for 72h (for a detailed flowchart of the T cell 
activation, transduction and selection procedure, please see figure 1A and supplementary figure 
1A, B).  
 
Adoptive T cell therapy  
Experiments with mice were approved by the Experimental Animal Committee of the Erasmus MC 
Cancer Institute and carried out in accordance with institutional and national guidelines. For 
adoptive T cell therapy studies we used HLA-A2 transgenic (tg) mice that express a chimeric HLA-
A*0201 transgene (HHD, referred to as HLA-A2) (30). Adoptive transfer of T cells was done as 
described before (27). In short, at day -15, HLA-A2 tg mice were injected subcutaneously with 
0.5×106 of a B16:A2-YLEP clone and at days -4 and -3 mice received a total of two Busulfan 
injections intraperitoneally (16.5 μg/kg ea.), followed a day later by a single Cyclophosphamide 
injection intraperitoneally (200 mg/kg). In some experiments, the mice were not transplanted with 
tumor cells, but followed the same conditioning and T cell treatment protocol. Mice were treated 
with T cells at day 0 and grouped according to one of the following treatments: mock T cells 
(number of T cells equal to TCR T cell group); TCR T cells (total number corrected for 7.5×106 
transduced T cells); TCR+iIL-12 T cells; TCR+iIL-18 T cells; and TCR+iIL12+18 T cells). Tumor 
growth was measured by caliper 3 times a week and tumor volumes were estimated with the 
formula 0.4 x (AxB2) where A represents the largest diameter and B the diameter perpendicular to 
A. Tumor regression or response to treatment was defined as a >30% reduction in size compared 
to day 0, while relapse was defined as a size-increase of the tumor over the course of at least 3 
days preceded by response to treatment. Survival was monitored daily for up to 45 days after 
administration of T cells. Body weight and edema like symptoms were recorded starting at the day 
of tumor inoculation and every third day thereafter. Peripheral blood was collected at day 6 after T 
cell transfer and at weekly intervals thereafter and used to determine numbers of administered T 
cells, whereas plasma was collected at days 16 and day 21 and used to measure cytokine levels. 
Tumor tissues of regressing tumors were collected at day 5 after T cell transfer and snap-frozen in 
liquid nitrogen and stored at -80°C for downstream assessment of cytokines in tumor lysates and 
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Figure 1. Protocol to generate T cells equipped with a TCR and an inducible cytokine construct 
(A) Timeline for transduction procedure that yields TCR- and induced (i) cytokine-positive T cells Optimization of 
individual aspects of the procedure are described in materials and methods and supplementary figure 1. (B) At 
the end of T cell selection (day 7 after T cell activation) T cells that were transduced with TCR and iIL-12 or 
TCR+iIL-18 were labeled with CD8-APC antibody and gp100/HLA-A2 tetramer-PE. Mock and TCR-only transduced 
T cells were stained as controls. T cells were gated for live cells and dotplots are representative of three different 
experiments. Percentages in upper right quadrants represent fractions of CD8+ T cells binding to tetramer. 
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performance of in situ immune fluorescence. Another part of tumor tissue was directly processed 
into TIL suspensions. To this end, tissue was cut into smaller fragments, incubated with 
collagenase (1mg/ml; Sigma, St. Louis, MI) for 45 minutes at 37°C, checked microscopically and 
washed prior to flow cytometry.  
 
Flow cytometry 
T cells or TILs (5×105) were washed with PBS and incubated with antibodies at 4°C or with pMHC 
multimers at 37°C for 30 min. Following staining, T cells were washed again and fixed with 1% 
paraformaldehyde. Absolute T cell counts in mouse blood samples were determined using Flow-
Count Fluorospheres. Events were acquired on a FACS Canto flow cytometer and analysed using 
FCS Express 4 software (BD Biosciences).  
 
Measurement of cytokines 
T cells (6×104/well of 96-wellsplate) were co-cultured with either antigen-positive or negative B16 
cells (2×104/well) in a total volume of 200 µl of T cell assay medium (RPMI 1640, L-glutamine, 
10% FBS, and antibiotics) for 24h at 37°C and 5% CO2. Stimulation with medium was used as a 
control. Subsequently, supernatants were harvested and used to determine cytokine levels by 
standard ELISAs (IL-2, IL-10, IL-12, IFNγ, TNFα: eBioscience, San Diego, CA; IL-18: MBL, Nagoya, 
Japan). Plasma levels of selected cytokines were measured using the ProcartaPlex Mouse 
Th1/Th2/Th9/Th17/Th22/Treg Cytokine Panel (eBioscience) according to manufacturer’s 
instructions. Tumor lysates were generated following sonication (3 cycles of 10s using SoniPrep 
150, MSE, London, UK) of frozen tissue suspended in PBS with protease inhibitors (Protease 
inhibitor cocktail tablets, Roche), and subsequently analyzed for concentrations of IL-12 and IL-18 
via ELISA. 
 
 
In situ immune fluorescence 
Tissue sections were cut at 5 µm and fixed with acetone for 10 min, dried, washed, and blocked 
with PBS/10% donkey serum/0.3% Triton for 30 min prior to immune staining. Next, sections were 
incubated with the primary antibody overnight at 4°C, washed and incubated with the donkey anti-
rat IgG Alexa Fluor 488 for 2h at room temperature in the dark. Sections were covered with 
Vectashield, and kept subsequently at room temperature for 2 h and at 4°C overnight. Sections 
were examined microscopically (Leica, DM IL, 200x magnification) and photographed (Leica DFC 
3000G camera and LAS4 software). Recorded photographs were analyzed using Fiji software (31). 
The number of pictures from each tumor ranged between 12 and 16, and using an in-house 
developed algorithm, the mean number of positively stained cells was determined, and normalized 
for percentages of nucleated cells (DAPI staining).  
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Statistical analyses 
The different treatment groups were compared with the Student’s t-tests, or the Mantel-Cox test in 
case of survival data, using GraphPad Prism5 (GraphPad Software, La Jolla, CA). P values < 0.05 
were considered statistically significant. 
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RESULTS 
TCR+iIL-12 T cells, and to a lesser extent TCR+iIL-18 T cells, produce enhanced levels of 
IFNγ 
We developed a protocol that yielded high numbers of T cells transduced with both the gp100/HLA-
A2-specific TCR and iIL-12 or IL-18. Such inducible T cells showed maximal responsiveness 
towards antigen-positive tumor cells (see figure 1A and supplementary figure 1A+B for details). 
Surface expression of TCR genes and binding to cognate pMHC ranged between 65-75%, 
irrespective of the presence of iIL-12 or iIL-18 (figure 1B). TCR+iIL-12 T cells produced 
>5.5ng/106 cells of IL-12, and TCR+iIL18 T cells produced >75pg/106 cells of IL-18 upon co-
culture with antigen-positive cells (see figure 2A). Co-culturing TCR+iIL-12 T cells and TCR+iIL-18 
T cells at a 1:1 ratio (TCR+iIL-12+iIL-18) demonstrated an expected drop in the antigen-specific 
production of IL-12 and IL-18. Notably, T cells that harbor iIL-12 produced minor amounts of IL-12 
independent of TCR engagement, which was not the case for T cells harbouring iIL-18 (see figure 
2A). When testing antigen-specific production of IFNγ by these T cell populations, we observed a 
significant increase in case T cells harbored iIL-12, iIL-18 or both (see figure 2B) when compared 
to TCR T cells. TCR+iIL-12 and TCR+iIL-12+iIL-18 T cells produced more than twice as much IFNγ 
than TCR+iIL-18 T cells. Furthermore, testing for antigen-specific production of IL-10 revealed that 
both TCR+iIL-12 and TCR+iIL-12+iIL-18 T cells produced significantly increased levels of this 
cytokine. While the various T cell populations also produced IL-2 as well as TNFα upon co-culture 
with antigen-positive B16 cells, their levels of were not affected by either iIL-12, IL-18 or both (see 
figure 2B).  
 
Treatment of melanoma-bearing mice with TCR+iIL-18 T cells results in more cures, yet 
treatment with TCR+iIL-12 T cells adversely affects survival 
We treated HLA-A2 transgenic mice with palpable B16:A2-YLEP tumor (~400mm3) either with 
7.5×106 TCR, TCR+iIL-12, TCR+iIL-18, TCR+iIL-12+iIL-18 or mock T cells (see Materials and 
Methods for details). In the TCR T cell group, 66% of mice showed tumor regression, whereas in 
the TCR+iIL-12, TCR+iIL-18 and TCR+iIL-12+iIL-18 T cell groups these percentages were 66, 100 
and 78, respectively (see figure 3A; for individual tumor growth curves, see supplementary figure 
2). Moreover, treatment with TCR T cells resulted in complete responses (i.e., no detectable 
tumor) until the end of the experiment (day 45 after T cell transfer) in 11% of mice, a result that 
was not improved by treatment with TCR+iIL-12 T cells (see figure 3B). In contrast, treatment 
with TCR+iIL-18 or TCR+iIL-12+iIL-18 T cells resulted in complete responses in 33% of mice. In 
addition, in the group treated with TCR+iIL-12 T cells, mice suffered from tumor recurrence at 
earlier time points than mice in the group treated with TCR+iIL-18 T cells (see supplementary 
figure 2). Figure 3 B provides an overview of the fractions of complete, partial and no responses 
among the different treatment groups. When assessing survival, 29% and 14% of mice treated 
with TCR or TCR+iIL-12 T cells were alive at the end of experiment, respectively, whereas 57%   
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Figure 2. Inducible T cells produce IL-12 and IL-18 upon recognition of cognate antigen, which 
results in enhanced production of IFNγ 
T cells were transduced with one or a combination of the following constructs: empty retroviral vector (mock); 
gp100 TCR (TCR); gp100 TCR and iIL-12 (TCR+iIL-12); gp100 TCR and iIL-18 (TCR+iIL-18). In an additional set 
of experiments, TCR+iIL-12 and TCR+iIL-18 T cells were mixed at a 1:1 ratio (TCR+iIL-12+iIL-18). These T cell 
populations were co-cultured with B16 melanoma cells that were either positive or negative for the gp100 target 
antigen at an effector:target (E:T) ratio of 3:1 for 24h. As a control, T cells were cultured in medium only. (A) 
Levels of IL-12 and IL-18 in culture supernatants were measured via ELISA, and displayed as mean cytokine 
production per 106 T cells ±SEM (n=5). (B) Levels of IFNγ, IL-10, IL-2 and TNFα in culture supernatants were 
measured via ELISA, and displayed as mean cytokine production per 106 T cells ±SEM (n=5). Statistically 
significant differences between T cell populations that were co-cultured with antigen-positive B16 cells were 
calculated with Student’s t-test: *p<0.05; **p<0.01; ***p<0.005. 
 
 
and 43% of mice treated with TCR+iIL-18 or TCR+iIL-12+iIL-18 T cells were alive at the end of 
experiment (see figure 3C). Treatment-related mortality, defined as death of mice after T cell 
treatment not coinciding with tumor outgrowth, occurred in TCR+iIL-12 and TCR+iIL-12+iIL-18 T 
cell-treated mice, with percentages of mice that died within 14 days after T cell transfer being 33 
and 22, respectively. Treatment-related mortality was absent in the TCR and TCR+iIL-18 T cell-
treated mice (see figure 3B). Along these lines, we observed enhanced loss of weight in 56-78% 
(see supplementary figure 3) as well as edema-like toxicities in 29% of the treatment groups with 
iIL-12. Table I provides details on observed therapy-related effects. 
 
 
Administration of TCR+iIL-12 T cells results in compromised T cell persistence and 
enhanced plasma levels of inflammatory cytokines 
As peripheral T cell persistence has been directly linked to clinical anti-tumor efficacy (32), blood 
samples were taken at various time points after T cell transfer and analyzed by flow cytometry for 
the presence of TCR-engineered T cells. We observed increased numbers of pMHC-binding T cells 
in blood of TCR+iIL-18 and the TCR+iIL-IL-12+iIL-18 T cell-treated mice at day 6 after T cell 
transfer when compared to TCR T cell-treated mice (see figure 4A). Numbers of pMHC-binding T 
cells were decreased in the blood at day 6 after treatment with TCR+iIL-12 T cells. It is 
noteworthy, that the ratio of CD8 to CD4 positive T cells was significantly enhanced in the 
treatment groups that received treatment with iIL-18 when compared to the TCR+iIL-12 group 
(see figure 4B). These findings are in line with our in vitro observation that cultures of TCR+iIL-12 
T cells yielded lower cell numbers when compared to cultures of TCR+iIL-18 or TCR T cells (see 
supplementary figure 1A, lower panel). In addition to whole blood, we also collected plasma 
samples on day 16 after T cell transfer, which were analyzed via multiplex assay for the presence 
of cytokines (see figure 5). While plasma levels of IL-12 were low in all treatment groups 
(<7pg/ml), plasma levels of IL-18 were considerably high in all groups (>700pg/ml) and highest in 
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Figure 3. Treatment with TCR+iIL-18 T cells reduces tumor growth and prolongs survival 
HLA-A2 transgenic mice bearing established tumors derived from inoculated B16:A2-YLEP cells were conditioned 
with Busulfan and Cyclophosphamide and treated with 7.5×106 T cells that were mock transduced or transduced 
with TCR, TCR+iIL-12, or TCR+iIL-18; or mice were treated with a mixture of 3.75× 106 T cells transduced with 
TCR+iIL-12 and 3.75× 106 T cells transduced with TCR+iIL-18 (TCR+iIL-12+iIL-18). (A) Waterfall graph of 
percentage change in tumor size between days 3 and 14 after T cell transfer, with each bar representing a single 
mouse. Tumor sizes were measured three times a week with a caliper. Dashed lines indicate average tumor size 
per treatment group. ‘†’ indicates death of mouse, in which case latest record of tumor size has been used. (B) 
Stacked bars representing percentages of mice with different responses to therapy at day 45 after T cell transfer. 
Complete response is defined as absence of a palpable tumor at the end of the experiment (day 45); partial 
response is defined as ≥ 30% tumor regression followed by relapse; no-response is defined as < 30% tumor 
regression; and therapy-related death is defined as death not coinciding with tumor progression (n=9 per 
group). (C) Survival curves of treatment groups. Two mice of each group were sacrificed at day 5 after T cell 
transfer to collect tumors and are omitted from this figure (n=7 per group). 
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Figure 4. Treatment with TCR+iIL-12 T cells results in lowered numbers of CD8 and TCR transgene-
positive T cells in blood 
HLA-A2 transgenic mice bearing established B16:A2-YLEP tumors were conditioned and treated with T cells as 
described in legend to figure 3. (A) Peripheral blood was collected from mice at the indicated time points after T 
cell transfer and absolute numbers of gp100/HLA-A2 pMHC-binding CD8 T cells were determined by flow 
cytometry. Data are presented as mean numbers per μl blood±SEM (n=4-6). (B) depicts the mean ratio of 
CD8/CD4 positive therapeutic T cells at day 6 after T cell transfer ±SEM (n=4-6). Statistically significant 
differences between treatment groups were calculated with Student’s t-test: *p<0.05; **p<0.01. 
 
 
 
 
 
Table I. Therapy-related side-effects of T cells gene-engineered with TCR and iIL-12 and/or iIL-18 
treatment 
maximum weight 
lossa 
edemab 
therapy-related 
deathc 
overall survivald 
mock 57% 0% 0% 0% 
TCR only 11% 0% 0% 29% 
TCR+iIL-12 78% 29% 43% 14% 
TCR+iIL-18 0% 0% 0% 57% 
TCR+iIL-12+iIL-18 56% 29% 29% 43% 
a percentage of mice showing a loss of weight exceeding 10% of starting weight (day -15) 
b percentage of mice developing edema; mice were scored positive for edema according to both, visual 
evaluation by a pathologist and increase in body weight of >3.0% per day over a period of 7 or more days 
c percentage of mice dying within the first 10 days after T cell administration while no tumor growth was detected 
d percentage of mice alive at day 45 
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Figure 5. Treatment with TCR+iIL-12 T cells results in increased plasma levels of inflammatory 
cytokines 
Plasma samples were collected from mice on days 16 and 21 after T cell transfer and were screened for the 
presence of multiple cytokines via multiplex assay (“ProcartaPlex Mouse Th1/ Th2/ Th9/ Th17/ Th22/ Treg 
Cytokine Panel (17 plex)” by eBioscience). Concentrations of IL-12, IL-18, IFNγ, IL-2, TNFα and IL-10 on day 16 
are presented as mean±SEM (n=3). Statistically significant differences between treatment groups were 
calculated with Student’s t-test: *p<0.05; **p<0.01; ***p<0.005. 
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mice treated with TCR+iIL-12+iIL-18 T cells (>1300pg/ml). Of interest, in particular in relation to 
the above-mentioned toxicities, is the observation that plasma levels of IFNγ and TNFα were 
significantly higher in the TCR+iIL-12 and TCR+iIL-12+iIL-18 T cell groups (and negligible in the 
TCR and TCR+iIL-18 T cell groups). IL-2 plasma levels showed no significant difference among the 
tested groups. Plasma levels of IL-10 were increased in mice treated with TCR+iIL-12 T cells 
compared with those mice treated with TCR+iIL-18 and TCR+iIL-12+iIL-18 T cells. 
 
Treatment with TCR+iIL-18 T cells results in enhanced accumulation of CD8 and TCR-
transgene-positive T cells within the tumor 
To better understand the in vivo behavior of TCR+iIL-12 and TCR+iIL-18 T cells, we assessed how 
the different treatments affect T cell infiltration into solid tumors and the phenotype of intra-
tumoral T cells. To this end, we have performed flow cytometry analyses of TILs and observed an 
enhanced frequency of CD8+TCR+ T cells amongst CD3+ TILs upon treatment with TCR+iIL-18 T 
cells when compared to TCR+iIL-12 T cells (39 vs 9%) (see figure 6A, left graph). Looking into the 
ratio of CD8+ and CD4+ T cells, it became apparent that treatment with TCR+iIL-18 but not with 
iIL-12 T cells results in an enrichment of CD8+ TILs (~ 7 vs 0.5, respectively; see figure 6A, right 
graph). Next, we studied the phenotype of  TILs, in particular with respect to co-stimulatory as 
well as co-inhibitory receptor expression. The analysis of percentages of individual co-stimulatory 
or co-inhibitory receptors by CD8+ TILs, nor analysis of their co-expression by these cells, revealed 
no significant difference between treatment groups (see figure 6B and C). Also, phenotypic 
differences were not observed when analyzing CD4+ TILs or analyzing mean fluorescence 
intensities (data not shown).  
 
Mice treated with TCR+iIL-12 T cells demonstrate extensive intra-tumoral infiltration of 
macrophages 
In addition to numbers and phenotype of intra-tumoral T cells, we also assessed the cellular 
composition of the immune infiltrate in more detail. TILs from the different treatment groups were 
assessed by flow cytometry for the presence of T cells (CD3+), macrophages (CD68+), NK cells 
(CD335+) and neutrophils (Ly6G+). Strikingly, we observed that frequencies of macrophages were 
increased in mice receiving TCR+iIL-12 T cells, an observation that went hand in hand with a 
decrease in frequencies of T cells (see figure 7). Neither NK cell nor neutrophil numbers showed 
significant differences between treatment groups. To substantiate these findings we assessed the 
presence of IL-12 and IL-18 in lysates from the same tumor, and showed that the concentrations 
of IL-12 were higher in tumors from the groups treated with TCR+iIL-12 or TCR+iIL-12+iIL-18 T 
cells, whereas the concentrations of IL-18 were higher in tumors from the groups treated with 
TCR+iIL-18 when compared to treatment with TCR T cells. Endogenous levels of IL-18 ranged 
between 400 and 1000pg/ml, while those of IL-12 were below 100pg/ml (see supplementary figure 
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Figure 6. Upon treatment with TCR+iIL-18 T cells, numbers of CD8-positive TILs are enhanced 
without a change in expression of co-signaling receptors 
Mice with regressing tumors (treated with TCR T cells with or without inducible cytokines) were sacrificed (n=4 
per group). TILs were isolated as described in Materials and Methods and analyzed via flow cytometry for the 
expression of CD3, CD4, CD8, TCR, 4-1BB, CD40L, ICOS, OX40, PD-1, TIM3, LAG3 and CTLA-4. (A) depicts the 
percentage of CD8+TCR+ T cells amongst CD3+ TILs (left panel) and the CD8/CD4 ratio of TCR+ T cells within 
CD3+ TILs. Bars in (B) show the mean expression of individual co-stimulatory (left panel) and co-inhibitory (right 
panel) receptors of CD3+CD8+ TILs. (C) provides an overview of the degree of co-expression of co-stimulatory 
receptors (upper charts) as well as co-inhibitory receptors (lower charts). Statistically significant differences 
between treatment groups were calculated with Student’s t-test: *p<0.05. 
 
 
4A). Furthermore, we also assessed the composition of the immune infiltrate using in situ immune 
fluorescence, and quantified the various immune cell types per area tumor tissue. The numbers of 
T cells (CD3+), macrophages (F4/80+), NK cells (CD335+) and neutrophils (Ly6G+) that were found 
in the tumors from the different treatment groups confirmed the findings of the flow cytometric 
analysis (see supplementary figure 4B and C). It is noteworthy that NK cells and neutrophils were 
readily detectable by flow cytometry, while staining for the same markers in tissues slices yielded 
no to negligible detection of either cell type. This discrepancy between both techniques most likely 
relates to the use of different antibodies in different applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mice treated with TCR+iIL-12 T cells show an enhanced number of tumor-infiltrating 
macrophages 
Following T cell treatment, regressing tumors were collected at day 5 after T cell transfer. Tumors were 
dissociated into a single-cell suspension, stained with antibodies directed against CD3 (T cells), CD68 
(macrophages), CD335 (NK cells) or Ly6G (neutrophils), and analyzed by flow cytometry. Figure depicts the 
mean number for each cell type ±SEM (n=4). Statistically significant differences between treatment groups were 
calculated with Student’s t-test: *p<0.05; **p<0.01 
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DISCUSSION 
In this study, we compared the therapeutic impact of IL-12 and/or IL-18 secretion at the tumor 
site by antigen-triggered T cells. To this end, we equipped murine T cells both with gp100-specific 
TCRα/β genes and an inducible cytokine construct. T cells were antigen-responsive and, besides 
being producers of IL-12 or IL-18, produced enhanced levels of IFNγ. The production of IFNγ was 
prominent in case of TCR+iIL-12 T cells and highest in TCR+iIL-12+iIL-18 T cells, which is in line 
with previous reports where T cells were exposed to a combination of recombinant IL-12 and IL-18 
(33). TCR T cells harboring iIL-18, when transferred to mice bearing melanoma positive for the 
gp100 target antigen, resulted in enhanced and more durable anti-tumor responses when 
compared to T cells engineered with a TCR only or TCR and iIL-12. Furthermore, treatment with 
TCR+iIL-18 T cells, but not TCR+iIL-12 T cells, prolonged survival when compared to treatment 
with TCR T cells. 
The low survival in the TCR+iIL-12 T cell treatment group is most likely a result of IL-12-mediated 
toxicities. Mice receiving TCR+iIL-12 or TCR+ iIL-12+iIL-18 T cells demonstrated elevated plasma 
levels of IFNγ and TNFα, clear weight loss, edema-like symptoms and in some cases death. The 
detection of IFNγ and TNFα in plasma is considered a consequence of IL-12-mediated productions 
of these cytokines by tumor-infiltrating immune cells (34). IFNγ is most likely derived from 
administered T cells following infiltration and activation in the tumor tissue. This notion is 
strengthened by our observation that CD335-positive NK cells, as an alternative source of IFNγ, 
were only present at low frequency within the tumors of treated mice. TNFα is most likely derived 
from macrophages since we detected an enhanced frequency of CD68 as well as F4/80-positive 
macrophages in tumors isolated from mice treated with TCR+iIL-12 T cells, and in vitro assays 
revealed no enhanced TNFα production by these T cells. Collectively, our findings extend previous 
clinical studies, where systemic administration of recombinant protein or cDNA encoding IL-12 was 
reported to result in enhanced production of IFNγ and TNFα, changes in blood vessel wall 
permeability, edema and even sepsis-like symptoms (34,35). In fact, a recent study demonstrated 
that treatment of melanoma patients with iIL-12-transduced TILs was accompanied by liver 
dysfunction, high fever, and hemodynamic instability (36). To further assess the observed 
toxicities, we also treated mice without tumor-implant with TCR+iIL-12 T cells and still observed 
enhanced weight loss when compared to mice treated with TCR T cells (see supplementary figure 
3). These findings extend our in vitro observations showing target-independent release of IL-12 by 
these T cells (Figure 2A) as well as those by Zhang and colleagues, who also reported non-specific 
release of IL-12 and reduced fitness when culturing iIL-12-expressing TILs (36). It is noteworthy 
that none of the mice without a tumor implant developed edema or showed therapy-related 
mortality, arguing that although toxicities are related to antigen-independent release of IL-12, they 
may exacerbate in the presence of antigen-positive tumor cells. Non-specific release of IL-12, in 
particular in the setting of TCR-engineered T cells, may be explained by the size of the inserted 
construct. IL-12 is a relatively large cytokine with 550 aa, while IL-18 encompasses 192 aa and, 
like other smaller constructs we tested (data not shown), shows no antigen non-specific release. 
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Finally, we cannot exclude the contribution of host, co-treatment and tumor to the observed 
toxicities. In one of our earlier studies, where we tested iIL-12 in mouse models utilizing CAR-
transduced T cells (18), we did not observe the toxicities as reported in this study, which may 
suggest that mouse strain (C57BL/6 vs NIH-III), pre-conditioning protocol 
(Busulfan/Cyclophosphamide vs no pre-treatment), and type of tumor (melanoma cells vs colon 
carcinoma cells) affect the extent of IL-12-mediated toxicities. 
Treatment with TCR+iIL-18 T cells, not revealing any toxicity, resulted in clearly enhanced anti-
tumor responses. To better understand the immune-enhancing effect of this treatment, we have 
assessed numbers and phenotype of intra-tumoral T cells as well as the presence of other immune 
cell types within tumors. Notably, we observed an enhanced density of TCR-transduced TILs, in 
particular of the CD8 subset, when mice were treated with TCR+iIL-18 but not TCR+iIL-12 T cells. 
Enhanced numbers of CD8+ T cells within tumors are generally considered a beneficial factor with 
respect to tumor evolution and therapy response (7,37,38). The differential treatment effect with 
respect to numbers of TILs can be explained by two lines of arguments. First, our in vivo analysis 
of tumors showed that treatment with TCR+iIL-12 when compared to TCR+iIL-18 T cells results in 
an enhanced presence of macrophages (see figure 7 and supplementary figure 4). These results, 
together with enhanced TNFα levels in sera, argue that macrophages and their product TNFα may 
limit the infiltration of CD8+ T cells as was observed previously using various mouse models 
(39,40). Second, in vitro analysis of T cells demonstrated that iIL-18 when compared to iIL-12 
provides T cells with high expression of co-stimulatory receptors and a low expression of co-
inhibitory receptors (see supplementary figure 5). These traits may be representative of a 
preferred T cell phenotype at the time of adoptive transfer for an effective tumor response. 
Interestingly, when studying the phenotype of TILs, we observed no significant differences in the 
expression of co-stimulatory or inhibitory receptors by CD8+ TILs. When zooming in on TCR 
transgene-expressing TILs, however, we did observe that treatment with TCR+iIL-18 T cells 
resulted in enhanced expression of the co-stimulatory receptor ICOS and the co-inhibitory 
receptors PD-1 and CTLA-4, whereas treatment with TCR+iIL-12 T cells resulted in enhanced 
expression of the co-stimulatory receptors 4-1BB and CD40L and the co-inhibitory receptors LAG3 
and CTLA-4 (see supplementary figure 6). These latter data are difficult to interpret given the fact 
that numbers of TCR+ TILs are extremely low in case of treatment with TCR+iIL-12 T cells. With 
respect to treatment with TCR+iIL-18 T cells, ICOS may contribute to enhanced tumor infiltration 
and prolonged T cell persistence as was demonstrated in adoptive T cell therapy studies ((41); 
Kunert, manuscript in preparation). PD-1, on the other hand, may mark successful antigen-specific 
TCR triggering and T cell activation (42). Notably, the fact that TCR+iIL-12 T cell treatment, when 
compared to TCR+iIL-18 T cells, results in the highest CTLA-4 and LAG3 expressions may provide 
an additional explanation for their lowered ability to mediate tumor clearance. 
The above findings argue that IL-12 has potent immune-stimulatory effects, which may rapidly 
initiate the expression of immune checkpoints. In an effort to downscale negative feedback on T 
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cell activation, we titrated down TCR+iIL-12 T cells and observed that lowering the numbers of 
these cells did not change the effects this cytokine has on the production of IFNγ nor the 
expression of PD-1 (supplementary figure 7; same results were observed for production of IL-10 
and expression of FOXP3, data not shown), arguing that it is difficult to maintain beneficial effects 
of IL-12 towards anti-tumor T cell activity while preventing the induction of a negative feedback. 
These data, together with the toxic effects we noted when using TCR+iIL-12 T cells, do not favor 
further therapeutic studies with T cells carrying iIL-12.  
In conclusion, our findings demonstrate that the therapeutic use of TCR-engineered T cells 
equipped with inducible IL-12 leads to limited anti-tumor effects and severe toxicities in vivo, in 
part due to antigen non-specific release, whereas equipment of TCR T cells with inducible IL-18 
results in enhanced anti-tumor responses without toxicities, most clearly related to increased 
accumulation of CD8 and TCR-transgene-positive T cells within tumors. Taken together, these 
findings advocate further studies towards the use of iIL-18 T cells to address therapy resistance in 
the setting of adoptive T cell therapy. 
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Supplementary figure 1. Generation of T cells expressing TCR and inducible IL-12 or IL-18  
Optimal transduction and selection procedure with respect to numbers of T cells expressing both gp100/HLA-A2-
specific TCR and inducible (i)IL-12 or IL-18. (A) depicts the effect of titrated amounts of neomycin (upper panel) 
on the number of untransduced (mock) T cells and the effect of start (relative to transduction) and duration of 
neomycin treatment (middle panel) on the number of transduced T cells from healthy donors. Mock and 
transduced T cells were cultured according to (Pouw et al., 2007) and used as controls; T cell numbers are 
indicated as fold increase compared to indicated days; and the test condition yielding highest fold-increase is 
indicated in bold. Upon identifying the optimal procedure, T cells were transduced with either empty retroviral 
vector (mock); gp100 TCR (TCR); gp100 TCR and iIL-12 (TCR+iIL-12); and gp100 TCR and iIL-18 (TCR+iIL-18). 
These T cell populations were seeded at 1x106 cells/ml in T75 flasks, and cultured in mouse T cell medium →  
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including 50 IU/ml human rIL-2 up to day 8 following activation of freshly isolated splenocytes. T cell yield was 
monitored microscopically using Trypan Blue exclusion (lower panel). (B) T cells transduced with both TCR and 
inducible mediator were labeled with CD8-APC antibody and gp100/HLA-A2-PE tetramer before start of selection 
(day 2 after T cell activation) and at the end of selection (day 7 after T cell activation).  T cells were gated for live 
cells and dotplots are representative of three different experiments. Mock and TCR-transduced T cells were 
stained as controls. Percentages in upper right quadrants represent fractions of CD8+ T cells binding to pMHC 
complex; test procedure 3 or 4 as in (A) that yielded highest TCR expression is indicated in bold in (A, middle 
panel). 
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Supplementary figure 2. Treatment of mice with TCR+iIL-18 T cells results in prolonged anti-tumor 
response  
HLA-A2 transgenic mice bearing established B16:A2-YLEP tumors were conditioned and treated with T cells as 
described in legend to figure 3. Tumor growth was measured by caliper 3 times a week and tumor volumes were 
estimated with the formula 0.4 x (A x B) where A represents the largest diameter and B the diameter 
perpendicular to A. Depicted are the individual tumor growth curves of mice for each treatment group. Mice 
exceeding a tumor volume of 1200 mm2 were sacrificed while growth lines marked with ‘†’ indicate mice dying of 
causes unrelated to the outgrowth of tumors. 
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Supplementary figure 3. Treatment with TCR+iIL-12 T cells is accompanied by excessive weight loss 
HLA-A2 transgenic mice bearing either established B16:A2-YLEP tumors or no tumor were conditioned and 
treated with T cells as described in legend to figure 3. Body weight of treated mice was recorded starting at 
either the day of tumor inoculation or in case of tumor-free mice at day of conditioning and every third day 
thereafter. Shown is the maximum weight loss during treatment ± SEM (n=6-7) compared to initial weight 
measurements (weight range: 14.6-26.6 grams). Statistically significant differences between treatment groups 
were calculated with Student’s t-test: *p<0.05; **p<0.01; ***p<0.005. 
 
 
 
 
Supplementary Figure 4. Mice treated with TCR+iIL-12 show an enhanced number of tumor-
infiltrating macrophages 
Following T cell treatment, mice with regressing were sacrificed (n=4 per group) on day 5 after T cell transfer. 
Part of tumor was lysed to measure levels of intra-tumoral IL-12 or IL-18; other part of tumor was used for in 
situ staining with CD3 (T cells), F4/80 (macrophages), CD335 (NK cells) and Ly6G (neutrophils) antibodies (all 
rat; secondary antibody: donkey anti-rat IgG Alexa Fluor 488). DAPI stainings were performed to quantify tissue 
areas containing nucleated tumor cells per picture (not depicted). Cell numbers in tissue stainings were 
quantified using FIJI software. (A) lists levels of IL-12 or IL-18 in tumors (n=2). (B) depicts exemplary images of 
the in situ stainings indicating the number of cells for that particular picture (200× magnified, Leica DM IL 
microscope and Leica DFC 3000G camera), while (C) shows the mean number of cells quantified from these 
stainings for each treatment group ±SEM (n=4). Statistically significant differences between treatment groups 
were calculated with Student’s t-test: *p<0.05 
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Supplementary figure 5. CD8 T cells engineered with TCR and iIL-18, when stimulated with tumor 
antigen in vitro, demonstrate no enhanced expression of ICOS but a decreased expression of PD1 in 
vitro. 
T cells were transduced as described in legend to figure 2 and co-cultured with B16 melanoma cells that were 
positive or negative for the gp100 target antigen at an E:T ratio of 3:1. After 24h, T cells were harvested and 
stained for CD3, CD8, TCR and either the co-stimulatory receptors 4-1BB, CD40L, OX40, CD28, and ICOS, or the 
co-inhibitory receptors PD-1, TIM3, LAG3, CTLA4, and BTLA. (A) Expression levels of individual receptors on T 
cells positive for CD3, CD8 and TCR upon antigen-stimulation (%, mean±SEM, n=4 for all treatment groups). 
Statistically significant differences between treatment groups were calculated with Student’s t-test: *p<0.05; 
**p<0.01; ***p<0.005. (B) Fold-changes in expression levels of individual receptors on TCR+iIL-12, TCR+iIL-18 
and TCR+iIL-12+iIL-18 T cells compared to TCR T cells (mean%±SEM; n=4). 
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Supplementary figure 6. Upon treatment with TCR+iIL-12 T cells, CD8 and TCR-transgene-positive 
TILs show enhanced expression of both co-stimulatory and co-inhibitory receptors 
Following T cell treatment, mice with regressing tumors were sacrificed (n=4 per group). TILs were isolated as 
described in Materials and Methods and analyzed via flow cytometry for the expression of CD3, CD8, TCR, 4-1BB, 
CD40L, ICOS, OX40, PD-1, TIM3, LAG3 and CTLA-4. Bars in (A) show the mean expression levels of individual 
co-stimulatory (left panel) and co-inhibitory (right panel) receptors within the CD3+CD8+TCR+ TIL population. (B) 
provides an overview of the degree of co-expression of co-stimulatory receptors (upper charts) as well as co-
inhibitory receptors (lower charts). Statistically significant differences between treatment groups were calculated 
with Student’s t-test: *p<0.05; **p<0.01. 
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Supplementary figure 7. Production of T cell IFNγ as well as T cell expression of PD1 are governed by 
low numbers of TCR+iIL-12 T cells 
T cells were transduced and co-cultured with B16 melanoma cells as described in legend to figure 2. In this series 
of experiments, T cell populations either comprised a single population of T cells (mock, TCR, TCR+iIL-12, 
TCR+iIL-18) or a combination of TCR+iIL-12 and TCR+iIL-18 T cells at the indicated ratios. After 24h, 
supernatants were collected and T cells were harvested. (A) Levels of IFNγ in culture supernatants are measured 
by ELISA and displayed as mean±SEM (n=4). (B) Percentages of PD-1 staining within CD3+ CD8+ TCR+ T cells 
are determined by flow cytometry and displayed as mean±SEM (n=3). Statistically significant differences 
between T cell populations were calculated with Student’s t-test: *p<0.05; **p<0.01; ***p<0.005. 
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In the preceding four chapters, I aimed to address major challenges that may currently impede 
TCR gene therapy of solid tumors through the following means: 
 
1. Selection and validation of tumor specific target antigens and corresponding TCRs 
2. T cell engineering to counteract local immune suppression 
 
In this chapter, I aim to summarize my findings and put them into perspective with respect to 
recent developments in the field of immune-oncology. Finally, I aim to propose future designs for 
clinical trials with TCR-engineered T cells, incorporating beneficial aspects outlined in previous 
chapters. 
 
 
7.1. Selecting suitable antigens and TCRs 
Evidently, the search for an ideal T cell target antigen and a therapeutic TCR cannot be conducted 
independently from each other. This is due to the molecularly complex relationship between 
antigen expression/processing and TCR expression/affinity that within a window of set criteria 
results in full activation of TCR-transduced T cells (explained below). The following three 
subheadings detail and discuss our own and others’ attempts to select antigens and obtain TCRs 
that provide optimal antigen:TCR efficacy. 
 
7.1.1. Target antigens 
Ideally, T cell target antigens are selectively expressed by tumor tissue and not by healthy tissue. 
Hence, they are not expected to evoke a response against self. At the same time, target antigens 
should have proficient immunogenicity to initiate an effective anti-tumor response. Since reported 
differences between cancer cells and healthy cells are generally based on self-peptides, these 
requirements have been one of the major challenges of TCR gene therapy. In most cases, 
disturbances of the cell-cycle or other regulatory mechanisms lead to altered expression levels of 
antigens that were already present in cancer cells, rather than presentation of entirely novel 
antigens (1,2). Initial clinical trials utilized TCRs directed against differentiation or over-expressed 
self- antigens in tumor tissues such as MART-1, CEA or gp100 (3-6). The on-target toxicity 
observed in these trials however, led to a shift in preferred target targets. Recent trials have 
focused more on cancer germline antigens (CGAs) such as NY-ESO1 (5). One of the favorable 
characteristics of these antigens is, at least for some CGAs, that expression is limited to cancer as 
well as germline cells (i.e. gonads, where lack of MHC expression renders these antigens invisible 
to TCRs). While expression of CGAs is thus more restricted to immune-privileged organs, the 
average expression levels of these antigens are lower compared to that of differentiation or over-
expressed antigens and more heterogeneous between different tumor types and even within 
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individual tumors (7). In chapter 3 of this thesis we have established that MAGE-C2 (MC2), a 
member of the CGA family, represents an antigen that can be targeted in tumor cell lines derived 
from different histologies such as melanoma, head and neck cancer, triple negative breast cancer s 
well as bladder cancer. Furthermore, we have established that the level of T cell response directly 
correlates to the level of MC2 expression, but not to the expression level of co-signaling molecules 
that are involved in T cell activation. In chapter 4 we provided additional evidence that MC2 
expression is virtually absent in most healthy tissues, with the exception of the testis. 
Summarizing our own findings, MC2 fulfilled criteria that we set for an ideal target antigen to be 
targeted in a clinical trial, namely a safe expression profile and initiating T cell responsiveness. In 
addition, MC2 is expressed in various tumor types, and MC2 expression levels have been reported 
to correlate to poor patient prognosis as well as mesenchymal to epithelial transition in breast 
cancer  (8,9), highlighting its role in driving cancer development. It is noteworthy that the 
strongest arguments for MC2 as a safe, yet effective target antigen come from observations of a 
clinical trial, where clearance of solid melanoma tumors occurred due to high numbers of 
endogenous MC2-specific T cells. At the same time, no signs of T cell mediated toxicity were 
observed. Validation of the MC2-specific TCRs, which we identified from these patient-derived T 
cell clones, is discussed in more detail in the next subheading.  
 
When discussing selection of target antigens, one particular group of antigens has been receiving 
increased interest recently: neoantigens. These are antigens derived from somatic mutations 
occurring throughout carcinogenesis. Studies have shown that tumor-infiltrating lymphocytes that 
specifically recognize mutated antigens do occur in patients (10-13). In addition, boosting 
endogenous T cell responses using checkpoint inhibitors seems to have a higher impact on patients 
with a higher mutational burden (14,15). Moreover, targeting neo-epitopes either via vaccination 
(16,17) or transfer of peripheral blood mononuclear cell (PBMC) or tumor-infiltrating lymphocyte 
(TIL) populations (18-20) resulted in measurable tumor regression in melanoma and colorectal 
cancer patients. While targeting neoantigens has proven its feasibility as indicated by the above 
studies, detection and prediction of these mutations remains challenging. The diverse genetic 
landscapes in tumors, due to different histological origins or the fundamental genetic variation 
between patients, makes this process a highly personalized approach. In fact, overlap in specific 
mutations remains rather rare and just like CGAs and overexpressed antigens, immunogenic 
mutations remain subject to dynamic changes induced by T cell pressure (18,21,22). The isolation 
or selective expansion of neoantigen-specific T cells from autologous patient material is a critical 
element towards development of such personalized adoptive T cell therapy. Novel approaches to 
facilitate these processes encompass expansion from TILs or peripheral blood through co-culture 
with autologous APCs expressing neoantigen minigenes (12,23) or cell sorting with the use of 
peptide MHC multimer libraries (24,25). Notably, both TIL and vaccination approaches, rely on the 
condition that a patient’s endogenous T cell repertoire contains T cell clones with sufficient avidity 
towards their target. 
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7.1.2. T cell receptors 
Once a target antigen is chosen or selected, one can start isolating and selecting corresponding 
TCRs for therapeutic use. Also the latter selection has to adhere to several criteria. In order to 
trigger an adequate immune response, TCRs require sufficient affinity for their respective target 
antigen to ensure optimal T cell activation and subsequent display of effector functions, while at 
the same time the TCR requires sufficient specificity to prevent or limit T cell activation when 
encountering peptide-MHC complexes that are similar yet not identical to the cognate peptide-MHC 
complex. The range of a TCR’s affinity, contributing to a T cell’s avidity, may differ depending on 
the source of T cells. On the one hand, TCRs derived from patient material (TILs, PBMC after 
peptide vaccination, etc.) have passed thymic selection, resulting in TCRs of only low to 
intermediate affinity for self-antigens (26,27). On the other hand, TCRs derived from a non-
tolerant repertoire of T cells that were co-cultured with artificial antigen-presenting cells pulsed 
with peptides of interest (28) or from transgenic mouse models equipped with human TCR and HLA 
repertoires (29) can reach high affinities for the chosen target antigen. The affinity requirements 
for a TCR intended for therapeutic use depend on properties of the cognate antigen, such as extent 
and homogeneity (i.e., fraction of cells within a tissue) of expression, and epitope binding to MHC. 
The MC2 specific TCRs we evaluated in chapter 3 of this thesis were derived from patient T cell 
clones. As these TCRs are derived from a tolerant repertoire, our expectations were that their 
affinities would be low to intermediate, and their specificities high. Indeed, four TCRs recognizing 
MC2 epitopes in the context of HLA-A2 (TCRs 4, 6, 11 and 16) displayed a low to intermediate 
range of affinities for their cognate epitopes. Responses of TCR-engineered T cells towards tumor 
cell lines that demonstrated low expression of MC2 were negligible, whereas enhancement of MC2 
expression (see 7.1.3) enhanced T cell responses. No T cell responses to healthy cell lines were 
observed. TCRs 6 and 16 showed strongest MC2-specific activation of T cells and displayed a clear 
breadth of responsiveness across tumor cell lines of different histological origins (see chapter 4, 
table I for an overview). Safety assessment of both TCRs was conducted in chapter 4. Although 
both TCR 6 and TCR 16 were derived from an autologous repertoire and have a low-risk of cross-
reactivity versus self-antigens, negative thymic selection of T cells may not have been 100% 
waterproof. The reporting of autoimmune side effects following adoptive transfer of T cells using 
patient-derived TCRs, or checkpoint blockade-mediated reactivation of endogenous T cells 
substantiate this notion. The thymic escape of self-reactive T cells is most likely a trade-off 
between producing a self-tolerant yet sufficiently diverse and responsive TCR repertoire (30). In 
order to assess the risk of cross-reactivity, we carried out initial, unbiased testing of TCR-
transduced T cells by exposing them to a library of 114 HLA-A2-eluted peptides. In these assays, 
none of the TCRs showed signs of activation aside from responses towards their respective cognate 
peptides. For a more individual, TCR-specific approach we determined recognition motifs, meaning 
the amino acids and their positions within the target epitope that are critical for recognition by the 
TCR. To this end we used a set of altered peptide ligands (APLs). Subsequently, we determined the 
frequency of these recognition motifs within the human antigenome (31) and tested whether T 
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cells transduced with TCR 6 or TCR 16 were able to respond to these matched peptides in an 
artificial (peptide loaded cells) or endogenously expressed and presented (cell lines) setting. It is 
noteworthy that TCR 16 showed a highly restrictive recognition motif, with 7 out of 9 consecutive 
amino acids that could not be altered without losing TCR recognition (xLKDVEERx). Antigenome 
screens revealed only a single additional antigen that harbors this recognition motif: MAGE-C1 
(MC1). Subsequent co-culture of TCR-engineered T cells with target cells loaded with the MC1 
peptide revealed a 5-fold higher EC50 value of TCR 16 when compared to the cognate peptide. Co-
culture with tumor cells expressing native MC1, however, failed to initiate T cell activation. Only 
one other TCR with such a restricted recognition motif and lack of cross-reactivities has been 
described to date in vitro: a TCR specific for the over-expressed survivin antigen (32). TCR 6, 
possessing a less restricted recognition motif, was predicted to recognize 27 additional epitopes, 
yet the peptide of only a single antigen was able to trigger T cell activation at a 2.5-fold higher 
EC50 value when compared to the MC2 peptide. Also this antigen turned out to be a CGA, namely 
MAGE-B4 (MB4). Similar to TCR 16, TCR 6 failed to initiate T cell activation when co-cultured with 
tumor cells expressing MB4. 
It is important to note that the use of APLs, in which an alanine or glycine is generally used to 
substitute a single amino acid, does not cover all possible amino acid changes at any given position 
and may thus under-estimate the cross-reactivity of a TCR. To improve the assessment of a TCR’s 
recognition motif, it would be possible to use extensive peptide libraries that contain random 
amino acid substitutions at multiple positions (30,33). Notwithstanding that testing such extended 
libraries provides a better coverage of non-cognate peptides (including foreign peptides), we would 
like to emphasize that cross-reactivities against self-peptides as observed in patient studies using 
TCR-engineered T cells so far (34,35) have been identified by the proposed assays in chapter 4. 
In fact, we would like to argue that the proposed identification of recognition motifs, together with 
other assays mentioned in chapter 4, should be considered a useful tool to significantly narrow 
down the list of cross-reactive self-peptides when assessing clinical TCRs. Taken together, in 
chapters 3 and 4, we have established that the patient-derived TCRs we obtained, once 
introduced into T cells, provide functional avidity towards their cognate peptide as well as 
negligible cross-reactivity against self-peptides. 
 
7.1.3. Enhancing T cell efficacy through epigenetic drugs 
The optimal window of TCR:antigen interactions, as pointed out earlier, is governed by a 
molecularly complex relationship between antigen expression (including affinity of peptide for 
MHC) and TCR affinity for pMHC. Despite the fact that this window may be narrow, it can be shifted 
towards enhanced TCR:antigen interactions and hence enhanced T cell responses. For this 
purpose, different TCR-modifications or patient pre-treatments can be employed to enhance the 
efficacy of T cell treatments (see figure 1). 
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The first modification is TCR affinity enhancement, which has been applied for clinical TCRs derived 
from tolerant patient repertoires or vaccinated mice ((6,22,36), see also Table 2 of Chapter 2). In 
order to increase the affinity of a TCR for its cognate peptide, amino acid in one or several of the 
complementarity determining regions (CDRs) of the TCR are substituted ((37); Govers, manuscript 
submitted). Although TCR affinity clearly governs T cell avidity, it is important to realize that there 
may be a strict window of TCR affinities within which antigen-specificity is preserved. TCR affinities 
outside such a window may result in loss of specificity and/or T cell function, i.e., minor affinity 
enhancements resulting in a KD ≥4µM improved antigen-specific T cell function, while TCRs 
enhanced to a KD <1µM drastically lost peptide-fine specificity ((38); Govers manuscript 
submitted). Thus, T cells transduced with an affinity enhanced TCR may result in enhanced clinical 
response rates, such a modification may be accompanied by an increased degeneracy of the TCR 
recognition motif (Govers, manuscript submitted; chapter 4 of this thesis). This increases the 
general risk of off-target toxicity as seen in adverse effects described in recent clinical trials 
(35,39) and highlights the need for thorough safety assessments as discussed in chapter 4.  
 
The second modification is upregulation of target antigens, which we applied through the use of 
epigenetic drugs in chapter 3. In particular two types of epigenetic drugs are currently 
investigated in combination with immune therapy: histone deacetylase (HDAC) inhibitors and DNA-
methylation (DNMT) inhibitors. HDACs aim at reducing DNA packaging around histones, thus 
allowing for the (over-)expression of genes usually repressed in cancer cells. DNMTs prevent 
methylation of genes which is also a means to reduce expression. While both these types of agents 
were initially thought to contribute towards an anti-tumor response by primarily de-repressing 
cancer suppressor genes or cell cycle regulators in hematological diseases (reviewed in (40,41)), in 
recent years the understanding emerged that their epigenetic effect impacts anti-tumor immune 
responses as well. One recently appreciated mechanism is enhancement of tumor cell 
immunogenicity through expression of usually silenced genes. These genes may be derived from 
benign retroviruses (42-44) or from for instance CGAs such as MC2 or NY-ESO1. We were able to 
show that treating tumor cell lines of various origins with the DNMT inhibitor Azacytidine and the 
HDAC inhibitor Valproate upregulated existing or enabled de novo gene expression of MC2. 
Treatment of cell lines of healthy origin did not affect CGA expression. De-repression of CGAs is 
usually the combined result of DNA de-methylation, dissociation of polycomb proteins and shifting 
of euchromatin markers such as for example BORIS (a CCCTC-binding factor (CTCF)-paralog) at 
the cancer-germline promotor site (45). Healthy cells demonstrate strict epigenetic silencing of 
CGAs, and are usually devoid of for instance BORIS, which prevents transcriptional activity of 
certain chromatin areas (46,47). In contrast, tumor cells are generally intrinsically disrupted in 
their gene silencing, in which case treatment with epigenetic drugs is thought to further counteract 
gene silencing while healthy cells remain unaffected (48,49). Next to making tumor cells more 
‘visible’ to the immune system, another mechanism by which epigenetic drugs enhance tumor 
immunogenicity is enhancement of the production of chemokines involved in immune cell migra- 
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Figure 1. Manipulating TCR:antigen interactions to enhance TCR gene therapy 
TCR:antigen interaction dictates T cell responsiveness, which occurs within a window (schematically illustrated by 
red rectangle) that is set by antigen expression (bottom triangle) and TCR affinity (upper triangle). In the 
endogenous setting (top panel) low affinity TCRs (as a consequence of thymic selection against self-antigens) or 
low or no expression of CGAs may prevent effective anti-tumor responses. One can shift the TCR:antigen 
interactions towards improved T cell responses by enhancing a TCR’s affinity (middle panel); this shift potentially 
introduces the risk of  reducing TCR specificity. One can also favorably shift the TCR:antigen interactions by 
enhancing antigen expression through epigenetic drugs (lower panel); this shift requires to check for 
maintenance of tumor-specific antigen expression. 
 
tion as well as production of IFNγ and TNFα by effector cells (50). These epigenetic drugs may 
trigger the viral defense pathway through enhanced levels of retroviral RNAs (42), resulting in up-
regulation of the type I and type II interferon families, such as interferon-gamma receptor 1 and 
STAT, as well as antigen processing and subsequent presentation (51). Interestingly, the up-
regulation of type I interferons such as IFNα may further potentiate the anti-tumor effects of 
Azacytidine (52). 
When it comes to the utilization of epigenetic drugs in combination with immune therapy, there are 
already several exemplary clinical trials ongoing. The majority of these trials focusses on 
combination treatments of PD-1 blockade (Nivolumab, Pembrolizumab) with DNMTis (Azacytidine, 
Vorinostat) (53). Previous trials revealed how crucial timing and dosage of these agents are in a 
clinical setting. For instance, epigenetic drugs are intrinsically toxic to hematopoietic cells (hence 
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their initial use in treating hematological malignancies). Recent preclinical studies demonstrated 
that gene expression effects of epigenetic drugs on tumor cells may already occur at low doses, 
thus reducing toxicity risks (54,55). 
 
In line with these findings and our own observations, we plan to include epigenetic pre-treatment 
of patients as part of a Phase I clinical trial that utilizes TCR 16 transduced T cells for patients 
suffering from MC2/HLA-A2-positive melanoma as well as head-and-neck cancer.  
 
Box 1. Major Findings of chapters 3 and 4 
Selecting and testing antigen and TCRs 
 Patient blood with enhanced frequencies of tumor-specific T cell clones, potentially following 
treatment, provide source a good starting point to obtain effective and safe TCRs. 
 Expression of MAGE-C2 (MC2) may be upregulated through the use of epigenetic drugs such 
as Azacytidine and Valproate in cancer cell lines of various histological origins. 
 Epigenetic drugs do not upregulate MC2 expression in healthy cell lines. 
 Responsiveness of MC2-specific TCRs is directly correlated to expression levels of MC2, but 
independent of expression levels of CD80, CD86, programmed death-ligand 1 (PD-L1) and PD-
L2. 
 Epigenetic drug-pretreatment of tumors in combination with MC2-specific TCRs provides an 
effective therapy when testing cell lines from melanoma, head-and-neck, bladder and triple-
negative breast cancers in vitro. 
 
In vitro safety assessment of TCRs 
 TCR gene therapy trials of recent years highlight the need to thoroughly assess the risk of on-
target and off-target toxicity. 
 Transcriptomic analyses and RT-PCRs, and in some cases immune histochemistry, of healthy 
tissues are suitable tools to assess the expression of candidate target antigens and the risk of 
on-target toxicity. 
 Initial safety assessment of TCRs can be conducted by testing responsiveness of transduced T 
cells to HLA-restricted peptide libraries and cell lines transduced with allogenic HLA molecules. 
 For TCRs with a therapeutic intent, it is recommended to identify individual recognition motifs 
to properly assess risk of off-target toxicity. 
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7.2. T cell engineering to counter the immune suppressive tumor 
microenvironment 
Solid tumors possess numerous ways of avoiding detection or inhibiting a response mounted by 
the immune system (in part reviewed in chapter 2; also see Chapter 1, figure 2 for an overview 
of evasive mechanisms). Next to up-regulation of checkpoint inhibitors or down-regulation or loss 
of HLA (or other antigen-presenting) molecules, tumors may prevent T cells from entering the 
tumor site. Furthermore, enhanced recruitment of immune inhibitory cell types and changes in the 
cytokine milieu may interfere with the activity of T cells. The following two subheadings propose 
approaches to modify therapeutic T cells in an attempt to counter immune-suppressive 
mechanisms in the tumor micro-environment. 
 
7.2.1 Co-stimulatory TCRs and enhanced T cell fitness 
Full activation of therapeutic T cells requires multiple interactions, primarily the binding of TCR to 
its cognate antigen and secondarily the binding of a co-stimulatory receptor on the T cell to a 
corresponding ligand on an antigen presenting or tumor cell (i.e. CD28 and CD80/86) (56). Tumors 
are known to down-regulate or completely abrogate the expression of co-stimulatory ligands (see 
Chapter 1, figure 2 for an overview of evasive mechanisms). Due to the lack of co-signaling, T 
cells can become anergic despite continuous TCR stimulation, reducing their proliferation and anti-
tumor effector functions (57). In chapter 5 we propose to address early T cell anergy by 
integrating co-stimulatory signaling elements into TCRs. This approach has proven feasible in CAR-
mediated T cell therapy (58-60) and has also been shown by our laboratory to enhance treatment 
responses in TCR-mediated T cell therapy (61,62). The latter observations were obtained using an 
expression cassette, which integrated CD28 and CD3ε signaling elements into a gp100-specific 
TCR, and which was defined by re-iterative optimization experiments. We made further attempts, 
using this expression cassette, to enhance TCRs by replacing the intracellular domain of CD28 with 
those of OX40, ICOS, 4-1BB and CD40L. Initial in vitro assays revealed that the TCR:28-4-1BBε 
and the TCR:28-CD40Lε variant were not expressed by T cells and that TCR:28ε, TCR:28-OX40ε 
and TCR:28-ICOSε, although mediating T cell function, showed reduced affinity towards the 
cognate peptide when compared to the wtTCR (see chapter 5 for details). However, when 
evaluating the impact of TCR:28ε, TCR:28-ICOSε and TCR:28-OX40ε TCRs in our gp100 melanoma 
mouse model, we observed that all three co-stimulatory TCRs improved therapy significantly when 
compared to wtTCR. TCR:28-ICOSε T cells in particular led to complete cures in 50% of the mice 
and more than doubled the time till tumor recurrence up to 40 days after T cell injection. We found 
that one of the most outstanding features of these co-stimulatory TCR T cells was their enhanced 
persistence in blood and increased numbers in regressing tumors, which in general is considered a 
beneficial factor with respect to therapy response (63,64). Notably, the number of therapeutic T 
cells within the blood one week after transfer correlated with the day of relapse, similar to 
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observations made in clinical trials (65). To better understand enhanced T cell persistence, we are 
currently investigating the impact of co-stimulatory signaling on T cell phenotype and metabolism. 
With regard to the former, the enhanced expression of CD40L in TCR:28-ICOSε T cells is of 
particular interest. The interaction of CD40L on T cells with CD40-bearing dendritic cells (DCs) 
within the tumor was determined essential in successful tumor clearance through adoptive T cell 
therapy (66,67). With regard to the latter, skewing the energetics of T cells towards glycolysis has 
been described as a result of triggering both ICOS and OX40 pathways (68-70), possibly providing 
them with a proliferative advantage within the tumor microenvironment.  
With the aim to translate our findings from this gp100 model into a clinical trial, we will test the 
use of TCR:ICOS specific for an antigen with a more restricted, safer expression (i.e. MC2) and 
evaluate such TCRs further. 
 
7.2.2 Smart T cells and production of immune-stimulating cytokines 
Cytokines impact T cell differentiation and effector function (reviewed in (71)) and tumors have 
been shown to drive differentiation of effector T cells towards a more exhausted phenotype. While 
it is possible to drive therapeutic T cells into a preferential differentiation and/or effector state 
using cytokines ex vivo prior to transfer into the patient (72,73), other can be used enhance T cell 
effector functions. Two examples of cytokines we would like to administer locally in order to 
enhance T cell function are the pro-inflammatory cytokine IL-12 which is known to enhance 
cytolytic activity of T cells (74) and IL-18, a pro-inflammatory cytokine able to drive T and NK cell 
maturation (75). Systemic application of IL-12 in patients was is not considered feasible due to 
toxic side effects (76). Systemic application of IL-18 on the other hand, while non-toxic yielded no 
clinical responses (77,78). In chapter 6 of this thesis we have set up a system that allows for 
inducible, local production of either IL-12 or IL-18 at the tumor site. We optimized transduction 
conditions in order to sequentially equip primary T cells with a gp100-specific TCR, and either 
murine IL-12 and/or IL-18 under the control of a nuclear-factor of activated T-cell (NFAT)-sensitive 
promoter (iIL-12 and iIL-18, respectively). Initial assessments of these double transduced T cells 
in vitro indicated that antigen-specific activation was required to induce cytokine production. 
However, when assessing the value of TCR+(i)cytokine in our in vivo model, we observed that use 
of TCR+iIL-12 T cells in tumor bearing mice triggered severe side effects such as severe weight 
loss as well as edema and reduced overall survival compared to treatment with TCR T cells without 
iIL-12. Alongside these toxicities we observed enhanced infiltration of the tumor by macrophages 
and enhanced serum levels of IFNγ and TNFα. The later finding mirrors observations from studies 
that tested systemic administration of IL-12 (76,79). Notably, treatment of melanoma patients 
with iIL-12 TILs resulted in similar side effects (80). In contrast, the use of TCR+iIL-18 T cells 
enhanced anti-tumor responses and prolonged survival without any kind of overt side effects. This 
can be in part accredited to an enhanced frequency of therapeutic CD8+ T cells within tumors 
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(63,64) compared to the mice treated with TCR+iIL-12 T cell . Our findings highlight that while the 
inducible release of cytokines at the tumor site seems a promising approach to enhance T cell 
therapy, the choice of cytokine (or other mediator) and confirmation of restricted release are 
crucial. Our in vitro studies showed that the T cell activation leads to production of massive 
amounts of IL-12 under antigen-positive conditions as well as unspecific release of small amounts 
of IL-12 under antigen-negative conditions. In vivo we observed an enhanced infiltration of 
macrophages into the tumors of TCR+iIL-12 T cell-treated mice, which may argue that the effect is 
localized, but it cannot be excluded that part of the produced IL-12 is leaking from the tumor 
microenvironment into the periphery, resulting in the systemic effects we observed. The type of 
tumor and its antigen targeted (location, vascularity, etc.) or the targeting receptor may further 
affect the risk for toxicities. Indeed, Chmielewski and colleagues did not observe toxic side effects 
in a colon-carcinoma model using CAR+iIL-12 T cells (81), while we in a melanoma model and 
Zhang and colleagues in melanoma patients did observe side effects when using TCR+iIL-12 T cells 
(80). As our findings with iIL-18 indicated, inducible production of cytokines without leakage and 
no side effects can be achieved. In extension to IL18, we are currently also assessing the value of 
inducible chemokine constructs which have both proven their importance and value in clinical trials 
(82-86). 
 
7.3. Suggested improvements of TCR gene therapy 
Cancer is a highly diverse disease that is challenging to target specifically and that actively 
counteracts the immune system. The latter probably being one of the major factors that allows its 
growth and treatment resistance to begin with (2,87). In order to provide a most optimal therapy 
approach using TCR engineered T cells, these challenges can be addressed at multiple levels as 
exemplified in this thesis: i.e., selection of target antigen and corresponding TCRs, costimulatory 
TCRs, inducible cytokine production and epigenetic pre-treatment of patients (see figure 2). 
A proposed future TCR T cell trial should center around the proper selection of a tumor-restricted, 
sufficiently expressed target antigen (i.e., MC2) as well as the use of a TCR with sufficient affinity 
for its target (i.e., TCR 16) as described in 7.1. Both, antigen and TCR should undergo stringent 
safety assessment to limit the risk of on- and off-target toxicities. To further enhance anti-tumor T 
cell responsiveness in particular against CGAs, epigenetic drugs (i.e. Azacytidine and Valproate) 
should be used to further boost antigen expression and sensitize tumors to T cell treatment. In 
order to counteract the immune suppressive tumor micro-environment, multiple approaches are 
available and may be individually selected to match dominant suppressive mechanisms:  
therapeutic T cells could be equipped with co-stimulatory TCRs (i.e., TCR:28-ICOSε), making their 
activation independent of co-signaling ligand expression by tumor cells, or inducible and local 
production of cytokines (i.e., iIL-18) may be employed to enhance effective T cell responses.  
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Box 2. Major Findings of chapters 5 and 6 
Co-stimulatory T cells 
 An optimal expression cassette (harboring tmCD28 and icCD3ε) enables T cell surface 
expression of TCRs equipped with ic domains of the co-stimulatory receptors CD28, ICOS or 
OX40 
 TCRs equipped with CD28, ICOS or OX40 delay tumor relapse in a gp100 melanoma mouse 
model. 
 TCR:28-ICOSε T cells mediate enhanced tumor-free survival. 
 TCR:28-ICOSε and TCR:28-OX40ε T cells persist longer in peripheral blood than wt TCRs and 
show enhanced numbers within the tumor. 
 
Inducible cytokine production 
 Therapeutic T cells transduced with a TCR and an inducible cytokine construct produce such a 
cytokine only upon antigen-specific activation. 
 Adoptive transfer of TCR T cells with inducible (i)IL-12 to melanoma-bearing mice resulted in 
severe, edema-like toxicity, enhanced levels of inflammatory cytokines in blood, enhanced 
infiltration of macrophages into the tumor and reduced overall survival. 
 Adoptive transfer of TCR T cells with iIL-18 to melanoma-bearing mice resulted in significantly 
reduced tumor burden and prolonged overall survival, without side effects. 
 iIL-12 T cells show enhanced expression of co-inhibitory receptors, while iIL-18 T cells 
exhibited a favorable profile of T cell co-stimulatory and inhibitory receptors. 
 
While the above-mentioned approaches carry the potential to improve therapy for patients, 
resulting in tumor clearance and prolonged survival, it is important to realize that cancer is a 
dynamic disease. The mechanisms underlying immune evasions may be distinctive for certain 
tumor types or change depending on the choice of therapy (88). Clinical trials with checkpoint 
inhibitors in advanced melanoma show long lasting effects in a fraction of patients, however ~25% 
of these patients relapse after a median follow-up of 21 months (89). While initial blockade of the 
PD-1/PD-L1 axis is sufficient to treat the disease, other immune suppressive mechanisms such as 
defects in interferon-receptor signaling pathway or antigen presentation may arise as the dominant 
drivers of immune evasion (90). As stated in chapter 1 of this thesis, many patients suffer from 
such relapses after initial response to T cell therapy due to acquisition of or change within an 
immune suppressive tumor micro-environment. It is noteworthy that the proposed approaches in 
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this thesis are designed to counter selected mechanisms such as lack of co-stimulation or 
decreased T cell activity, and may be included (or not) dependent on the tumor type and (other) 
treatment components of choice.  
Therefore, in extension to research conducted with the intention to improve T cell therapy, it is 
necessary to gain a better, more basic understanding of how this myriad of evasive mechanisms 
are connected with each other, how to detect their emergence throughout therapy and how to 
counter them successfully. To this end, research is extending its efforts in regard to immune 
monitoring of patients undergoing immune therapy as well as its attempts to understand the 
processes underlying immune evasion in preclinical models. 
 
 
 
Figure 2. Improving TCR gene therapy requires multiple angles 
Depicted is the standard procedure of TCR gene therapy (within circle), amended with individual approaches to 
enhance therapy efficacy and safety as indicated in this thesis (within green boxes). 
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Summary 
Immune therapy has proven its feasibility in cancer treatment and in some cases even its 
preeminence over other treatment modalities such as chemotherapy. Despite promising results 
observed in clinical trials utilizing or targeting various components of the patient’s own immune 
system, new challenges emerged as a significant fraction of patients demonstrate inherent or 
acquired non-responsiveness to therapy or therapy-related toxicity. In this thesis, I provide an 
overview over pre-clinical approaches we have undertaken in order to optimize T cell receptor 
(TCR) gene therapy, a treatment that involves genetic introduction of a TCR specific for a selected 
tumor antigen into patient derived T cells.  
 
Chapter 1 starts with a short overview of some of the currently employed immune therapies: 
checkpoint inhibitor treatment, vaccination therapy and adoptive T cell therapy. Given the focus of 
this thesis, this chapter continues to outline the current challenges facing TCR gene therapy, 
namely the search for safe, effective target antigens as well as overcoming tumor-mediated T cell 
evasion. Following these challenges, we designed approaches to improve TCR gene therapy along 
two lines: 
(1) Selection and validation of tumor specific target antigens and corresponding TCRs; and 
(2) T cell engineering to counteract local immune suppression. 
These research lines are explained and introduce the work presented and discussed in subsequent 
chapters. Lastly, this chapter provides the aims of this thesis and how individual chapter contribute 
to addressing the main challenges described above. 
 
Chapter 2 provides a literature review covering the challenges mentioned in chapter 1, which is 
evident from its subheadings: ‘Choice of Target Antigen’, ‘T cell Fitness’ and ‘Sensitization of Micro 
Milieu for T cell Therapy’. This review deals with translational and clinical approaches, some of 
which find application within this thesis. 
 
In chapter 3 we have used patient blood with enhanced frequencies of tumor-specific T cell clones 
is as a source for TCRs. The utilized T cell clones demonstrated specificity for the cancer germline 
antigen (CGA) MAGE-C2 (MC2) and were obtained from patients that showed clinical responses 
following vaccination without apparent side effects. We have isolated ten sets of TCRα/β chains 
from eight clones and introduced these into retroviral vectors for in vitro assessment. Four of these 
TCRs revealed functional expression in T cells as verified by pMHC stainings as well as co-culture 
with peptide loaded cells. T cell performances and tumor-specific recognition were further assessed 
through co-culture with cell lines of melanoma, head-and-neck, bladder and triple-negative breast 
cancer origin. Another observation from this chapter was that expression of MC2 becomes 
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pregulated through use of the DNA methyl transferase inhibitor Azacytidine and the histone 
deacetylase inhibitor Valproate in various cancer cell lines. Notably, the use of epigenetic drugs 
neither induced MC2 expression nor did it evoke MC2-specific T cell activation by healthy cell lines. 
With tumor cell lines however, epigenetic drug treatment led to an enhanced responsiveness of 
MC2-specific TCRs, which was dependent on expression of antigen, but not CD80, CD86, PD-L1 
and 2. 
 
Chapter 4 revolves around the safety assessment of antigens and TCRs. Due to the occurrence of 
adverse events in clinical TCR gene therapy trials, we advocate that target antigens as well as 
TCRs intended for clinical use need to undergo stringent testing in a series of in vitro and in silico 
assays. Using the MC2 antigen and two of the MC2-specific TCRs from chapter 3 as examples, we 
proposed a pipeline consisting of two major elements. First, antigen safety is defined by sufficient 
expression and presentation by tumor cells, and absent expression by healthy cells. Using RNA- 
and tissue libraries of healthy samples as well as tumor cell lines, together with qPCR analysis and 
histochemistry, we were able to demonstrate that the MC2 expression profile is safe and does 
justify its targeting in human cancers. Secondly, TCR safety is defined by a low potential for cross-
reactivity. For initial evaluation, TCR transduced T cells were exposed to HLA-A2-restricted peptide 
libraries. For a subsequent, more TCR-specific approach, we assessed the recognition motif using 
altered peptide ligands, after which peptides with matching recognition motifs were evaluated for 
their ability to induce T cell activation. TCRs assessed in this manner revealed a single other, non-
cognate peptide derived from the CGAs MAGE-C1 or MAGE-B4. T cell avidities for these non-
cognate peptides were decreased compared to the cognate peptide, and T cells showed no 
response to target cells natively expressing these antigens. In both cases the cross-reactive 
epitopes were part of another CGA (MAGE-C1 or MAGE-B4). 
 
Chapter 5 further builds on an approach to engineer T cells in order to counter immune 
suppression mediated by reduced expression of co-stimulatory ligands. Following inclusion of 
intracellular (ic) domains of the co-signaling receptors CD28, OX40, ICOS, 4-1BB and CD40L into a 
TCR, we generated a panel of co-stimulatory TCRs that were expected to signal via co-stimulatory 
pathways upon antigen binding but independent of co-stimulatory ligand binding. Transduction of 
these constructs into primary T cells revealed that both the 4-1BB- as well as the CD40L-TCR 
variant were not functionally expressed and the three other TCR constructs yielded T cells with 
reduced functional avidity when compared to the wt TCR. When assessing their capacity in immune 
competent mice however, it became apparent that all co-stimulatory TCRs delayed tumor 
recurrence and in particular, TCR:28-ICOSε T cells mediate enhanced tumor-free survival. Both 
TCR:28-ICOSε and TCR:28-OX40ε T cells persisted longer in peripheral blood than wt TCR T cells 
and showed enhanced numbers within regressing tumors. 
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In chapter 6 we propose the generation of therapeutic T cells possessing the capacity to reverse 
local immune suppression through the release of cytokines at the tumor site. For this purpose, we 
have established a protocol to generate T cells equipped with both a TCR as well as an inducible 
(i)IL-12 or iIL-18 construct under the control of a nuclear-factor of activated T-cell (NFAT)-
sensitive promoter. Both T cell variants demonstrated antigen-specific release in vitro. While 
adoptive transfer of TCR+iIL-18 T cells to melanoma-bearing mice resulted in significantly reduced 
tumor burden and prolonged overall survival, transfer of TCR+iIL-12 T cells led to severe, edema-
like toxicity and reduced overall survival, accompanied by enhanced levels of IFNγ and TNFα in 
blood as well as enhanced infiltration of macrophages into the tumor.  
 
In chapter 7 the two main challenges of TCR gene therapy as mentioned in chapter 1 are 
discussed according to the results of chapters 3 to 6. I have placed the approaches put forward by 
this thesis into context of recent developments within the TCR gene therapy field, have made an 
effort to explain findings using illustrations, and have drafted an ‘ideal’ treatment design. 
Furthermore, I have discussed which additional investigations are necessary in order to further 
improve and utilize these approaches. 
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Samenvatting 
In de behandeling van kanker heeft immuuntherapie zich de laatste jaren gevestigd als een 
standaard behandelingsoptie voor bepaalde kankersoorten, en een plaats afgedwongen naast de 
reeds bestaande behandelingsopties zoals chemotherapie. In sommige gevallen blijkt 
immuuntherapie zelfs een betere behandelingsmethode dan deze “klassieke” 
behandelingsstrategieën.  
Ondanks veelbelovende resultaten van immuuntherapie tijdens (pre-)klinische onderzoek is er 
vooralsnog een significant deel van de patiënten dat niet reageert op de therapie of last heeft van 
bijwerkingen. In dit proefschrift geef ik een overzicht van de preklinisch benadering die wij in het 
laboratorium hebben gehanteerd om T cel receptor (TCR) gentherapie te verbeteren, zowel qua 
therapeutische veiligheid als effectiviteit. TCR T cel therapie is een behandeling waarbij witte 
bloedlichaampjes van een patiënt, zogenaamde T cellen, worden afgenomen en genetisch worden 
gemoduleerd om een TCR tot expressie brengen. Vervolgens worden deze cellen gekweekt 
waardoor het cel aantal fors toeneemt waarna ze worden teruggeplaatst in de patiënt. 
 
Hoofdstuk 1 start met een korte opsomming van verschillende immuuntherapieën zoals 
checkpoint therapie, vaccinatie therapie en T cel therapie. Verder beschrijft dit hoofdstuk waar de 
uitdagingen liggen in het verbeteren van TCR gentherapie, namelijk de selectie van veilige, 
effectieve antigenen en het overwinnen van tumor gemedieerde immuun ontwijking. Hiertoe wordt 
een tweetal manieren gepresenteerd: 
(1) Selectie en validatie van tumor specifieke antigenen en de daarbij horende TCRs. 
(2) Ontwikkeling van T cellen welk de lokale immuunsuppressie tegen gaan. 
 
Deze twee manieren worden in de latere hoofdstukken meer in detail besproken. Tenslotte wordt 
in hoofdstuk 1 het doel van dit proefschrift uiteen gezet en wordt beschreven hoe de individuele 
hoofdstukken specifiek bijdragen om dit doel te verwezenlijken. 
 
Hoofdstuk 2 geeft een overzicht van de literatuur van de in hoofdstuk 1 genoemde uitdagingen 
aan de hand van de volgende drie hoofdonderdelen: keuze van het antigeen herkent door T cellen; 
fitheid van T cellen; en het gevoelig maken van tumoren voor T cellen. 
 
In Hoofdstuk 3 beschrijven we hoe we uit het bloed van patiënten T cellen specifiek voor het 
zogenaamde ‘Cancer Germline Antigen (CGA)’ MAGE-C2 (MC2) hebben geïsoleerd. Uit deze T 
cellen hebben wij de TCRs in handen gekregen. Tien TCRα/β ketens van verschillende T cel klonen 
zijn in retrovirale vectoren gezet, die op hun beurt gebruikt zijn voor genetische introductie in T 
cellen. Vier van deze 10 TCRs werden door T cellen tot expressie gebracht, aangetoond door 
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middel van flow cytometrie, en resulteerden in de verwachte T cel functie, dat laatste aangetoond 
middels in vitro blootstelling aan antigeen (dwz buiten proefdieren om). Herkenning van tumoren 
is verder geanalyseerd door T cellen te co-cultiveren met cellijnen afkomstig van huid, hoofd-hals, 
blaas en borstkanker. In dit hoofdstuk worden ook experimenten beschreven die het belang van de 
mate van expressie van MC2 onderstrepen en dat deze expressie positief wordt beïnvloed door 
medicatie die de toegankelijkheid van DNA voor gentranscriptie bevordert. Belangrijk te melden is 
dat het gebruik van deze zogenaamde epigenetische middelen MC2 expressie in noch een T cel 
reactie tegen cellijnen van gezond weefsel veroorzaakt, hetgeen een basis vormt voor mogelijke 
combinatietherapie. 
 
Hoofdstuk 4 beschrijft een voorstel hoe veilige antigenen en TCRs voor T cel therapie aan de 
hand van in vitro en in silico (dwz computer-gerelateerde) technieken geselecteerd kunnen 
worden. Uit patiënten studies met TCR T cellen werden onder sommige condities ernstige 
bijwerkingen geconstateerd. Wij bepleiten dat zowel gekozen antigenen als TCRs die geselecteerd 
worden voor klinisch gebruik aan grondig onderzoek moeten worden blootgesteld voordat deze 
TCRs aan patiënten gegeven kunnen worden. Hiertoe raden we het volgende stappenplan aan, 
bestaande uit 2 belangrijke componenten. Ten eerste wordt de toepasbaarheid en veiligheid van 
een antigeen gedefinieerd door voldoende expressie van antigeen door tumorweefsel en 
afwezigheid van deze expressie door gezond weefsel. Hiervoor gebruikte technieken analyseren 
zowel antigeen expressie op RNA als eiwitniveau. Met deze technieken laten we in hoofdstuk 4 zien 
dat MC2 een geschikt antigeen is voor T celtherapie. Ten tweede wordt de toepasbaarheid en 
veiligheid van een TCR gedefinieerd door voldoende reactiviteit van deze TCR voor het bedoelde 
antigeen (‘cognate antigen’), en afwezigheid van of minimale kruis-reactiviteit voor andere 
antigenen. Hiervoor gebruikte technieken analyseren TCR-gemedieerde T cel reactiviteit tegen. Met 
deze technieken laten we in hoofdstuk 4 zien dat MC2 TCR6 een geschikte TCR is voor T 
celtherapie, en deze TCR is ook uitgangspunt van een geplande klinische test bij patiënten met 
huid en hoofd-hals-kanker in 2018.  
 
Hoofdstuk 5 gaat verder in op het verbeteren van T cel fitheid. Door het toevoegen van co-
stimulatoire domeinen (afkomstig van bijvoorbeeld CD28, OX40, of ICOS) in TCR ketens, en deze 
te introduceren in T cellen, wordt verondersteld dat deze T cellen beter bestand zullen zijn tegen 
het immuun-suppressieve milieu van tumorweefsel. Dergelijke co-stimulatoire TCRs resulteren in 
enige afname van T cel reactiviteit in vitro, echter in in vivo proeven met immuun competente 
muizen laten deze nieuwe TCRs een verbetering zien in anti-tumor response en overleving. Deze 
effecten gaan gepaard met hoge aantallen T cellen in bloed en tumor. In het bijzonder is de TCR 
met ingebouwd ICOS domain effectief welke leidt tot zelfs 50% genezing van muizen met 
huidtumoren (waar dat normaal 10% is). 
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In Hoofdstuk 6 beschrijven we een andere methode om de therapeutische potentie van T cellen 
te verbeteren, met de nadruk op afgifte van moleculen in het tumorweefsel om de anti-tumor T cel 
response verder te ondersteunen. T cellen krijgen naast een TCR ook een induceerbaar (i)IL-12 of 
iIL-18 construct, waarin de expressie en afgifte het genoemde molecuul gecontroleerd wordt door 
T cel activatie. Zowel iIL-12 als ook iIL-18 T cellen laten in vitro zien dat IL-12 of IL-18 productie 
inderdaad bepaald wordt door T cel activatie met antigeen. In vivo veroorzaken deze T cellen een 
significante afname van de tumorgroei en een langere overleving. Het behaalde voordeel was 
vooral het geval voor behandeling met iIL-18 T cellen, en blijkt gerelateerd aan hoge aantallen 
CD8 T cellen in bloed en tumor. Behandeling met iIL-12 T cellen resulteert helaas in ernstige 
bijwerkingen, waaronder oedeem en dood.  
 
In Hoofdstuk 7 worden uitdagingen van de TCR T cel therapie (zoals eerder omschreven in 
hoofdstuk 1) besproken aan de hand van de resultaten in hoofdstuk 3 tot en met 6. Ik heb de 
verschillende uitkomsten die in dit proefschrift worden beschreven geplaatst in de context van 
recente ontwikkelingen binnen de T cel therapie. Daarnaast worden bevindingen samengevat door 
middel van illustraties. Ook worden er voorstellen gedaan om de patiëntbehandeling met TCR T 
cellen te verbeteren door gebruik te maken van benaderingen die in dit proefschrift worden 
besproken, en welke aanvullende onderzoeken er nodig zijn om combinatie behandelingen met T 
cellen te testen. 
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